JP5619907B2 - α7ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 - Google Patents
α7ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 Download PDFInfo
- Publication number
- JP5619907B2 JP5619907B2 JP2012536772A JP2012536772A JP5619907B2 JP 5619907 B2 JP5619907 B2 JP 5619907B2 JP 2012536772 A JP2012536772 A JP 2012536772A JP 2012536772 A JP2012536772 A JP 2012536772A JP 5619907 B2 JP5619907 B2 JP 5619907B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- amine
- octane
- bicyclo
- oxazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003446 ligand Substances 0.000 title description 5
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 title description 3
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 title description 3
- 150000008584 quinuclidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 87
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 18
- 201000000980 schizophrenia Diseases 0.000 claims description 16
- 208000024827 Alzheimer disease Diseases 0.000 claims description 15
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 description 710
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 497
- -1 2-indolonyl Chemical group 0.000 description 494
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 420
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 349
- 238000005481 NMR spectroscopy Methods 0.000 description 297
- 239000000203 mixture Substances 0.000 description 264
- 238000006243 chemical reaction Methods 0.000 description 240
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 201
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 182
- 235000019439 ethyl acetate Nutrition 0.000 description 169
- 239000007787 solid Substances 0.000 description 147
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 134
- 239000000047 product Substances 0.000 description 122
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 120
- 238000000034 method Methods 0.000 description 118
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 116
- 239000000843 powder Substances 0.000 description 103
- 239000000243 solution Substances 0.000 description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 92
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 91
- 238000004587 chromatography analysis Methods 0.000 description 88
- 239000000741 silica gel Substances 0.000 description 84
- 229910002027 silica gel Inorganic materials 0.000 description 84
- 239000011541 reaction mixture Substances 0.000 description 73
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 64
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 62
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 53
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 50
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 49
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 48
- 239000012043 crude product Substances 0.000 description 48
- 239000000725 suspension Substances 0.000 description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- 239000002244 precipitate Substances 0.000 description 41
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
- 239000003921 oil Substances 0.000 description 39
- 235000019198 oils Nutrition 0.000 description 39
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 34
- 239000000908 ammonium hydroxide Substances 0.000 description 34
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 33
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 33
- 229910052938 sodium sulfate Inorganic materials 0.000 description 33
- 235000011152 sodium sulphate Nutrition 0.000 description 33
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 31
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 238000004440 column chromatography Methods 0.000 description 30
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
- 239000012267 brine Substances 0.000 description 29
- 239000013058 crude material Substances 0.000 description 29
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 29
- KXMMNJQMGILZDB-UHFFFAOYSA-N 1-(2-oxopyridine-1-carbothioyl)pyridin-2-one Chemical compound O=C1C=CC=CN1C(=S)N1C(=O)C=CC=C1 KXMMNJQMGILZDB-UHFFFAOYSA-N 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 26
- 238000003818 flash chromatography Methods 0.000 description 26
- 239000010410 layer Substances 0.000 description 26
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 24
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 24
- 235000019341 magnesium sulphate Nutrition 0.000 description 24
- 239000012044 organic layer Substances 0.000 description 24
- 239000012071 phase Substances 0.000 description 22
- 238000000746 purification Methods 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 21
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 21
- 238000001914 filtration Methods 0.000 description 21
- 238000004809 thin layer chromatography Methods 0.000 description 21
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 20
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 19
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 19
- 229910000024 caesium carbonate Inorganic materials 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 18
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 239000007858 starting material Substances 0.000 description 18
- 150000001412 amines Chemical class 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 17
- 239000000556 agonist Substances 0.000 description 16
- 239000011575 calcium Substances 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- 238000010898 silica gel chromatography Methods 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- OUKVGTYIZUXBIR-JZGIKJSDSA-N [(3s)-3-hydroxy-1-azoniabicyclo[2.2.2]octan-3-yl]methylazanium;dichloride Chemical compound Cl.Cl.C1CC2[C@@](CN)(O)CN1CC2 OUKVGTYIZUXBIR-JZGIKJSDSA-N 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- 230000003287 optical effect Effects 0.000 description 13
- 125000004076 pyridyl group Chemical group 0.000 description 13
- GRECAEAUENSRIP-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-ol dihydrochloride Chemical compound N12CC(C(CC1)CC2)O.Cl.Cl GRECAEAUENSRIP-UHFFFAOYSA-N 0.000 description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- ZGGNERQUFKZVBA-UHFFFAOYSA-N azanium;chloroform;hydroxide Chemical compound [NH4+].[OH-].ClC(Cl)Cl ZGGNERQUFKZVBA-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 12
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- CAACGBPGDBJKFK-UHFFFAOYSA-N azanium;ethyl acetate;hydroxide Chemical compound [NH4+].[OH-].CCOC(C)=O CAACGBPGDBJKFK-UHFFFAOYSA-N 0.000 description 10
- 239000004202 carbamide Substances 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 208000015122 neurodegenerative disease Diseases 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 9
- 238000002953 preparative HPLC Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 8
- BAQKUNMKVAPWGU-UHFFFAOYSA-N 4-bromopyridin-2-amine Chemical compound NC1=CC(Br)=CC=N1 BAQKUNMKVAPWGU-UHFFFAOYSA-N 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 description 8
- 239000000376 reactant Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108091006146 Channels Proteins 0.000 description 7
- 208000019022 Mood disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- YKOUABZEDZDJEY-UHFFFAOYSA-N methyl 2,2-diethoxyethanimidate Chemical compound CCOC(OCC)C(=N)OC YKOUABZEDZDJEY-UHFFFAOYSA-N 0.000 description 7
- 229960002715 nicotine Drugs 0.000 description 7
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- DUKKRSPKJMHASP-UHFFFAOYSA-N 6-chloropyrimidin-4-amine Chemical compound NC1=CC(Cl)=NC=N1 DUKKRSPKJMHASP-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 229940045348 brown mixture Drugs 0.000 description 6
- FKGQRXQOODICAT-UHFFFAOYSA-N di(imidazol-1-yl)methanimine Chemical compound C1=CN=CN1C(=N)N1C=CN=C1 FKGQRXQOODICAT-UHFFFAOYSA-N 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 6
- 239000004031 partial agonist Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- ADKICMRIVXDIOP-UHFFFAOYSA-N 4-isothiocyanato-6-methoxypyrimidine Chemical compound COC1=CC(N=C=S)=NC=N1 ADKICMRIVXDIOP-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 150000002540 isothiocyanates Chemical class 0.000 description 5
- IWZSFFYAXNHSIT-UHFFFAOYSA-N n-(7-methoxy-5-methyl-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-1,1-bis(methylsulfanyl)methanimine Chemical compound COC1=NC(C)=NC2=C1N=C(N=C(SC)SC)S2 IWZSFFYAXNHSIT-UHFFFAOYSA-N 0.000 description 5
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 5
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 5
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 125000000335 thiazolyl group Chemical group 0.000 description 5
- 125000001425 triazolyl group Chemical group 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 4
- OHUNPVCHRGBDHH-AWEZNQCLSA-N (3r)-n-(6-methoxypyrimidin-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(OC)=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=N1 OHUNPVCHRGBDHH-AWEZNQCLSA-N 0.000 description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 4
- JPBLHOJFMBOCAF-UHFFFAOYSA-N 1,3-benzoxazol-2-amine Chemical compound C1=CC=C2OC(N)=NC2=C1 JPBLHOJFMBOCAF-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- YYHYJXGSBDBGSF-UHFFFAOYSA-N 4-isothiocyanato-6-(3-methoxyphenyl)pyrimidine Chemical compound COC1=CC=CC(C=2N=CN=C(N=C=S)C=2)=C1 YYHYJXGSBDBGSF-UHFFFAOYSA-N 0.000 description 4
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 4
- KRRTXVSBTPCDOS-UHFFFAOYSA-N 5-bromopyrazin-2-amine Chemical compound NC1=CN=C(Br)C=N1 KRRTXVSBTPCDOS-UHFFFAOYSA-N 0.000 description 4
- BLGYAIWJMVWVDS-UHFFFAOYSA-N 6-methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1=C(OC)C=CC2=NC(N)=NN21 BLGYAIWJMVWVDS-UHFFFAOYSA-N 0.000 description 4
- VPRKGLYZWQCCHU-UHFFFAOYSA-N 6-pyridin-3-ylpyrimidin-4-amine Chemical compound C1=NC(N)=CC(C=2C=NC=CC=2)=N1 VPRKGLYZWQCCHU-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 4
- 235000019502 Orange oil Nutrition 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- VUSUESCSIUWQMT-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2C21OC(NC=1SC3=CC=CC=C3N=1)=NC2 VUSUESCSIUWQMT-UHFFFAOYSA-N 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 239000010502 orange oil Substances 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- VZBQNKTUVDZSCW-UHFFFAOYSA-N (2-amino-1,3-benzothiazol-6-yl)-pyrrolidin-1-ylmethanone Chemical compound C1=C2SC(N)=NC2=CC=C1C(=O)N1CCCC1 VZBQNKTUVDZSCW-UHFFFAOYSA-N 0.000 description 3
- NQIJONATHKMORV-INIZCTEOSA-N (3r)-n-(1,3-benzoxazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]21OC(NC=1OC3=CC=CC=C3N=1)=NC2 NQIJONATHKMORV-INIZCTEOSA-N 0.000 description 3
- XXCHCVVLHLOEDV-AWEZNQCLSA-N (3r)-n-(4,5-dichloropyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=C(Cl)C(Cl)=CN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 XXCHCVVLHLOEDV-AWEZNQCLSA-N 0.000 description 3
- WGPOVCLCAWPGGU-INIZCTEOSA-N (3r)-n-(5-bromo-4-propan-2-ylpyrimidin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=C(Br)C(C(C)C)=NC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=N1 WGPOVCLCAWPGGU-INIZCTEOSA-N 0.000 description 3
- KRNABMMFSKMSJJ-INIZCTEOSA-N (3r)-n-(5-chloro-1,3-benzoxazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=CC(Cl)=CC=C2O1 KRNABMMFSKMSJJ-INIZCTEOSA-N 0.000 description 3
- JORBPZWZVPZZKU-SFHVURJKSA-N (3r)-n-(5-cyclopentyloxypyrimidin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1CCCC1OC(C=N1)=CN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 JORBPZWZVPZZKU-SFHVURJKSA-N 0.000 description 3
- RHHQETAYCGOKDB-QFIPXVFZSA-N (3r)-n-(5-phenylmethoxy-[1,3]thiazolo[5,4-b]pyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C=1C=C2N=C(NC=3O[C@@]4(C5CCN(CC5)C4)CN=3)SC2=NC=1OCC1=CC=CC=C1 RHHQETAYCGOKDB-QFIPXVFZSA-N 0.000 description 3
- MMPRRMIZZMKFAF-SFHVURJKSA-N (3r)-n-(6-cyclopentyloxypyrimidin-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1CCCC1OC1=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=NC=N1 MMPRRMIZZMKFAF-SFHVURJKSA-N 0.000 description 3
- OEBYXCLQXOTPJE-SFHVURJKSA-N (3r)-n-(6-pyridin-4-ylpyrimidin-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C([C@]1(C2CCN(CC2)C1)O1)N=C1NC(N=CN=1)=CC=1C1=CC=NC=C1 OEBYXCLQXOTPJE-SFHVURJKSA-N 0.000 description 3
- YOORWGRUIPLNSG-SFHVURJKSA-N (3r)-n-(7-chloro-8-fluoroisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC=C2C(F)=C(Cl)C=CC2=C1 YOORWGRUIPLNSG-SFHVURJKSA-N 0.000 description 3
- PCLVDKIBTLXQTR-INIZCTEOSA-N (3r)-n-(7-methoxy-5-methyl-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC(S1)=NC2=C1N=C(C)N=C2OC PCLVDKIBTLXQTR-INIZCTEOSA-N 0.000 description 3
- XEHLPXIKSPZCIB-INIZCTEOSA-N (3r)-n-[5-(difluoromethoxy)-[1,3]thiazolo[5,4-b]pyridin-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=CC=C(OC(F)F)N=C2S1 XEHLPXIKSPZCIB-INIZCTEOSA-N 0.000 description 3
- ZIXIFHSPOBDBRO-ZDUSSCGKSA-N (3r)-n-[5-(trifluoromethyl)pyrazin-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(C(F)(F)F)=CN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 ZIXIFHSPOBDBRO-ZDUSSCGKSA-N 0.000 description 3
- WOJCVPHCTJFPKM-KRWDZBQOSA-N (3r)-n-[6-(difluoromethoxy)-1,3-benzothiazol-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=CC=C(OC(F)F)C=C2S1 WOJCVPHCTJFPKM-KRWDZBQOSA-N 0.000 description 3
- NHLSXQSQHXPPDQ-UHFFFAOYSA-N 1,1-bis(methylsulfanyl)-n-(5-phenylmethoxy-[1,3]thiazolo[5,4-b]pyridin-2-yl)methanimine Chemical compound N1=C2SC(N=C(SC)SC)=NC2=CC=C1OCC1=CC=CC=C1 NHLSXQSQHXPPDQ-UHFFFAOYSA-N 0.000 description 3
- IXZYSKNWHPRGKV-UHFFFAOYSA-N 1,1-bis(methylsulfanyl)-n-([1,3]oxazolo[4,5-b]pyridin-2-yl)methanimine Chemical compound C1=CC=C2OC(N=C(SC)SC)=NC2=N1 IXZYSKNWHPRGKV-UHFFFAOYSA-N 0.000 description 3
- OKGNEHOXHXVIMK-KRWDZBQOSA-N 1-[5-[[(3r)-spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-yl]amino]pyrazin-2-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C(N=C1)=CN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 OKGNEHOXHXVIMK-KRWDZBQOSA-N 0.000 description 3
- WLHADOSXRICWAB-UHFFFAOYSA-N 2-(difluoromethoxy)-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(OC(F)F)N=C1 WLHADOSXRICWAB-UHFFFAOYSA-N 0.000 description 3
- YJOBZEMOBFJWDV-UHFFFAOYSA-N 2-[bis(methylsulfanyl)methylideneamino]-n,n-dimethyl-[1,3]thiazolo[5,4-d]pyrimidin-5-amine Chemical compound N1=C(N(C)C)N=C2SC(N=C(SC)SC)=NC2=C1 YJOBZEMOBFJWDV-UHFFFAOYSA-N 0.000 description 3
- VSOBZMWGTWAHSR-UHFFFAOYSA-N 2-bromo-6-isothiocyanatopyridine Chemical compound BrC1=CC=CC(N=C=S)=N1 VSOBZMWGTWAHSR-UHFFFAOYSA-N 0.000 description 3
- MANHSBQXHPLZSR-UHFFFAOYSA-N 2-chloro-5-cyclopentyloxypyrimidine Chemical compound C1=NC(Cl)=NC=C1OC1CCCC1 MANHSBQXHPLZSR-UHFFFAOYSA-N 0.000 description 3
- WUACEPTXSRKMEX-UHFFFAOYSA-N 2-isothiocyanato-5-methylsulfanylpyrazine Chemical compound CSC1=CN=C(N=C=S)C=N1 WUACEPTXSRKMEX-UHFFFAOYSA-N 0.000 description 3
- RZAZBVCZBWDSBJ-INIZCTEOSA-N 2-methyl-6-[[(3r)-spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-yl]amino]pyridine-3-carbonitrile Chemical compound C1=C(C#N)C(C)=NC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=C1 RZAZBVCZBWDSBJ-INIZCTEOSA-N 0.000 description 3
- WSGPQEKGIAKLME-UHFFFAOYSA-N 3-isothiocyanato-6,8-dimethylisoquinoline Chemical compound C1=NC(N=C=S)=CC2=CC(C)=CC(C)=C21 WSGPQEKGIAKLME-UHFFFAOYSA-N 0.000 description 3
- HPDLWLVRGCHZGT-UHFFFAOYSA-N 3-isothiocyanato-6-methylisoquinoline Chemical compound C1=NC(N=C=S)=CC2=CC(C)=CC=C21 HPDLWLVRGCHZGT-UHFFFAOYSA-N 0.000 description 3
- PFCDPPOYVKKKCP-UHFFFAOYSA-N 4,5-dichloro-2-isothiocyanatopyridine Chemical compound ClC1=CN=C(N=C=S)C=C1Cl PFCDPPOYVKKKCP-UHFFFAOYSA-N 0.000 description 3
- IELZPOFKHRZRGS-UHFFFAOYSA-N 4,5-dimethylpyrimidin-2-amine Chemical compound CC1=CN=C(N)N=C1C IELZPOFKHRZRGS-UHFFFAOYSA-N 0.000 description 3
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 3
- IUNZNINLPZAQDM-UHFFFAOYSA-N 4-(3-chlorophenyl)-6-isothiocyanatopyrimidine Chemical compound ClC1=CC=CC(C=2N=CN=C(N=C=S)C=2)=C1 IUNZNINLPZAQDM-UHFFFAOYSA-N 0.000 description 3
- YKDAOJYJASPGDM-UHFFFAOYSA-N 4-(4-chlorophenyl)-6-isothiocyanatopyrimidine Chemical compound C1=CC(Cl)=CC=C1C1=CC(N=C=S)=NC=N1 YKDAOJYJASPGDM-UHFFFAOYSA-N 0.000 description 3
- CJTDPEZNGURNJL-UHFFFAOYSA-N 4-chloro-6-(2,2,2-trifluoroethoxy)pyrimidine Chemical compound FC(F)(F)COC1=CC(Cl)=NC=N1 CJTDPEZNGURNJL-UHFFFAOYSA-N 0.000 description 3
- DQHCEDCSEAGFRM-UHFFFAOYSA-N 4-chloro-6-cyclopentyloxypyrimidine Chemical compound C1=NC(Cl)=CC(OC2CCCC2)=N1 DQHCEDCSEAGFRM-UHFFFAOYSA-N 0.000 description 3
- SJTOQNJGUHMDEZ-UHFFFAOYSA-N 4-chloroisoquinolin-3-amine Chemical compound C1=CC=CC2=C(Cl)C(N)=NC=C21 SJTOQNJGUHMDEZ-UHFFFAOYSA-N 0.000 description 3
- ABIDGJQJJGUVID-UHFFFAOYSA-N 4-isothiocyanato-6-phenoxypyrimidine Chemical compound C1=NC(N=C=S)=CC(OC=2C=CC=CC=2)=N1 ABIDGJQJJGUVID-UHFFFAOYSA-N 0.000 description 3
- CIIVQXITBPFBAK-UHFFFAOYSA-N 4-isothiocyanato-6-pyridin-4-ylpyrimidine Chemical compound C1=NC(N=C=S)=CC(C=2C=CN=CC=2)=N1 CIIVQXITBPFBAK-UHFFFAOYSA-N 0.000 description 3
- IKECPQGVQXXBSD-UHFFFAOYSA-N 5,6-dichloro-3-isothiocyanatoisoquinoline Chemical compound C1=NC(N=C=S)=CC2=C(Cl)C(Cl)=CC=C21 IKECPQGVQXXBSD-UHFFFAOYSA-N 0.000 description 3
- LULBBYYBHKFKBH-UHFFFAOYSA-N 5,6-dichloropyridin-2-amine Chemical compound NC1=CC=C(Cl)C(Cl)=N1 LULBBYYBHKFKBH-UHFFFAOYSA-N 0.000 description 3
- ILDRNIDSVAZBMZ-UHFFFAOYSA-N 5-(trifluoromethyl)pyrazin-2-amine Chemical compound NC1=CN=C(C(F)(F)F)C=N1 ILDRNIDSVAZBMZ-UHFFFAOYSA-N 0.000 description 3
- ZRZKHMJBGSDIMH-UHFFFAOYSA-N 5-bromo-3-isothiocyanatoisoquinoline Chemical compound N1=C(N=C=S)C=C2C(Br)=CC=CC2=C1 ZRZKHMJBGSDIMH-UHFFFAOYSA-N 0.000 description 3
- LLPVJZMTIYQTGU-UHFFFAOYSA-N 5-methoxy-[1,3]thiazolo[5,4-b]pyridin-2-amine Chemical compound COC1=CC=C2N=C(N)SC2=N1 LLPVJZMTIYQTGU-UHFFFAOYSA-N 0.000 description 3
- BYMNUSPCTDNOFF-INIZCTEOSA-N 5-n,5-n-dimethyl-2-n-[(3r)-spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-yl]-[1,3]thiazolo[5,4-d]pyrimidine-2,5-diamine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=CN=C(N(C)C)N=C2S1 BYMNUSPCTDNOFF-INIZCTEOSA-N 0.000 description 3
- XSYBQTMVQZSLGQ-UHFFFAOYSA-N 5-pyrrolidin-1-ylpyrazin-2-amine Chemical compound C1=NC(N)=CN=C1N1CCCC1 XSYBQTMVQZSLGQ-UHFFFAOYSA-N 0.000 description 3
- UAKAFAPSKXVOLF-UHFFFAOYSA-N 6,7-dichloro-3-isothiocyanatoisoquinoline Chemical compound N1=C(N=C=S)C=C2C=C(Cl)C(Cl)=CC2=C1 UAKAFAPSKXVOLF-UHFFFAOYSA-N 0.000 description 3
- QQKNHPWFFIATKE-UHFFFAOYSA-N 6,8-dimethylisoquinolin-3-amine Chemical compound C1=NC(N)=CC2=CC(C)=CC(C)=C21 QQKNHPWFFIATKE-UHFFFAOYSA-N 0.000 description 3
- LHRMIXPETPBOOD-UHFFFAOYSA-N 6-(difluoromethoxy)-1-methylindazol-3-amine Chemical compound C1=C(OC(F)F)C=C2N(C)N=C(N)C2=C1 LHRMIXPETPBOOD-UHFFFAOYSA-N 0.000 description 3
- LZPYGFBASUNYEY-UHFFFAOYSA-N 6-(difluoromethoxy)pyridin-3-amine Chemical compound NC1=CC=C(OC(F)F)N=C1 LZPYGFBASUNYEY-UHFFFAOYSA-N 0.000 description 3
- ZEEJRACEEDQANN-UHFFFAOYSA-N 6-(methoxymethyl)pyrimidin-4-amine Chemical compound COCC1=CC(N)=NC=N1 ZEEJRACEEDQANN-UHFFFAOYSA-N 0.000 description 3
- IKJPWKKDLNSXGW-UHFFFAOYSA-N 6-bromo-3-isothiocyanatoisoquinoline Chemical compound C1=NC(N=C=S)=CC2=CC(Br)=CC=C21 IKJPWKKDLNSXGW-UHFFFAOYSA-N 0.000 description 3
- WTTQQWHDRLGJSP-UHFFFAOYSA-N 6-isothiocyanato-2-methylpyridine-3-carbonitrile Chemical compound CC1=NC(N=C=S)=CC=C1C#N WTTQQWHDRLGJSP-UHFFFAOYSA-N 0.000 description 3
- SYEUUDPGKMMKRU-UHFFFAOYSA-N 6-methoxy-1h-quinoxalin-2-one Chemical compound N1C(=O)C=NC2=CC(OC)=CC=C21 SYEUUDPGKMMKRU-UHFFFAOYSA-N 0.000 description 3
- DBOBOPSSKJMSSY-UHFFFAOYSA-N 6-methylisoquinolin-3-amine Chemical compound C1=NC(N)=CC2=CC(C)=CC=C21 DBOBOPSSKJMSSY-UHFFFAOYSA-N 0.000 description 3
- ZZYGROXOXBQBHP-UHFFFAOYSA-N 7-bromo-3-isothiocyanatoisoquinoline Chemical compound C1=C(N=C=S)N=CC2=CC(Br)=CC=C21 ZZYGROXOXBQBHP-UHFFFAOYSA-N 0.000 description 3
- JOSRIKGEDSHSRP-UHFFFAOYSA-N 7-chloro-8-fluoroisoquinolin-3-amine Chemical compound C1=C(Cl)C(F)=C2C=NC(N)=CC2=C1 JOSRIKGEDSHSRP-UHFFFAOYSA-N 0.000 description 3
- GVERQUMLAYWTMA-UHFFFAOYSA-N 7-methoxy-1h-quinoxalin-2-one Chemical compound N1=CC(O)=NC2=CC(OC)=CC=C21 GVERQUMLAYWTMA-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- NLSCFLSNWRVGLP-QMMMGPOBSA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl]methanamine Chemical compound C1CC2[C@@H](CN)CN1CC2 NLSCFLSNWRVGLP-QMMMGPOBSA-N 0.000 description 3
- UUYSQAYUTMLLBO-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyrazin-2-amine Chemical compound C1=NC=CN2N=C(N)N=C21 UUYSQAYUTMLLBO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 125000006396 chloropyrazinyl group Chemical group 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- BDTDECDAHYOJRO-UHFFFAOYSA-N ethyl n-(sulfanylidenemethylidene)carbamate Chemical compound CCOC(=O)N=C=S BDTDECDAHYOJRO-UHFFFAOYSA-N 0.000 description 3
- FKZUMAMNRPWLKP-UHFFFAOYSA-N ethyl n-[5-(dimethylamino)-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]carbamate Chemical compound N1=C(N(C)C)N=C2SC(NC(=O)OCC)=NC2=C1 FKZUMAMNRPWLKP-UHFFFAOYSA-N 0.000 description 3
- XFSYPTPQPTXLEF-UHFFFAOYSA-N ethyl n-carbamothioylcarbamate;5-methoxypyridin-2-amine Chemical compound CCOC(=O)NC(N)=S.COC1=CC=C(N)N=C1 XFSYPTPQPTXLEF-UHFFFAOYSA-N 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 3
- RPGSTSWVRNPAKP-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)imidazole-1-carbothioamide Chemical compound N=1C2=CC=CC=C2SC=1NC(=S)N1C=CN=C1 RPGSTSWVRNPAKP-UHFFFAOYSA-N 0.000 description 3
- RWIHECXZMGLBKP-UHFFFAOYSA-N n-(1-methylbenzimidazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=CC=C2N(C)C(NC=3OC4(C5CCN(CC5)C4)CN=3)=NC2=C1 RWIHECXZMGLBKP-UHFFFAOYSA-N 0.000 description 3
- CWFZHFCDHUUVQO-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)imidazole-1-carbothioamide Chemical compound N=1C2=CC=CC=C2NC=1NC(=S)N1C=CN=C1 CWFZHFCDHUUVQO-UHFFFAOYSA-N 0.000 description 3
- PEOGXBWZFJKISZ-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2C21OC(NC=1NC3=CC=CC=C3N=1)=NC2 PEOGXBWZFJKISZ-UHFFFAOYSA-N 0.000 description 3
- YPYBXVUXWWJIND-UHFFFAOYSA-N n-(4-chloro-1,3-benzothiazol-2-yl)imidazole-1-carbothioamide Chemical compound N=1C=2C(Cl)=CC=CC=2SC=1NC(=S)N1C=CN=C1 YPYBXVUXWWJIND-UHFFFAOYSA-N 0.000 description 3
- OMNHZKWWQQBAMJ-UHFFFAOYSA-N n-(4-chloro-1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2C1(O1)CN=C1NC(S1)=NC2=C1C=CC=C2Cl OMNHZKWWQQBAMJ-UHFFFAOYSA-N 0.000 description 3
- NOALOJGCCOIRFR-UHFFFAOYSA-N n-(4-methyl-1,3-benzothiazol-2-yl)imidazole-1-carbothioamide Chemical compound N=1C=2C(C)=CC=CC=2SC=1NC(=S)N1C=CN=C1 NOALOJGCCOIRFR-UHFFFAOYSA-N 0.000 description 3
- OXMVTMRZGPMPEJ-UHFFFAOYSA-N n-(4-methyl-1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2C1(O1)CN=C1NC(S1)=NC2=C1C=CC=C2C OXMVTMRZGPMPEJ-UHFFFAOYSA-N 0.000 description 3
- LPCWBIDEYNTTTN-UHFFFAOYSA-N n-(4-propan-2-yl-1,3-thiazol-2-yl)imidazole-1-carbothioamide Chemical compound CC(C)C1=CSC(NC(=S)N2C=NC=C2)=N1 LPCWBIDEYNTTTN-UHFFFAOYSA-N 0.000 description 3
- LUMIIFRRDJKEKE-UHFFFAOYSA-N n-(4-propan-2-yl-1,3-thiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound CC(C)C1=CSC(NC=2OC3(C4CCN(CC4)C3)CN=2)=N1 LUMIIFRRDJKEKE-UHFFFAOYSA-N 0.000 description 3
- MTIALXJECNTTKZ-UHFFFAOYSA-N n-(5,6-dichloropyridin-2-yl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=C(Cl)C(Cl)=N1 MTIALXJECNTTKZ-UHFFFAOYSA-N 0.000 description 3
- CKYGNDBIVBKWDQ-UHFFFAOYSA-N n-(5-chloro-1,3-benzoxazol-2-yl)-1,1-bis(methylsulfanyl)methanimine Chemical compound ClC1=CC=C2OC(N=C(SC)SC)=NC2=C1 CKYGNDBIVBKWDQ-UHFFFAOYSA-N 0.000 description 3
- RSAYOWHRLDBGBO-UHFFFAOYSA-N n-(5-ethyl-1,3,4-oxadiazol-2-yl)-1,1-bis(methylsulfanyl)methanimine Chemical compound CCC1=NN=C(N=C(SC)SC)O1 RSAYOWHRLDBGBO-UHFFFAOYSA-N 0.000 description 3
- LSVLHXBLFBHBCC-UHFFFAOYSA-N n-(5-methoxy-[1,3]thiazolo[5,4-b]pyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2C1(O1)CN=C1NC1=NC2=CC=C(OC)N=C2S1 LSVLHXBLFBHBCC-UHFFFAOYSA-N 0.000 description 3
- HJELGMRULNTAPD-UHFFFAOYSA-N n-(5-methoxy-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-1,1-bis(methylsulfanyl)methanimine Chemical compound COC1=NC=C2N=C(N=C(SC)SC)SC2=N1 HJELGMRULNTAPD-UHFFFAOYSA-N 0.000 description 3
- CXQLQGQCIQXZMI-UHFFFAOYSA-N n-(5-methyl-1,3,4-oxadiazol-2-yl)-1,1-bis(methylsulfanyl)methanimine Chemical compound CSC(SC)=NC1=NN=C(C)O1 CXQLQGQCIQXZMI-UHFFFAOYSA-N 0.000 description 3
- VWTRVYZJIAPBHR-UHFFFAOYSA-N n-(6-chloro-1,3-benzothiazol-2-yl)imidazole-1-carbothioamide Chemical compound S1C2=CC(Cl)=CC=C2N=C1NC(=S)N1C=CN=C1 VWTRVYZJIAPBHR-UHFFFAOYSA-N 0.000 description 3
- JFPMKTAXLLHMRR-UHFFFAOYSA-N n-(6-chloro-1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2C1(O1)CN=C1NC1=NC2=CC=C(Cl)C=C2S1 JFPMKTAXLLHMRR-UHFFFAOYSA-N 0.000 description 3
- DUZMBBAWLGCEQE-UHFFFAOYSA-N n-(6-chloropyrimidin-4-yl)-1,1-bis(methylsulfanyl)methanimine Chemical compound CSC(SC)=NC1=CC(Cl)=NC=N1 DUZMBBAWLGCEQE-UHFFFAOYSA-N 0.000 description 3
- KIDXXFXVPLATJJ-UHFFFAOYSA-N n-(6-methoxy-1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2C1(O1)CN=C1NC1=NC2=CC=C(OC)C=C2S1 KIDXXFXVPLATJJ-UHFFFAOYSA-N 0.000 description 3
- AJVYWPXCDQCOEU-UHFFFAOYSA-N n-(6-methyl-1,3-benzothiazol-2-yl)imidazole-1-carbothioamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=S)N1C=CN=C1 AJVYWPXCDQCOEU-UHFFFAOYSA-N 0.000 description 3
- KOHDBHPGUHPVRI-UHFFFAOYSA-N n-(6-methyl-1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2C1(O1)CN=C1NC1=NC2=CC=C(C)C=C2S1 KOHDBHPGUHPVRI-UHFFFAOYSA-N 0.000 description 3
- WWBYXUSUDJVAED-UHFFFAOYSA-N n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=CC(OC)=CC=C1C1=CSC(NC=2OC3(C4CCN(CC4)C3)CN=2)=N1 WWBYXUSUDJVAED-UHFFFAOYSA-N 0.000 description 3
- OZEMQJOXYRKPEG-UHFFFAOYSA-N n-[4-(4-methoxyphenyl)-5-methyl-1,3-thiazol-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=CC(OC)=CC=C1C1=C(C)SC(NC=2OC3(C4CCN(CC4)C3)CN=2)=N1 OZEMQJOXYRKPEG-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 229940116357 potassium thiocyanate Drugs 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- CBNWMAMNZGMMAU-UHFFFAOYSA-N spiro[1-azabicyclo[2.2.2]octane-3,4'-5h-1,3-oxazole]-2'-amine Chemical compound C1OC(N)=NC21C(CC1)CCN1C2 CBNWMAMNZGMMAU-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 2
- OUKVGTYIZUXBIR-UHFFFAOYSA-N (3-hydroxy-1-azoniabicyclo[2.2.2]octan-3-yl)methylazanium;dichloride Chemical compound Cl.Cl.C1CC2C(CN)(O)CN1CC2 OUKVGTYIZUXBIR-UHFFFAOYSA-N 0.000 description 2
- QJJUSLVVKXQFHE-AWEZNQCLSA-N (3r)-n-(3,5-dichloropyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound ClC1=CC(Cl)=CN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 QJJUSLVVKXQFHE-AWEZNQCLSA-N 0.000 description 2
- ZPJGZIRGDFKHDQ-LBPRGKRZSA-N (3r)-n-(3-methyl-1,2,4-oxadiazol-5-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound CC1=NOC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=N1 ZPJGZIRGDFKHDQ-LBPRGKRZSA-N 0.000 description 2
- UHFZBJIRVAMIPP-LBPRGKRZSA-N (3r)-n-(3-methyl-1,2,4-thiadiazol-5-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound CC1=NSC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=N1 UHFZBJIRVAMIPP-LBPRGKRZSA-N 0.000 description 2
- KKACPMPKQNIXCY-AWEZNQCLSA-N (3r)-n-(4-chloro-5-methoxypyrimidin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound N1=C(Cl)C(OC)=CN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 KKACPMPKQNIXCY-AWEZNQCLSA-N 0.000 description 2
- KHQUNFNAMOIACW-AWEZNQCLSA-N (3r)-n-(5,6-dichloropyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound N1=C(Cl)C(Cl)=CC=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 KHQUNFNAMOIACW-AWEZNQCLSA-N 0.000 description 2
- USOMYWQXRPHQQC-SFHVURJKSA-N (3r)-n-(5-bromo-4-pyridin-3-ylpyrimidin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound BrC1=CN=C(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)N=C1C1=CC=CN=C1 USOMYWQXRPHQQC-SFHVURJKSA-N 0.000 description 2
- LBUXNSKRWJUOKM-AWEZNQCLSA-N (3r)-n-(5-chloro-3-fluoropyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound FC1=CC(Cl)=CN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 LBUXNSKRWJUOKM-AWEZNQCLSA-N 0.000 description 2
- ZUUCADJJZWDVNJ-HNNXBMFYSA-N (3r)-n-(5-chloro-6-methylpyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=C(Cl)C(C)=NC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=C1 ZUUCADJJZWDVNJ-HNNXBMFYSA-N 0.000 description 2
- QBDRIJRFLYTRHO-ZDUSSCGKSA-N (3r)-n-(5-ethyl-1,3,4-oxadiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound O1C(CC)=NN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 QBDRIJRFLYTRHO-ZDUSSCGKSA-N 0.000 description 2
- IBJLUMLTFOPFON-HNNXBMFYSA-N (3r)-n-(5-fluoro-4-methylpyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=C(F)C(C)=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=N1 IBJLUMLTFOPFON-HNNXBMFYSA-N 0.000 description 2
- DGEIXJTUYSVCBC-HNNXBMFYSA-N (3r)-n-(5-methoxy-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=CN=C(OC)N=C2S1 DGEIXJTUYSVCBC-HNNXBMFYSA-N 0.000 description 2
- LLSDHTXRWBJQEM-LBPRGKRZSA-N (3r)-n-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound O1C(C)=NN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 LLSDHTXRWBJQEM-LBPRGKRZSA-N 0.000 description 2
- HWESYGNLBMIHIM-AWEZNQCLSA-N (3r)-n-(5-methylsulfanylpyrazin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(SC)=CN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 HWESYGNLBMIHIM-AWEZNQCLSA-N 0.000 description 2
- PIFLATPNVAJZIA-SFHVURJKSA-N (3r)-n-(5-pyridin-3-ylpyrazin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C([C@]1(C2CCN(CC2)C1)O1)N=C1NC(N=C1)=CN=C1C1=CC=CN=C1 PIFLATPNVAJZIA-SFHVURJKSA-N 0.000 description 2
- HNEWBIIZRVBLEW-KRWDZBQOSA-N (3r)-n-(5-pyrrolidin-1-ylpyrazin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1CCCN1C(N=C1)=CN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 HNEWBIIZRVBLEW-KRWDZBQOSA-N 0.000 description 2
- FYNZWIIYAQHGJK-SFHVURJKSA-N (3r)-n-(6,7-dichloroisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC=C2C=C(Cl)C(Cl)=CC2=C1 FYNZWIIYAQHGJK-SFHVURJKSA-N 0.000 description 2
- GSQCSSCWJWNPFM-SFHVURJKSA-N (3r)-n-(6,8-dichloroisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=CC2=CC(Cl)=CC(Cl)=C2C=N1 GSQCSSCWJWNPFM-SFHVURJKSA-N 0.000 description 2
- GTWJGHJRSNOFFG-FQEVSTJZSA-N (3r)-n-(6,8-dimethylisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=CC2=CC(C)=CC(C)=C2C=N1 GTWJGHJRSNOFFG-FQEVSTJZSA-N 0.000 description 2
- JEIHYUJKPUPKOT-AWEZNQCLSA-N (3r)-n-(6-bromo-[1,3]thiazolo[4,5-b]pyrazin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=NC=C(Br)N=C2S1 JEIHYUJKPUPKOT-AWEZNQCLSA-N 0.000 description 2
- NEMULYBAMHEKLH-SFHVURJKSA-N (3r)-n-(6-bromoisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=CC2=CC(Br)=CC=C2C=N1 NEMULYBAMHEKLH-SFHVURJKSA-N 0.000 description 2
- FPSWJGVRCHKOKL-IBGZPJMESA-N (3r)-n-(6-chloro-1-methylisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound ClC1=CC=C2C(C)=NC(NC=3O[C@@]4(C5CCN(CC5)C4)CN=3)=CC2=C1 FPSWJGVRCHKOKL-IBGZPJMESA-N 0.000 description 2
- HBWAEIRAJKUWHA-IBGZPJMESA-N (3r)-n-(6-fluoro-1-methylisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound FC1=CC=C2C(C)=NC(NC=3O[C@@]4(C5CCN(CC5)C4)CN=3)=CC2=C1 HBWAEIRAJKUWHA-IBGZPJMESA-N 0.000 description 2
- PYHHMEHCCLGBHQ-INIZCTEOSA-N (3r)-n-(6-fluoro-1h-indazol-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NNC2=CC(F)=CC=C21 PYHHMEHCCLGBHQ-INIZCTEOSA-N 0.000 description 2
- AMXYESZREAWKMZ-AWEZNQCLSA-N (3r)-n-(6-methylsulfanylpyrimidin-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(SC)=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=N1 AMXYESZREAWKMZ-AWEZNQCLSA-N 0.000 description 2
- NTZKNOCUCKBRFH-IBGZPJMESA-N (3r)-n-(6-phenoxypyrimidin-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C([C@]1(C2CCN(CC2)C1)O1)N=C1NC(N=CN=1)=CC=1OC1=CC=CC=C1 NTZKNOCUCKBRFH-IBGZPJMESA-N 0.000 description 2
- PXWGDZJDUOPMGQ-IBGZPJMESA-N (3r)-n-(6-phenylpyridazin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C([C@]1(C2CCN(CC2)C1)O1)N=C1NC(N=N1)=CC=C1C1=CC=CC=C1 PXWGDZJDUOPMGQ-IBGZPJMESA-N 0.000 description 2
- QZJJQKHTYOGWRZ-IBGZPJMESA-N (3r)-n-(6-propan-2-yloxy-1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=CC=C(OC(C)C)C=C2S1 QZJJQKHTYOGWRZ-IBGZPJMESA-N 0.000 description 2
- ZWMSYCZQODVKCI-IBGZPJMESA-N (3r)-n-(7-fluoro-1-methylisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=C(F)C=C2C(C)=NC(NC=3O[C@@]4(C5CCN(CC5)C4)CN=3)=CC2=C1 ZWMSYCZQODVKCI-IBGZPJMESA-N 0.000 description 2
- ILVLLEPFLNGAPI-SFHVURJKSA-N (3r)-n-(7-fluoro-4-methylquinazolin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound FC1=CC=C2C(C)=NC(NC=3O[C@@]4(C5CCN(CC5)C4)CN=3)=NC2=C1 ILVLLEPFLNGAPI-SFHVURJKSA-N 0.000 description 2
- WSHYYBDHEUCZAU-HNNXBMFYSA-N (3r)-n-(7-methoxy-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC(S1)=NC2=C1N=CN=C2OC WSHYYBDHEUCZAU-HNNXBMFYSA-N 0.000 description 2
- XNKKRHBZOMRNQS-HNNXBMFYSA-N (3r)-n-([1,3]oxazolo[4,5-b]pyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]21OC(NC=1OC3=CC=CN=C3N=1)=NC2 XNKKRHBZOMRNQS-HNNXBMFYSA-N 0.000 description 2
- KRKCUYONLACVIN-AWEZNQCLSA-N (3r)-n-([1,3]thiazolo[4,5-b]pyrazin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]21OC(NC=1SC3=NC=CN=C3N=1)=NC2 KRKCUYONLACVIN-AWEZNQCLSA-N 0.000 description 2
- WMHGQZFNZDLVRU-HNNXBMFYSA-N (3r)-n-([1,3]thiazolo[5,4-b]pyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]21OC(NC=1SC3=NC=CC=C3N=1)=NC2 WMHGQZFNZDLVRU-HNNXBMFYSA-N 0.000 description 2
- KLNHHJHDWLLHPR-SFHVURJKSA-N (3r)-n-[4-(1-methylpyrazol-4-yl)pyridin-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NN(C)C=C1C1=CC=NC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=C1 KLNHHJHDWLLHPR-SFHVURJKSA-N 0.000 description 2
- YUEOFWMJRHKWOY-FQEVSTJZSA-N (3r)-n-[4-(2-methoxypyridin-3-yl)pyridin-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound COC1=NC=CC=C1C1=CC=NC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=C1 YUEOFWMJRHKWOY-FQEVSTJZSA-N 0.000 description 2
- SJPVKAKUEWDLOB-FQEVSTJZSA-N (3r)-n-[4-(3-chloro-4-fluorophenyl)pyridin-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=C(Cl)C(F)=CC=C1C1=CC=NC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=C1 SJPVKAKUEWDLOB-FQEVSTJZSA-N 0.000 description 2
- FTZDQURZBJNTLV-IBGZPJMESA-N (3r)-n-[5-(6-methoxypyridin-3-yl)pyrazin-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(OC)=CC=C1C(N=C1)=CN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 FTZDQURZBJNTLV-IBGZPJMESA-N 0.000 description 2
- JDVSSCUYTGNWQT-AWEZNQCLSA-N (3r)-n-[5-(difluoromethoxy)pyrimidin-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound N1=CC(OC(F)F)=CN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 JDVSSCUYTGNWQT-AWEZNQCLSA-N 0.000 description 2
- KXHUDEDKBAKSRV-AWEZNQCLSA-N (3r)-n-[6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(OCC(F)(F)F)=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=N1 KXHUDEDKBAKSRV-AWEZNQCLSA-N 0.000 description 2
- YFJQVJATGSDKAJ-IBGZPJMESA-N (3r)-n-[6-(3-chlorophenyl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound ClC1=CC=CC(C=2N=CN=C(NC=3O[C@@]4(C5CCN(CC5)C4)CN=3)C=2)=C1 YFJQVJATGSDKAJ-IBGZPJMESA-N 0.000 description 2
- KADSBSRLHVMCFL-IBGZPJMESA-N (3r)-n-[6-(3-fluorophenyl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound FC1=CC=CC(C=2N=CN=C(NC=3O[C@@]4(C5CCN(CC5)C4)CN=3)C=2)=C1 KADSBSRLHVMCFL-IBGZPJMESA-N 0.000 description 2
- DRVQSUFHLSUFFZ-IBGZPJMESA-N (3r)-n-[6-(4-fluorophenyl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=CC(F)=CC=C1C1=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=NC=N1 DRVQSUFHLSUFFZ-IBGZPJMESA-N 0.000 description 2
- LETXCYWPGGCZGQ-FQEVSTJZSA-N (3r)-n-[6-(4-methoxyphenyl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=CC(OC)=CC=C1C1=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=NC=N1 LETXCYWPGGCZGQ-FQEVSTJZSA-N 0.000 description 2
- UXOWDLFCRVKBGS-IBGZPJMESA-N (3r)-n-[6-(6-methoxypyridin-3-yl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(OC)=CC=C1C1=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=NC=N1 UXOWDLFCRVKBGS-IBGZPJMESA-N 0.000 description 2
- SNBBXZLFADZUSU-SFHVURJKSA-N (3r)-n-[6-(difluoromethoxy)-1-methylindazol-3-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C12=CC=C(OC(F)F)C=C2N(C)N=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 SNBBXZLFADZUSU-SFHVURJKSA-N 0.000 description 2
- UONKGCZCROZZCD-QMMMGPOBSA-N (3s)-3-(aminomethyl)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@@](CN)(O)CN1CC2 UONKGCZCROZZCD-QMMMGPOBSA-N 0.000 description 2
- VEGLDOGYVHCXAC-UHFFFAOYSA-N 1,1-bis(methylsulfanyl)-n-(3-methyl-1,2,4-thiadiazol-5-yl)methanimine Chemical compound CSC(SC)=NC1=NC(C)=NS1 VEGLDOGYVHCXAC-UHFFFAOYSA-N 0.000 description 2
- ACSARTICULWGBY-UHFFFAOYSA-N 1,1-bis(methylsulfanyl)-n-([1,2,4]triazolo[1,5-a]pyrazin-2-yl)methanimine Chemical compound C1=NC=CN2N=C(N=C(SC)SC)N=C21 ACSARTICULWGBY-UHFFFAOYSA-N 0.000 description 2
- KZGYCTBSZHPCAQ-UHFFFAOYSA-N 1,1-bis(methylsulfanyl)-n-([1,3]thiazolo[5,4-b]pyridin-2-yl)methanimine Chemical compound C1=CN=C2SC(N=C(SC)SC)=NC2=C1 KZGYCTBSZHPCAQ-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- FIBFRSFPAIRFOR-UHFFFAOYSA-N 1-(5-aminopyrazin-2-yl)pyrrolidin-2-one Chemical compound C1=NC(N)=CN=C1N1C(=O)CCC1 FIBFRSFPAIRFOR-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- MFJBJIDWQXSZHR-UHFFFAOYSA-N 2,3-dichloro-6-isothiocyanatopyridine Chemical compound ClC1=CC=C(N=C=S)N=C1Cl MFJBJIDWQXSZHR-UHFFFAOYSA-N 0.000 description 2
- DAMKLTBYCMQBPW-KRWDZBQOSA-N 2,4-dimethyl-6-[[(3r)-spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-yl]amino]pyridine-3-carbonitrile Chemical compound CC1=C(C#N)C(C)=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=N1 DAMKLTBYCMQBPW-KRWDZBQOSA-N 0.000 description 2
- UDLFPPHYXDHXCU-UHFFFAOYSA-N 2-(spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-ylamino)-1,3-benzothiazol-6-ol Chemical compound C1N(CC2)CCC2C1(O1)CN=C1NC1=NC2=CC=C(O)C=C2S1 UDLFPPHYXDHXCU-UHFFFAOYSA-N 0.000 description 2
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- WTSWSBPEZJCSMC-UHFFFAOYSA-N 2-chloro-5-(difluoromethoxy)pyrimidine Chemical compound FC(F)OC1=CN=C(Cl)N=C1 WTSWSBPEZJCSMC-UHFFFAOYSA-N 0.000 description 2
- SXUWYCHACCYVMS-UHFFFAOYSA-N 2-chloro-6-methoxyquinoxaline Chemical compound N1=C(Cl)C=NC2=CC(OC)=CC=C21 SXUWYCHACCYVMS-UHFFFAOYSA-N 0.000 description 2
- DKHLVVSSFRDDKS-UHFFFAOYSA-N 3,5-dichloro-2-isothiocyanatopyridine Chemical compound ClC1=CN=C(N=C=S)C(Cl)=C1 DKHLVVSSFRDDKS-UHFFFAOYSA-N 0.000 description 2
- SONYMVCCNUGPSP-UHFFFAOYSA-N 3-isothiocyanato-5,6-dimethylisoquinoline Chemical compound C1=NC(N=C=S)=CC2=C(C)C(C)=CC=C21 SONYMVCCNUGPSP-UHFFFAOYSA-N 0.000 description 2
- UGMQFWDSELPKKP-UHFFFAOYSA-N 3-isothiocyanatoisoquinoline Chemical compound C1=CC=C2C=NC(N=C=S)=CC2=C1 UGMQFWDSELPKKP-UHFFFAOYSA-N 0.000 description 2
- QOOQUMTZWQEHTR-UHFFFAOYSA-N 4-chloro-6-(methoxymethyl)pyrimidine Chemical compound COCC1=CC(Cl)=NC=N1 QOOQUMTZWQEHTR-UHFFFAOYSA-N 0.000 description 2
- MFDBYMJQLWCZKY-UHFFFAOYSA-N 4-isothiocyanato-6-(2-methoxypyrimidin-5-yl)pyrimidine Chemical compound C1=NC(OC)=NC=C1C1=CC(N=C=S)=NC=N1 MFDBYMJQLWCZKY-UHFFFAOYSA-N 0.000 description 2
- MAMAXQOBZXUYFN-UHFFFAOYSA-N 4-isothiocyanato-6-(methoxymethyl)pyrimidine Chemical compound COCC1=CC(N=C=S)=NC=N1 MAMAXQOBZXUYFN-UHFFFAOYSA-N 0.000 description 2
- OGBVYBGVSBZBLT-UHFFFAOYSA-N 4-isothiocyanato-6-pyridin-3-ylpyrimidine Chemical compound C1=NC(N=C=S)=CC(C=2C=NC=CC=2)=N1 OGBVYBGVSBZBLT-UHFFFAOYSA-N 0.000 description 2
- YTDSLQOPAQVPKD-UHFFFAOYSA-N 5,6-dichloroisoquinolin-3-amine Chemical compound ClC1=CC=C2C=NC(N)=CC2=C1Cl YTDSLQOPAQVPKD-UHFFFAOYSA-N 0.000 description 2
- BZMBSNJUKZMJTQ-UHFFFAOYSA-N 5,6-dimethylisoquinolin-3-amine Chemical compound C1=NC(N)=CC2=C(C)C(C)=CC=C21 BZMBSNJUKZMJTQ-UHFFFAOYSA-N 0.000 description 2
- LWYPLPIJTCQWCF-UHFFFAOYSA-N 5-(difluoromethoxy)-[1,3]thiazolo[5,4-b]pyridin-2-amine Chemical compound C1=C(OC(F)F)N=C2SC(N)=NC2=C1 LWYPLPIJTCQWCF-UHFFFAOYSA-N 0.000 description 2
- GSCRYWWEBZTTBF-UHFFFAOYSA-N 5-bromo-4-propan-2-ylpyrimidin-2-amine Chemical compound CC(C)C1=NC(N)=NC=C1Br GSCRYWWEBZTTBF-UHFFFAOYSA-N 0.000 description 2
- UNAQXMQWXKKBEK-UHFFFAOYSA-N 5-chloro-2-isothiocyanato-4-methylpyridine Chemical compound CC1=CC(N=C=S)=NC=C1Cl UNAQXMQWXKKBEK-UHFFFAOYSA-N 0.000 description 2
- KFKXUFHFJAKEKI-UHFFFAOYSA-N 5-methoxy-[1,3]thiazolo[5,4-d]pyrimidin-2-amine Chemical compound COC1=NC=C2N=C(N)SC2=N1 KFKXUFHFJAKEKI-UHFFFAOYSA-N 0.000 description 2
- XJKJHILCYUUVSJ-UHFFFAOYSA-N 5-methoxypyridin-2-amine Chemical compound COC1=CC=C(N)N=C1 XJKJHILCYUUVSJ-UHFFFAOYSA-N 0.000 description 2
- IPBKLPYWVRTALX-UHFFFAOYSA-N 5-methylsulfanylpyrazin-2-amine Chemical compound CSC1=CN=C(N)C=N1 IPBKLPYWVRTALX-UHFFFAOYSA-N 0.000 description 2
- VZKIMVYWEBBKGS-UHFFFAOYSA-N 5-phenylmethoxy-[1,3]thiazolo[5,4-b]pyridin-2-amine Chemical compound N1=C2SC(N)=NC2=CC=C1OCC1=CC=CC=C1 VZKIMVYWEBBKGS-UHFFFAOYSA-N 0.000 description 2
- BAXUDPKGRMMFBV-UHFFFAOYSA-N 5-phenylpyridin-3-amine Chemical compound NC1=CN=CC(C=2C=CC=CC=2)=C1 BAXUDPKGRMMFBV-UHFFFAOYSA-N 0.000 description 2
- SJGNIZFAJDLNQE-UHFFFAOYSA-N 5-pyridin-3-ylpyrazin-2-amine Chemical compound C1=NC(N)=CN=C1C1=CC=CN=C1 SJGNIZFAJDLNQE-UHFFFAOYSA-N 0.000 description 2
- SVFTZRIJBQMZKB-UHFFFAOYSA-N 6,7-dichloroisoquinolin-3-amine Chemical compound ClC1=C(Cl)C=C2C=NC(N)=CC2=C1 SVFTZRIJBQMZKB-UHFFFAOYSA-N 0.000 description 2
- DUXFKMMRXQOFRJ-UHFFFAOYSA-N 6,7-dimethylisoquinolin-3-amine Chemical compound N1=C(N)C=C2C=C(C)C(C)=CC2=C1 DUXFKMMRXQOFRJ-UHFFFAOYSA-N 0.000 description 2
- DZTSGWULIRGYOJ-UHFFFAOYSA-N 6,8-dichloro-3-isothiocyanatoisoquinoline Chemical compound C1=NC(N=C=S)=CC2=CC(Cl)=CC(Cl)=C21 DZTSGWULIRGYOJ-UHFFFAOYSA-N 0.000 description 2
- JMRHKUHTNHRFON-UHFFFAOYSA-N 6,8-dichloroisoquinolin-3-amine Chemical compound ClC1=CC(Cl)=C2C=NC(N)=CC2=C1 JMRHKUHTNHRFON-UHFFFAOYSA-N 0.000 description 2
- ZYQBVXRVGUVSCW-UHFFFAOYSA-N 6-(3-chlorophenyl)pyrimidin-4-amine Chemical compound C1=NC(N)=CC(C=2C=C(Cl)C=CC=2)=N1 ZYQBVXRVGUVSCW-UHFFFAOYSA-N 0.000 description 2
- TUABPDBZFQJDHM-UHFFFAOYSA-N 6-(3-methoxyphenyl)pyrimidin-4-amine Chemical compound COC1=CC=CC(C=2N=CN=C(N)C=2)=C1 TUABPDBZFQJDHM-UHFFFAOYSA-N 0.000 description 2
- PUXOOQNLQPZQFB-UHFFFAOYSA-N 6-(difluoromethoxy)-1,3-benzothiazol-2-amine Chemical compound C1=C(OC(F)F)C=C2SC(N)=NC2=C1 PUXOOQNLQPZQFB-UHFFFAOYSA-N 0.000 description 2
- TUWLYFAEAPMOJS-UHFFFAOYSA-N 6-(methoxymethyl)-1h-pyrimidin-4-one Chemical compound COCC1=CC(O)=NC=N1 TUWLYFAEAPMOJS-UHFFFAOYSA-N 0.000 description 2
- BKLJUYPLUWUEOQ-UHFFFAOYSA-N 6-bromopyridin-2-amine Chemical compound NC1=CC=CC(Br)=N1 BKLJUYPLUWUEOQ-UHFFFAOYSA-N 0.000 description 2
- JKOGFRGFWFEFNT-UHFFFAOYSA-N 6-fluoro-1h-indazol-3-amine Chemical compound FC1=CC=C2C(N)=NNC2=C1 JKOGFRGFWFEFNT-UHFFFAOYSA-N 0.000 description 2
- HIZUIPJBTXPNHO-UHFFFAOYSA-N 6-methyl-1,3-benzoxazol-2-amine Chemical compound CC1=CC=C2N=C(N)OC2=C1 HIZUIPJBTXPNHO-UHFFFAOYSA-N 0.000 description 2
- VZXLYMCMLMJTEI-UHFFFAOYSA-N 6-phenoxypyrimidin-4-amine Chemical compound C1=NC(N)=CC(OC=2C=CC=CC=2)=N1 VZXLYMCMLMJTEI-UHFFFAOYSA-N 0.000 description 2
- FBTKUAFGTDENLW-UHFFFAOYSA-N 7-bromoisoquinolin-3-amine Chemical compound C1=C(Br)C=C2C=NC(N)=CC2=C1 FBTKUAFGTDENLW-UHFFFAOYSA-N 0.000 description 2
- HBKLPXAQXMBLKA-UHFFFAOYSA-N 7-ethyl-5-n,5-n-dimethyl-[1,3]thiazolo[5,4-d]pyrimidine-2,5-diamine Chemical compound CCC1=NC(N(C)C)=NC2=C1N=C(N)S2 HBKLPXAQXMBLKA-UHFFFAOYSA-N 0.000 description 2
- CUOUUOGXWPOSHD-UHFFFAOYSA-N 7-methoxy-5-methyl-[1,3]thiazolo[5,4-d]pyrimidin-2-amine Chemical compound COC1=NC(C)=NC2=C1N=C(N)S2 CUOUUOGXWPOSHD-UHFFFAOYSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 2
- 101150049660 DRD2 gene Proteins 0.000 description 2
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- NCZQAIFOXJOCFI-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]pyridin-3-amine Chemical compound C1=CC=CN2C(N)=NN=C21 NCZQAIFOXJOCFI-UHFFFAOYSA-N 0.000 description 2
- AVSYPWBWFBPSEU-UHFFFAOYSA-N [1,3]oxazolo[4,5-b]pyridin-2-amine Chemical compound C1=CC=C2OC(N)=NC2=N1 AVSYPWBWFBPSEU-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical group [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- VVFKWBPGTKRJDO-UHFFFAOYSA-N ethyl n-(7-chloro-5-methyl-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)carbamate Chemical compound N1=C(C)N=C2SC(NC(=O)OCC)=NC2=C1Cl VVFKWBPGTKRJDO-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- IWMQAUYDCYPLFK-UHFFFAOYSA-N furo[3,2-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1C=CO2 IWMQAUYDCYPLFK-UHFFFAOYSA-N 0.000 description 2
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000005241 heteroarylamino group Chemical group 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- VYCKDIRCVDCQAE-UHFFFAOYSA-N isoquinolin-3-amine Chemical group C1=CC=C2C=NC(N)=CC2=C1 VYCKDIRCVDCQAE-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000350 mc(t) Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- PSQGPXUZFGQICZ-UHFFFAOYSA-N n'-[(2,4-dichlorophenyl)methyl]-2,2-diethoxyethanimidamide Chemical compound CCOC(OCC)C(=N)NCC1=CC=C(Cl)C=C1Cl PSQGPXUZFGQICZ-UHFFFAOYSA-N 0.000 description 2
- MWGISGHYSNLOIO-UHFFFAOYSA-N n'-[(3,4-dichlorophenyl)methyl]-2,2-diethoxyethanimidamide Chemical compound CCOC(OCC)C(=N)NCC1=CC=C(Cl)C(Cl)=C1 MWGISGHYSNLOIO-UHFFFAOYSA-N 0.000 description 2
- AUXMOQFCKHGVDD-UHFFFAOYSA-N n'-[(3-chloro-2-fluorophenyl)methyl]-2,2-diethoxyethanimidamide Chemical compound CCOC(OCC)C(=N)NCC1=CC=CC(Cl)=C1F AUXMOQFCKHGVDD-UHFFFAOYSA-N 0.000 description 2
- PEVWFQQFUKFJFK-UHFFFAOYSA-N n-(1,3-benzoxazol-2-yl)-1,1-bis(methylsulfanyl)methanimine Chemical compound C1=CC=C2OC(N=C(SC)SC)=NC2=C1 PEVWFQQFUKFJFK-UHFFFAOYSA-N 0.000 description 2
- XMJSRIGSOQCHNI-UHFFFAOYSA-N n-(1,3-thiazol-2-yl)imidazole-1-carbothioamide Chemical compound C1=CN=CN1C(=S)NC1=NC=CS1 XMJSRIGSOQCHNI-UHFFFAOYSA-N 0.000 description 2
- YKBNMVULSUSZJK-UHFFFAOYSA-N n-(1,3-thiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound O1C2(C3CCN(CC3)C2)CN=C1NC1=NC=CS1 YKBNMVULSUSZJK-UHFFFAOYSA-N 0.000 description 2
- FPSMMDVUWCGKIR-UHFFFAOYSA-N n-(1-methylbenzimidazol-2-yl)imidazole-1-carbothioamide Chemical compound N=1C2=CC=CC=C2N(C)C=1NC(=S)N1C=CN=C1 FPSMMDVUWCGKIR-UHFFFAOYSA-N 0.000 description 2
- NYKOHJDWRQIEQZ-UHFFFAOYSA-N n-(3-methyl-1,2,4-oxadiazol-5-yl)-1,1-bis(methylsulfanyl)methanimine Chemical compound CSC(SC)=NC1=NC(C)=NO1 NYKOHJDWRQIEQZ-UHFFFAOYSA-N 0.000 description 2
- KYEKKLZQGRIPLQ-UHFFFAOYSA-N n-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)imidazole-1-carbothioamide Chemical compound N=1C=2CCCCC=2SC=1NC(=S)N1C=CN=C1 KYEKKLZQGRIPLQ-UHFFFAOYSA-N 0.000 description 2
- MDSDFKBIYXYXNF-UHFFFAOYSA-N n-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2C21OC(NC=1SC=3CCCCC=3N=1)=NC2 MDSDFKBIYXYXNF-UHFFFAOYSA-N 0.000 description 2
- NBUYLEPFONRQCZ-UHFFFAOYSA-N n-(5-phenyl-1,3-thiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound O1C2(C3CCN(CC3)C2)CN=C1NC(S1)=NC=C1C1=CC=CC=C1 NBUYLEPFONRQCZ-UHFFFAOYSA-N 0.000 description 2
- URWMDWYEUVQFRS-UHFFFAOYSA-N n-(6-bromo-[1,3]thiazolo[4,5-b]pyrazin-2-yl)-1,1-bis(methylsulfanyl)methanimine Chemical compound C1=C(Br)N=C2SC(N=C(SC)SC)=NC2=N1 URWMDWYEUVQFRS-UHFFFAOYSA-N 0.000 description 2
- RYFJHYNEJKFKIE-UHFFFAOYSA-N n-(6-ethoxy-1,3-benzothiazol-2-yl)imidazole-1-carbothioamide Chemical compound S1C2=CC(OCC)=CC=C2N=C1NC(=S)N1C=CN=C1 RYFJHYNEJKFKIE-UHFFFAOYSA-N 0.000 description 2
- DYYIGENAVULQMH-UHFFFAOYSA-N n-(6-ethoxy-1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2C1(O1)CN=C1NC1=NC2=CC=C(OCC)C=C2S1 DYYIGENAVULQMH-UHFFFAOYSA-N 0.000 description 2
- FQXJYXQXFVMXOQ-UHFFFAOYSA-N n-(6-methoxy-1,3-benzothiazol-2-yl)imidazole-1-carbothioamide Chemical compound S1C2=CC(OC)=CC=C2N=C1NC(=S)N1C=CN=C1 FQXJYXQXFVMXOQ-UHFFFAOYSA-N 0.000 description 2
- BQYBQCMZQMTBFU-UHFFFAOYSA-N n-(6-methyl-1,3-benzoxazol-2-yl)-1,1-bis(methylsulfanyl)methanimine Chemical compound C1=C(C)C=C2OC(N=C(SC)SC)=NC2=C1 BQYBQCMZQMTBFU-UHFFFAOYSA-N 0.000 description 2
- PRRHVBDGWWFSRJ-SFHVURJKSA-N n-[2-[[(3r)-spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-yl]amino]-1,3-benzothiazol-6-yl]acetamide Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=CC=C(NC(=O)C)C=C2S1 PRRHVBDGWWFSRJ-SFHVURJKSA-N 0.000 description 2
- XXIXRNVGOZQCDX-UHFFFAOYSA-N n-[5-(difluoromethoxy)-[1,3]thiazolo[5,4-b]pyridin-2-yl]imidazole-1-carbothioamide Chemical compound S1C2=NC(OC(F)F)=CC=C2N=C1NC(=S)N1C=CN=C1 XXIXRNVGOZQCDX-UHFFFAOYSA-N 0.000 description 2
- YBDKBVGKMUKXGV-UHFFFAOYSA-N n-[6-(difluoromethoxy)-1,3-benzothiazol-2-yl]imidazole-1-carbothioamide Chemical compound S1C2=CC(OC(F)F)=CC=C2N=C1NC(=S)N1C=CN=C1 YBDKBVGKMUKXGV-UHFFFAOYSA-N 0.000 description 2
- KYMBMYMZVKUDDV-UHFFFAOYSA-N n-[6-[tert-butyl(dimethyl)silyl]oxy-1,3-benzothiazol-2-yl]imidazole-1-carbothioamide Chemical compound S1C2=CC(O[Si](C)(C)C(C)(C)C)=CC=C2N=C1NC(=S)N1C=CN=C1 KYMBMYMZVKUDDV-UHFFFAOYSA-N 0.000 description 2
- NWOGQPOGFKBIMN-UHFFFAOYSA-N n-pyridin-2-ylspiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound O1C2(C3CCN(CC3)C2)CN=C1NC1=CC=CC=N1 NWOGQPOGFKBIMN-UHFFFAOYSA-N 0.000 description 2
- KEEAZYDQOLFVOL-UHFFFAOYSA-N n-pyridin-3-ylspiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound O1C2(C3CCN(CC3)C2)CN\C1=N/C1=CC=CN=C1 KEEAZYDQOLFVOL-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 1
- QGCLEUGNYRXBMZ-LURJTMIESA-N (1s)-1-(4-fluorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(F)C=C1 QGCLEUGNYRXBMZ-LURJTMIESA-N 0.000 description 1
- GBSUVYGVEQDZPG-UHFFFAOYSA-N (2,4-dimethylphenyl)methanamine Chemical compound CC1=CC=C(CN)C(C)=C1 GBSUVYGVEQDZPG-UHFFFAOYSA-N 0.000 description 1
- GDFBHCMFIUBEQT-UHFFFAOYSA-N (2,5-difluorophenyl)methanamine Chemical compound NCC1=CC(F)=CC=C1F GDFBHCMFIUBEQT-UHFFFAOYSA-N 0.000 description 1
- YUHZIUAREWNXJT-UHFFFAOYSA-N (2-fluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=CN=C1F YUHZIUAREWNXJT-UHFFFAOYSA-N 0.000 description 1
- NVOLYUXUHWBCRJ-UHFFFAOYSA-N (2-methoxypyridin-3-yl)boronic acid Chemical compound COC1=NC=CC=C1B(O)O NVOLYUXUHWBCRJ-UHFFFAOYSA-N 0.000 description 1
- YPWAJLGHACDYQS-UHFFFAOYSA-N (2-methoxypyrimidin-5-yl)boronic acid Chemical compound COC1=NC=C(B(O)O)C=N1 YPWAJLGHACDYQS-UHFFFAOYSA-N 0.000 description 1
- PHLZUDXEBCQHKM-UHFFFAOYSA-N (3,4-difluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C(F)=C1 PHLZUDXEBCQHKM-UHFFFAOYSA-N 0.000 description 1
- VJNGGOMRUHYAMC-UHFFFAOYSA-N (3,5-difluorophenyl)methanamine Chemical compound NCC1=CC(F)=CC(F)=C1 VJNGGOMRUHYAMC-UHFFFAOYSA-N 0.000 description 1
- WJDZZXIDQYKVDG-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(Cl)=C1 WJDZZXIDQYKVDG-UHFFFAOYSA-N 0.000 description 1
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 1
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 1
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
- BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 1
- YKBNMVULSUSZJK-LBPRGKRZSA-N (3r)-n-(1,3-thiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C([C@]1(C2CCN(CC2)C1)O1)N=C1NC1=NC=CS1 YKBNMVULSUSZJK-LBPRGKRZSA-N 0.000 description 1
- DUOHVBDGULEPGZ-HNNXBMFYSA-N (3r)-n-(3,5-dichloro-6-methylpyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=C(Cl)C(C)=NC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=C1Cl DUOHVBDGULEPGZ-HNNXBMFYSA-N 0.000 description 1
- FKMFBGHZRUFUCP-HNNXBMFYSA-N (3r)-n-(4,5-dimethylpyrimidin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound N1=C(C)C(C)=CN=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 FKMFBGHZRUFUCP-HNNXBMFYSA-N 0.000 description 1
- OMNHZKWWQQBAMJ-INIZCTEOSA-N (3r)-n-(4-chloro-1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical group C1N(CC2)CCC2[C@]1(O1)CN=C1NC(S1)=NC2=C1C=CC=C2Cl OMNHZKWWQQBAMJ-INIZCTEOSA-N 0.000 description 1
- ACPANOGYMXHNOW-SFHVURJKSA-N (3r)-n-(4-chloroisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound N1=CC2=CC=CC=C2C(Cl)=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 ACPANOGYMXHNOW-SFHVURJKSA-N 0.000 description 1
- PHBGLPXGVKDHGS-SFHVURJKSA-N (3r)-n-(5,6-dichloroisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=CC2=C(Cl)C(Cl)=CC=C2C=N1 PHBGLPXGVKDHGS-SFHVURJKSA-N 0.000 description 1
- DEYGCGDLLXYRRT-IBGZPJMESA-N (3r)-n-(5,7-difluoro-1-methylisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=C(F)C=C2C(C)=NC(NC=3O[C@@]4(C5CCN(CC5)C4)CN=3)=CC2=C1F DEYGCGDLLXYRRT-IBGZPJMESA-N 0.000 description 1
- AKERCGDVAZEUON-HNNXBMFYSA-N (3r)-n-(5-chloro-4-methylpyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=C(Cl)C(C)=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=N1 AKERCGDVAZEUON-HNNXBMFYSA-N 0.000 description 1
- NLSADPPBWBUTDK-HNNXBMFYSA-N (3r)-n-(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=CC=C(Cl)N=C2S1 NLSADPPBWBUTDK-HNNXBMFYSA-N 0.000 description 1
- FTBWMNKCUZZEKB-FQEVSTJZSA-N (3r)-n-(5-phenylpyridin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C([C@]1(C2CCN(CC2)C1)O1)N=C1NC(C=1)=CN=CC=1C1=CC=CC=C1 FTBWMNKCUZZEKB-FQEVSTJZSA-N 0.000 description 1
- WWUOFOFWXPDGMJ-FQEVSTJZSA-N (3r)-n-(6,7-dimethylisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC=C2C=C(C)C(C)=CC2=C1 WWUOFOFWXPDGMJ-FQEVSTJZSA-N 0.000 description 1
- SPSBIAARVKFBRI-ZDUSSCGKSA-N (3r)-n-(6-bromopyridazin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound N1=NC(Br)=CC=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 SPSBIAARVKFBRI-ZDUSSCGKSA-N 0.000 description 1
- LENPKGRPSYLBFA-ZDUSSCGKSA-N (3r)-n-(6-chloropyridazin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound N1=NC(Cl)=CC=C1NC(O1)=NC[C@]11C(CC2)CCN2C1 LENPKGRPSYLBFA-ZDUSSCGKSA-N 0.000 description 1
- ARRIQLFAOHIHOY-INIZCTEOSA-N (3r)-n-(6-methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NN(C=C(OC)C=C2)C2=N1 ARRIQLFAOHIHOY-INIZCTEOSA-N 0.000 description 1
- CZLTXTIEEPGFOS-SFHVURJKSA-N (3r)-n-(6-methoxyquinoxalin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=CC=C(OC)C=C2N=C1 CZLTXTIEEPGFOS-SFHVURJKSA-N 0.000 description 1
- FXFYVPHOZHMBSI-KRWDZBQOSA-N (3r)-n-(6-methyl-1,3-benzoxazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=CC=C(C)C=C2O1 FXFYVPHOZHMBSI-KRWDZBQOSA-N 0.000 description 1
- FUAGQZJUHOGUOV-HNNXBMFYSA-N (3r)-n-(6-methylsulfanyl-[1,3]thiazolo[4,5-b]pyrazin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=NC=C(SC)N=C2S1 FUAGQZJUHOGUOV-HNNXBMFYSA-N 0.000 description 1
- BTWBGYYGCASTRI-QHCPKHFHSA-N (3r)-n-(6-naphthalen-2-ylpyrimidin-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]21OC(NC=1N=CN=C(C=1)C=1C=C3C=CC=CC3=CC=1)=NC2 BTWBGYYGCASTRI-QHCPKHFHSA-N 0.000 description 1
- WVNOFRZQUMORMI-IBGZPJMESA-N (3r)-n-(6-phenylpyrimidin-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C([C@]1(C2CCN(CC2)C1)O1)N=C1NC(N=CN=1)=CC=1C1=CC=CC=C1 WVNOFRZQUMORMI-IBGZPJMESA-N 0.000 description 1
- CUYGGCHVFXFFEU-KRWDZBQOSA-N (3r)-n-(6-pyrazin-2-ylpyrimidin-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C([C@]1(C2CCN(CC2)C1)O1)N=C1NC(N=CN=1)=CC=1C1=CN=CC=N1 CUYGGCHVFXFFEU-KRWDZBQOSA-N 0.000 description 1
- RUXRPJZJWBNJMF-SFHVURJKSA-N (3r)-n-(7-bromoisoquinolin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=CC2=CC=C(Br)C=C2C=N1 RUXRPJZJWBNJMF-SFHVURJKSA-N 0.000 description 1
- BFUZOQOYXKRRCU-SFHVURJKSA-N (3r)-n-(7-methoxyquinoxalin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC2=CC(OC)=CC=C2N=C1 BFUZOQOYXKRRCU-SFHVURJKSA-N 0.000 description 1
- ZLQWMWSYBIACCC-AWEZNQCLSA-N (3r)-n-([1,2,4]triazolo[1,5-a]pyrazin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]21OC(NC1=NN3C=CN=CC3=N1)=NC2 ZLQWMWSYBIACCC-AWEZNQCLSA-N 0.000 description 1
- LVWWSYBLTZWGDR-HNNXBMFYSA-N (3r)-n-([1,2,4]triazolo[4,3-a]pyridin-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]21OC(NC=1N3C=CC=CC3=NN=1)=NC2 LVWWSYBLTZWGDR-HNNXBMFYSA-N 0.000 description 1
- WWKKBRJCWMRNIZ-IBGZPJMESA-N (3r)-n-[4-(5-chloropyridin-3-yl)pyridin-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound ClC1=CN=CC(C=2C=C(NC=3O[C@@]4(C5CCN(CC5)C4)CN=3)N=CC=2)=C1 WWKKBRJCWMRNIZ-IBGZPJMESA-N 0.000 description 1
- NWECLLFAHQFRJU-IBGZPJMESA-N (3r)-n-[4-(6-fluoropyridin-3-yl)pyridin-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(F)=CC=C1C1=CC=NC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=C1 NWECLLFAHQFRJU-IBGZPJMESA-N 0.000 description 1
- XNOFNZNLGWGNPD-FQEVSTJZSA-N (3r)-n-[4-(6-methoxypyridin-3-yl)pyridin-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(OC)=CC=C1C1=CC=NC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=C1 XNOFNZNLGWGNPD-FQEVSTJZSA-N 0.000 description 1
- MZAIGRWVEVWXNO-HNNXBMFYSA-N (3r)-n-[6-(2,2-difluoroethoxy)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(OCC(F)F)=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=N1 MZAIGRWVEVWXNO-HNNXBMFYSA-N 0.000 description 1
- MFUDIUSJUANNQX-SFHVURJKSA-N (3r)-n-[6-(2-fluoropyridin-3-yl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound FC1=NC=CC=C1C1=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=NC=N1 MFUDIUSJUANNQX-SFHVURJKSA-N 0.000 description 1
- OHJILIYZJFKVAK-SFHVURJKSA-N (3r)-n-[6-(2-methoxypyrimidin-5-yl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(OC)=NC=C1C1=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=NC=N1 OHJILIYZJFKVAK-SFHVURJKSA-N 0.000 description 1
- YRUHTHITBLSWBC-KRWDZBQOSA-N (3r)-n-[6-(2-methylpyrazol-3-yl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound CN1N=CC=C1C1=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=NC=N1 YRUHTHITBLSWBC-KRWDZBQOSA-N 0.000 description 1
- WZQFQYUVIUGQRH-FQEVSTJZSA-N (3r)-n-[6-(3-methoxyphenyl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound COC1=CC=CC(C=2N=CN=C(NC=3O[C@@]4(C5CCN(CC5)C4)CN=3)C=2)=C1 WZQFQYUVIUGQRH-FQEVSTJZSA-N 0.000 description 1
- OKRKJTZZVNOCII-IBGZPJMESA-N (3r)-n-[6-(4-chlorophenyl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=CC(Cl)=CC=C1C1=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=NC=N1 OKRKJTZZVNOCII-IBGZPJMESA-N 0.000 description 1
- ZTYPYTZZYJOTEH-SFHVURJKSA-N (3r)-n-[6-(5-fluoropyridin-3-yl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound FC1=CN=CC(C=2N=CN=C(NC=3O[C@@]4(C5CCN(CC5)C4)CN=3)C=2)=C1 ZTYPYTZZYJOTEH-SFHVURJKSA-N 0.000 description 1
- WNVREXPUEHKKAT-SFHVURJKSA-N (3r)-n-[6-(6-fluoropyridin-3-yl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(F)=CC=C1C1=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=NC=N1 WNVREXPUEHKKAT-SFHVURJKSA-N 0.000 description 1
- VBEVNLXGJACWIE-HNNXBMFYSA-N (3r)-n-[6-(methoxymethyl)pyrimidin-4-yl]spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1=NC(COC)=CC(NC=2O[C@@]3(C4CCN(CC4)C3)CN=2)=N1 VBEVNLXGJACWIE-HNNXBMFYSA-N 0.000 description 1
- IMMCHFLTBDORJH-INIZCTEOSA-N (3r)-n-furo[3,2-c]pyridin-4-ylspiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]21OC(NC=1C=3C=COC=3C=CN=1)=NC2 IMMCHFLTBDORJH-INIZCTEOSA-N 0.000 description 1
- ZDTPXUKLGIDOCS-SFHVURJKSA-N (3r)-n-isoquinolin-3-ylspiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@]21OC(NC=1N=CC3=CC=CC=C3C=1)=NC2 ZDTPXUKLGIDOCS-SFHVURJKSA-N 0.000 description 1
- VUSUESCSIUWQMT-MRXNPFEDSA-N (3s)-n-(1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@@]21OC(NC=1SC3=CC=CC=C3N=1)=NC2 VUSUESCSIUWQMT-MRXNPFEDSA-N 0.000 description 1
- YKBNMVULSUSZJK-GFCCVEGCSA-N (3s)-n-(1,3-thiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C([C@@]1(C2CCN(CC2)C1)O1)N=C1NC1=NC=CS1 YKBNMVULSUSZJK-GFCCVEGCSA-N 0.000 description 1
- MDSDFKBIYXYXNF-MRXNPFEDSA-N (3s)-n-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@@]21OC(NC=1SC=3CCCCC=3N=1)=NC2 MDSDFKBIYXYXNF-MRXNPFEDSA-N 0.000 description 1
- OMNHZKWWQQBAMJ-MRXNPFEDSA-N (3s)-n-(4-chloro-1,3-benzothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound C1N(CC2)CCC2[C@@]1(O1)CN=C1NC(S1)=NC2=C1C=CC=C2Cl OMNHZKWWQQBAMJ-MRXNPFEDSA-N 0.000 description 1
- LUMIIFRRDJKEKE-OAHLLOKOSA-N (3s)-n-(4-propan-2-yl-1,3-thiazol-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound CC(C)C1=CSC(NC=2O[C@]3(C4CCN(CC4)C3)CN=2)=N1 LUMIIFRRDJKEKE-OAHLLOKOSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- HMTSWYPNXFHGEP-UHFFFAOYSA-N (4-methylphenyl)methanamine Chemical compound CC1=CC=C(CN)C=C1 HMTSWYPNXFHGEP-UHFFFAOYSA-N 0.000 description 1
- NJXYBTMCTZAUEE-UHFFFAOYSA-N (5-chloropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CN=CC(Cl)=C1 NJXYBTMCTZAUEE-UHFFFAOYSA-N 0.000 description 1
- FVEDGBRHTGXPOK-UHFFFAOYSA-N (5-fluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CN=CC(F)=C1 FVEDGBRHTGXPOK-UHFFFAOYSA-N 0.000 description 1
- HOLROQIWWMVXRR-CQSZACIVSA-N (5R)-3-(6-bromo-[1,3]thiazolo[4,5-b]pyrazin-2-yl)spiro[1,3-oxazolidine-5,3'-1-azabicyclo[2.2.2]octane] Chemical compound BrC1=CN=C2C(=N1)SC(=N2)N1CO[C@]2(CN3CCC2CC3)C1 HOLROQIWWMVXRR-CQSZACIVSA-N 0.000 description 1
- OJBYZWHAPXIJID-UHFFFAOYSA-N (6-fluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=C(F)N=C1 OJBYZWHAPXIJID-UHFFFAOYSA-N 0.000 description 1
- DHADXDMPEUWEAS-UHFFFAOYSA-N (6-methoxypyridin-3-yl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=N1 DHADXDMPEUWEAS-UHFFFAOYSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- NTVOVQVGWVDQKA-UHFFFAOYSA-N 1,1-bis(methylsulfanyl)-n-([1,2,4]triazolo[4,3-a]pyridin-3-yl)methanimine Chemical compound C1=CC=CN2C(N=C(SC)SC)=NN=C21 NTVOVQVGWVDQKA-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- FNLYFJIEFIZBFC-UHFFFAOYSA-N 1,6-naphthyridin-2-amine Chemical compound C1=NC=CC2=NC(N)=CC=C21 FNLYFJIEFIZBFC-UHFFFAOYSA-N 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- XTIXPIMMHGCRJD-UHFFFAOYSA-N 1-(3,5-difluorophenyl)ethanamine Chemical compound CC(N)C1=CC(F)=CC(F)=C1 XTIXPIMMHGCRJD-UHFFFAOYSA-N 0.000 description 1
- ASNVMKIDRJZXQZ-UHFFFAOYSA-N 1-(3-fluorophenyl)ethanamine Chemical compound CC(N)C1=CC=CC(F)=C1 ASNVMKIDRJZXQZ-UHFFFAOYSA-N 0.000 description 1
- PINPOEWMCLFRRB-UHFFFAOYSA-N 1-(4-chlorophenyl)ethanamine Chemical compound CC(N)C1=CC=C(Cl)C=C1 PINPOEWMCLFRRB-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ACJRDZFAGYZZNF-IBGZPJMESA-N 1-[[(3s)-3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl]methyl]-3-(6-methylisoquinolin-3-yl)thiourea Chemical compound C1N(CC2)CCC2[C@]1(O)CNC(=S)NC1=CC2=CC(C)=CC=C2C=N1 ACJRDZFAGYZZNF-IBGZPJMESA-N 0.000 description 1
- IGNPOXGBNFMJHE-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-2-amine Chemical compound C1CN2C(N)CC1CC2 IGNPOXGBNFMJHE-UHFFFAOYSA-N 0.000 description 1
- ZKMZPXWMMSBLNO-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2C(=O)CN1CC2 ZKMZPXWMMSBLNO-UHFFFAOYSA-N 0.000 description 1
- NLSCFLSNWRVGLP-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-ylmethanamine Chemical compound C1CC2C(CN)CN1CC2 NLSCFLSNWRVGLP-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- KGAKGNOATALEJF-UHFFFAOYSA-N 1-methyl-1,3-benzothiazol-1-ium-2-amine Chemical compound C[S+]1C(N)=Nc2ccccc12 KGAKGNOATALEJF-UHFFFAOYSA-N 0.000 description 1
- HLXOVAMYQUFLPE-UHFFFAOYSA-N 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CN1N=CC=C1B1OC(C)(C)C(C)(C)O1 HLXOVAMYQUFLPE-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- VYDQUABHDFWIIX-UHFFFAOYSA-N 2,2-difluoro-2-fluorosulfonylacetic acid Chemical compound OC(=O)C(F)(F)S(F)(=O)=O VYDQUABHDFWIIX-UHFFFAOYSA-N 0.000 description 1
- ALUQMCBDQKDRAK-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1,3-benzothiazole Chemical compound C1C=CC=C2SCNC21 ALUQMCBDQKDRAK-UHFFFAOYSA-N 0.000 description 1
- ZTHHRSBDBPCCMZ-UHFFFAOYSA-N 2,4-dichloro-5-methoxypyrimidine Chemical compound COC1=CN=C(Cl)N=C1Cl ZTHHRSBDBPCCMZ-UHFFFAOYSA-N 0.000 description 1
- RINHVELYMZLXIW-UHFFFAOYSA-N 2,4-dichloropyrimidin-5-amine Chemical compound NC1=CN=C(Cl)N=C1Cl RINHVELYMZLXIW-UHFFFAOYSA-N 0.000 description 1
- LJFDXXUKKMEQKE-UHFFFAOYSA-N 2,4-difluorobenzonitrile Chemical compound FC1=CC=C(C#N)C(F)=C1 LJFDXXUKKMEQKE-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- HMAATCOHUYHORT-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-benzothiazole-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2SC(NC(=O)OC(C)(C)C)=NC2=C1 HMAATCOHUYHORT-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VEAWPMXEROMSKF-HNNXBMFYSA-N 2-[[(3r)-spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-yl]amino]-4h-[1,3]thiazolo[5,4-b]pyridin-5-one Chemical compound C1N(CC2)CCC2[C@]1(O1)CN=C1NC1=NC(C=CC(N2)=O)=C2S1 VEAWPMXEROMSKF-HNNXBMFYSA-N 0.000 description 1
- UDLFPPHYXDHXCU-MRXNPFEDSA-N 2-[[(3s)-spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-yl]amino]-1,3-benzothiazol-6-ol Chemical compound C1N(CC2)CCC2[C@@]1(O1)CN=C1NC1=NC2=CC=C(O)C=C2S1 UDLFPPHYXDHXCU-MRXNPFEDSA-N 0.000 description 1
- YJTBHWXNEMGNDC-UHFFFAOYSA-N 2-amino-1,3-thiazole-5-carbonitrile Chemical compound NC1=NC=C(C#N)S1 YJTBHWXNEMGNDC-UHFFFAOYSA-N 0.000 description 1
- HCPJEHJGFKWRFM-UHFFFAOYSA-N 2-amino-5-methylphenol Chemical compound CC1=CC=C(N)C(O)=C1 HCPJEHJGFKWRFM-UHFFFAOYSA-N 0.000 description 1
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 1
- UHGULLIUJBCTEF-UHFFFAOYSA-N 2-aminobenzothiazole Chemical compound C1=CC=C2SC(N)=NC2=C1 UHGULLIUJBCTEF-UHFFFAOYSA-N 0.000 description 1
- BMTSZVZQNMNPCT-UHFFFAOYSA-N 2-aminopyridin-3-ol Chemical compound NC1=NC=CC=C1O BMTSZVZQNMNPCT-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- AOZNIFQUCUSYLD-UHFFFAOYSA-N 2-chloro-4-propan-2-ylpyrimidine Chemical compound CC(C)C1=CC=NC(Cl)=N1 AOZNIFQUCUSYLD-UHFFFAOYSA-N 0.000 description 1
- AGYUQBNABXVWMS-UHFFFAOYSA-N 2-chloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1 AGYUQBNABXVWMS-UHFFFAOYSA-N 0.000 description 1
- BOGPIHXNWPTGNH-UHFFFAOYSA-N 2-chloropyrimidin-5-ol Chemical compound OC1=CN=C(Cl)N=C1 BOGPIHXNWPTGNH-UHFFFAOYSA-N 0.000 description 1
- ZKSRQMCKFLGPQU-UHFFFAOYSA-N 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(F)N=C1 ZKSRQMCKFLGPQU-UHFFFAOYSA-N 0.000 description 1
- MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 description 1
- UCMJVPUVABQMFV-UHFFFAOYSA-N 2-isothiocyanato-4-(2-methoxypyridin-3-yl)pyridine Chemical compound COC1=NC=CC=C1C1=CC=NC(N=C=S)=C1 UCMJVPUVABQMFV-UHFFFAOYSA-N 0.000 description 1
- CMKGLMUSTXZJBU-UHFFFAOYSA-N 2-isothiocyanato-6-methoxy-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=C(OC)C=CC2=NC(N=C=S)=NN21 CMKGLMUSTXZJBU-UHFFFAOYSA-N 0.000 description 1
- ZZQSEVQIMITDMU-UHFFFAOYSA-N 2-isothiocyanato-6-methylquinoxaline Chemical compound N1=C(N=C=S)C=NC2=CC(C)=CC=C21 ZZQSEVQIMITDMU-UHFFFAOYSA-N 0.000 description 1
- KBFBGQUDRKPWIP-UHFFFAOYSA-N 2-isothiocyanato-7-methoxyquinoxaline Chemical compound N1=CC(N=C=S)=NC2=CC(OC)=CC=C21 KBFBGQUDRKPWIP-UHFFFAOYSA-N 0.000 description 1
- XUDBPGPIBCBAAW-UHFFFAOYSA-N 2-isothiocyanato-7-methylquinoxaline Chemical compound N1=CC(N=C=S)=NC2=CC(C)=CC=C21 XUDBPGPIBCBAAW-UHFFFAOYSA-N 0.000 description 1
- RHVXTBTTZKLODC-UHFFFAOYSA-N 2-methoxy-5-pyrimidin-4-ylpyrimidine Chemical compound COC1=NC=C(C=N1)C1=NC=NC=C1 RHVXTBTTZKLODC-UHFFFAOYSA-N 0.000 description 1
- KEOFPCPNACMWHS-UHFFFAOYSA-N 2-nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C([N+]([O-])=O)N=C1 KEOFPCPNACMWHS-UHFFFAOYSA-N 0.000 description 1
- USBDVWRRXXQEOL-UHFFFAOYSA-N 2-pyridin-3-ylpyrimidin-4-amine Chemical compound NC1=CC=NC(C=2C=NC=CC=2)=N1 USBDVWRRXXQEOL-UHFFFAOYSA-N 0.000 description 1
- WLIWKYZJBIUWSG-UHFFFAOYSA-N 3,4-dichloropyridin-2-amine Chemical compound NC1=NC=CC(Cl)=C1Cl WLIWKYZJBIUWSG-UHFFFAOYSA-N 0.000 description 1
- NQYNSMVHXHIGHZ-UHFFFAOYSA-N 3,5-dichloro-6-methylpyridin-2-amine Chemical compound CC1=NC(N)=C(Cl)C=C1Cl NQYNSMVHXHIGHZ-UHFFFAOYSA-N 0.000 description 1
- OCWBGKZFOYMCCN-UHFFFAOYSA-N 3,5-dichloropyridin-2-amine Chemical compound NC1=NC=C(Cl)C=C1Cl OCWBGKZFOYMCCN-UHFFFAOYSA-N 0.000 description 1
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 1
- RBCARPJOEUEZLS-UHFFFAOYSA-N 3-bromopyridin-2-amine Chemical compound NC1=NC=CC=C1Br RBCARPJOEUEZLS-UHFFFAOYSA-N 0.000 description 1
- RZJPBQGRCNJYBU-UHFFFAOYSA-N 3-chloropyridin-2-amine Chemical compound NC1=NC=CC=C1Cl RZJPBQGRCNJYBU-UHFFFAOYSA-N 0.000 description 1
- YMVLHYBAEVCYIM-UHFFFAOYSA-N 3-isothiocyanato-6,7-dimethylisoquinoline Chemical compound N1=C(N=C=S)C=C2C=C(C)C(C)=CC2=C1 YMVLHYBAEVCYIM-UHFFFAOYSA-N 0.000 description 1
- VMSZFBSYWXMXRF-UHFFFAOYSA-N 3-isothiocyanatopyridine Chemical compound S=C=NC1=CC=CN=C1 VMSZFBSYWXMXRF-UHFFFAOYSA-N 0.000 description 1
- LGNNZKURGCOEJY-UHFFFAOYSA-N 3-methyl-1,2,4-oxadiazol-5-amine Chemical compound CC1=NOC(N)=N1 LGNNZKURGCOEJY-UHFFFAOYSA-N 0.000 description 1
- DJKUIGPCSNRFRK-UHFFFAOYSA-N 3-methyl-1,2,4-thiadiazol-5-amine Chemical compound CC1=NSC(N)=N1 DJKUIGPCSNRFRK-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BOUIZPWBFIVJPD-UHFFFAOYSA-N 3h-1,2,4-triazin-4-amine Chemical compound NN1CN=NC=C1 BOUIZPWBFIVJPD-UHFFFAOYSA-N 0.000 description 1
- CRRAQLWJVYODCL-UHFFFAOYSA-N 4,5-dichloropyridin-2-amine Chemical compound NC1=CC(Cl)=C(Cl)C=N1 CRRAQLWJVYODCL-UHFFFAOYSA-N 0.000 description 1
- VYQFIVPHBLAONR-UHFFFAOYSA-N 4,5-dimethylpyridin-2-amine Chemical compound CC1=CN=C(N)C=C1C VYQFIVPHBLAONR-UHFFFAOYSA-N 0.000 description 1
- FKRXXAMAHOGYNT-UHFFFAOYSA-N 4,6-dichloro-2-methylpyrimidin-5-amine Chemical compound CC1=NC(Cl)=C(N)C(Cl)=N1 FKRXXAMAHOGYNT-UHFFFAOYSA-N 0.000 description 1
- AGJMDETXSYICGZ-UHFFFAOYSA-N 4,6-dichloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC(Cl)=N1 AGJMDETXSYICGZ-UHFFFAOYSA-N 0.000 description 1
- ZLSWQLRAMWOZEM-UHFFFAOYSA-N 4-(2-fluoropyridin-3-yl)-6-isothiocyanatopyrimidine Chemical compound FC1=NC=CC=C1C1=CC(N=C=S)=NC=N1 ZLSWQLRAMWOZEM-UHFFFAOYSA-N 0.000 description 1
- DXZLXKWCQCYQBC-UHFFFAOYSA-N 4-(2-methoxypyridin-3-yl)pyridin-2-amine Chemical compound COC1=NC=CC=C1C1=CC=NC(N)=C1 DXZLXKWCQCYQBC-UHFFFAOYSA-N 0.000 description 1
- OERIHGQAGTVWPN-UHFFFAOYSA-N 4-(difluoromethoxy)-2-fluorobenzonitrile Chemical compound FC(F)OC1=CC=C(C#N)C(F)=C1 OERIHGQAGTVWPN-UHFFFAOYSA-N 0.000 description 1
- NDEZTSHWEPQVBX-UHFFFAOYSA-N 4-(difluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)F)C=C1 NDEZTSHWEPQVBX-UHFFFAOYSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- OEQQFQXMCPMEIH-UHFFFAOYSA-N 4-chloro-1,3-benzothiazol-2-amine Chemical compound C1=CC=C2SC(N)=NC2=C1Cl OEQQFQXMCPMEIH-UHFFFAOYSA-N 0.000 description 1
- RRMVDLLCVGZDMH-UHFFFAOYSA-N 4-chloro-5,6-dimethylpyrimidin-2-amine Chemical compound CC1=NC(N)=NC(Cl)=C1C RRMVDLLCVGZDMH-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- AGAHETWGCFCMDK-UHFFFAOYSA-N 4-methoxybenzene-1,2-diamine Chemical compound COC1=CC=C(N)C(N)=C1 AGAHETWGCFCMDK-UHFFFAOYSA-N 0.000 description 1
- GRIATXVEXOFBGO-UHFFFAOYSA-N 4-methyl-1,3-benzothiazol-2-amine Chemical compound CC1=CC=CC2=C1N=C(N)S2 GRIATXVEXOFBGO-UHFFFAOYSA-N 0.000 description 1
- SJISCEAZUHNOMD-UHFFFAOYSA-N 4-phenylcyclohexan-1-amine Chemical compound C1CC(N)CCC1C1=CC=CC=C1 SJISCEAZUHNOMD-UHFFFAOYSA-N 0.000 description 1
- LGPVXXJBWWYOSL-UHFFFAOYSA-N 4-propan-2-yl-1,3-thiazol-2-amine Chemical compound CC(C)C1=CSC(N)=N1 LGPVXXJBWWYOSL-UHFFFAOYSA-N 0.000 description 1
- MLNFMFAMNBGAQT-UHFFFAOYSA-N 4-propan-2-yloxyaniline Chemical compound CC(C)OC1=CC=C(N)C=C1 MLNFMFAMNBGAQT-UHFFFAOYSA-N 0.000 description 1
- AVRNZAITOUMSPB-UHFFFAOYSA-N 4-propan-2-ylpyrimidin-2-amine Chemical compound CC(C)C1=CC=NC(N)=N1 AVRNZAITOUMSPB-UHFFFAOYSA-N 0.000 description 1
- LQHQKYWYKPLKCH-UHFFFAOYSA-N 4-pyridin-3-ylpyrimidin-2-amine Chemical compound NC1=NC=CC(C=2C=NC=CC=2)=N1 LQHQKYWYKPLKCH-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- MPGDXNFGLHUWKH-UHFFFAOYSA-N 4h-[1,3]thiazolo[5,4-b]pyridin-5-one Chemical compound N1C(=O)C=CC2=C1SC=N2 MPGDXNFGLHUWKH-UHFFFAOYSA-N 0.000 description 1
- PWRHKLKFADDKHS-UHFFFAOYSA-N 5,6-diamino-1h-pyrimidin-4-one Chemical compound NC=1NC=NC(=O)C=1N PWRHKLKFADDKHS-UHFFFAOYSA-N 0.000 description 1
- VKULPGMHEHWFFN-UHFFFAOYSA-N 5,7-dichloroisoquinolin-1-amine Chemical compound C1=C(Cl)C=C2C(N)=NC=CC2=C1Cl VKULPGMHEHWFFN-UHFFFAOYSA-N 0.000 description 1
- FPUPPVDVOFJSEP-UHFFFAOYSA-N 5-chloro-3-fluoropyridin-2-amine Chemical compound NC1=NC=C(Cl)C=C1F FPUPPVDVOFJSEP-UHFFFAOYSA-N 0.000 description 1
- DGRCJSWXMGENMG-UHFFFAOYSA-N 5-chloro-4-methylpyridin-2-amine Chemical compound CC1=CC(N)=NC=C1Cl DGRCJSWXMGENMG-UHFFFAOYSA-N 0.000 description 1
- SHIKRPPKGCWKJO-UHFFFAOYSA-N 5-chloro-6-methylpyridin-2-amine Chemical compound CC1=NC(N)=CC=C1Cl SHIKRPPKGCWKJO-UHFFFAOYSA-N 0.000 description 1
- WCCLUBJCLSIZOC-UHFFFAOYSA-N 5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-amine Chemical compound C1=C(Cl)N=C2SC(N)=NC2=C1 WCCLUBJCLSIZOC-UHFFFAOYSA-N 0.000 description 1
- NUJGYORYWLHYGS-UHFFFAOYSA-N 5-chloroquinazolin-2-amine Chemical compound ClC1=CC=CC2=NC(N)=NC=C21 NUJGYORYWLHYGS-UHFFFAOYSA-N 0.000 description 1
- XGAKNUPZXKPFOS-UHFFFAOYSA-N 5-cyclopentyloxypyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1OC1CCCC1 XGAKNUPZXKPFOS-UHFFFAOYSA-N 0.000 description 1
- XHSTYRIUVMKGDX-UHFFFAOYSA-N 5-ethyl-1,3,4-oxadiazol-2-amine Chemical compound CCC1=NN=C(N)O1 XHSTYRIUVMKGDX-UHFFFAOYSA-N 0.000 description 1
- RKMOPXJNMQWPLH-UHFFFAOYSA-N 5-fluoro-4-methylpyridin-2-amine Chemical compound CC1=CC(N)=NC=C1F RKMOPXJNMQWPLH-UHFFFAOYSA-N 0.000 description 1
- NXHNWFRDSLYMON-UHFFFAOYSA-N 5-fluoroquinazolin-2-amine Chemical compound FC1=CC=CC2=NC(N)=NC=C21 NXHNWFRDSLYMON-UHFFFAOYSA-N 0.000 description 1
- XPXWYVCQCNFIIJ-UHFFFAOYSA-N 5-methyl-1,3,4-oxadiazol-2-amine Chemical compound CC1=NN=C(N)O1 XPXWYVCQCNFIIJ-UHFFFAOYSA-N 0.000 description 1
- XKWSQIMYNVLGBO-UHFFFAOYSA-N 5-nitro-1h-pyridin-2-one Chemical compound OC1=CC=C([N+]([O-])=O)C=N1 XKWSQIMYNVLGBO-UHFFFAOYSA-N 0.000 description 1
- LSLUWQIENURREM-UHFFFAOYSA-N 5-phenyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC=C1C1=CC=CC=C1 LSLUWQIENURREM-UHFFFAOYSA-N 0.000 description 1
- ZMYWWCNMEJGOKC-UHFFFAOYSA-N 5-phenylmethoxy-[1,3]thiazolo[5,4-b]pyridine Chemical compound C1=CC=C(C=C1)COC2=NC3=C(C=C2)N=CS3 ZMYWWCNMEJGOKC-UHFFFAOYSA-N 0.000 description 1
- LXRKXJMZWGBMOV-UHFFFAOYSA-N 6,7-dichloroisoquinolin-1-amine Chemical compound ClC1=C(Cl)C=C2C(N)=NC=CC2=C1 LXRKXJMZWGBMOV-UHFFFAOYSA-N 0.000 description 1
- KQJHSCZATVSGTO-UHFFFAOYSA-N 6-(2,2,2-trifluoroethoxy)pyrimidin-4-amine Chemical compound NC1=CC(OCC(F)(F)F)=NC=N1 KQJHSCZATVSGTO-UHFFFAOYSA-N 0.000 description 1
- WNNCHODGNVCRLP-UHFFFAOYSA-N 6-(2-fluoropyridin-3-yl)pyrimidin-4-amine Chemical compound C1=NC(N)=CC(C=2C(=NC=CC=2)F)=N1 WNNCHODGNVCRLP-UHFFFAOYSA-N 0.000 description 1
- AJWURYOLKGMWBS-UHFFFAOYSA-N 6-(2-methoxypyrimidin-5-yl)pyrimidin-4-amine Chemical compound C1=NC(OC)=NC=C1C1=CC(N)=NC=N1 AJWURYOLKGMWBS-UHFFFAOYSA-N 0.000 description 1
- HTWQXUINJKVXIO-UHFFFAOYSA-N 6-(4-chlorophenyl)pyrimidin-4-amine Chemical compound C1=NC(N)=CC(C=2C=CC(Cl)=CC=2)=N1 HTWQXUINJKVXIO-UHFFFAOYSA-N 0.000 description 1
- GCSRTEPXIPYDSS-UHFFFAOYSA-N 6-(6-fluoropyridin-3-yl)pyrimidin-4-amine Chemical compound C1=NC(N)=CC(C=2C=NC(F)=CC=2)=N1 GCSRTEPXIPYDSS-UHFFFAOYSA-N 0.000 description 1
- OZAIJUZOQOBQDW-UHFFFAOYSA-N 6-amino-2-methylpyridine-3-carbonitrile Chemical compound CC1=NC(N)=CC=C1C#N OZAIJUZOQOBQDW-UHFFFAOYSA-N 0.000 description 1
- XYAFECHDSIQGHU-UHFFFAOYSA-N 6-bromo-[1,3]thiazolo[4,5-b]pyrazin-2-amine Chemical compound C1=C(Br)N=C2SC(N)=NC2=N1 XYAFECHDSIQGHU-UHFFFAOYSA-N 0.000 description 1
- PQKLBIXLXFRNKT-UHFFFAOYSA-N 6-bromoisoquinolin-3-amine Chemical compound BrC1=CC=C2C=NC(N)=CC2=C1 PQKLBIXLXFRNKT-UHFFFAOYSA-N 0.000 description 1
- OBYJTLDIQBWBHM-UHFFFAOYSA-N 6-chloropyridin-2-amine Chemical compound NC1=CC=CC(Cl)=N1 OBYJTLDIQBWBHM-UHFFFAOYSA-N 0.000 description 1
- IVIXRMWFVKQEBE-UHFFFAOYSA-N 6-cyclopentyloxypyrimidin-4-amine Chemical compound C1=NC(N)=CC(OC2CCCC2)=N1 IVIXRMWFVKQEBE-UHFFFAOYSA-N 0.000 description 1
- KOYJWFGMEBETBU-UHFFFAOYSA-N 6-ethoxy-1,3-benzothiazol-2-amine Chemical compound CCOC1=CC=C2N=C(N)SC2=C1 KOYJWFGMEBETBU-UHFFFAOYSA-N 0.000 description 1
- QZPQDBMKUYEGQK-UHFFFAOYSA-N 6-fluoro-3-isothiocyanato-1h-indazole Chemical compound FC1=CC=C2C(N=C=S)=NNC2=C1 QZPQDBMKUYEGQK-UHFFFAOYSA-N 0.000 description 1
- YZSMZWMPCQWUOQ-UHFFFAOYSA-N 6-isothiocyanato-2,4-dimethylpyridine-3-carbonitrile Chemical compound CC1=CC(N=C=S)=NC(C)=C1C#N YZSMZWMPCQWUOQ-UHFFFAOYSA-N 0.000 description 1
- UUVDJIWRSIJEBS-UHFFFAOYSA-N 6-methoxypyridin-3-amine Chemical compound COC1=CC=C(N)C=N1 UUVDJIWRSIJEBS-UHFFFAOYSA-N 0.000 description 1
- VELRBZDRGTVGGT-UHFFFAOYSA-N 6-methoxypyrimidin-4-amine Chemical compound COC1=CC(N)=NC=N1 VELRBZDRGTVGGT-UHFFFAOYSA-N 0.000 description 1
- QOBXQIQOGCQMTH-UHFFFAOYSA-N 6-methylquinoxalin-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=C(N)C=NC2=CC(C)=CC=C21 QOBXQIQOGCQMTH-UHFFFAOYSA-N 0.000 description 1
- CDCFXBSOKSIQPU-UHFFFAOYSA-N 6-phenylmethoxypyridin-3-amine Chemical compound N1=CC(N)=CC=C1OCC1=CC=CC=C1 CDCFXBSOKSIQPU-UHFFFAOYSA-N 0.000 description 1
- NYXYYBHDSNBGOS-UHFFFAOYSA-N 6-phenylpyrimidin-4-amine Chemical compound C1=NC(N)=CC(C=2C=CC=CC=2)=N1 NYXYYBHDSNBGOS-UHFFFAOYSA-N 0.000 description 1
- UNQYAAAWKOOBFQ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-8-[4-chloro-3-(trifluoromethoxy)phenoxy]-1-(3-hydroxypropyl)-3-methylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1OC1=CC=C(Cl)C(OC(F)(F)F)=C1 UNQYAAAWKOOBFQ-UHFFFAOYSA-N 0.000 description 1
- PVLKWKGKEVHEJF-UHFFFAOYSA-N 7-fluoro-4-methylquinazolin-2-amine Chemical compound FC1=CC=C2C(C)=NC(N)=NC2=C1 PVLKWKGKEVHEJF-UHFFFAOYSA-N 0.000 description 1
- LEJSJPUMRRROQB-UHFFFAOYSA-N 7-fluoroquinazolin-2-amine Chemical compound C1=CC(F)=CC2=NC(N)=NC=C21 LEJSJPUMRRROQB-UHFFFAOYSA-N 0.000 description 1
- QPKYPGWRTFUFOU-UHFFFAOYSA-N 7-methoxy-[1,3]thiazolo[5,4-d]pyrimidin-2-amine Chemical compound COC1=NC=NC2=C1N=C(N)S2 QPKYPGWRTFUFOU-UHFFFAOYSA-N 0.000 description 1
- DKJWBGHKXDXECN-UHFFFAOYSA-N 7-methoxyquinoxalin-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=CC(N)=NC2=CC(OC)=CC=C21 DKJWBGHKXDXECN-UHFFFAOYSA-N 0.000 description 1
- ODGPJSALOCAXRG-UHFFFAOYSA-N 7-methylquinoxalin-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=CC(N)=NC2=CC(C)=CC=C21 ODGPJSALOCAXRG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- SAQKPETWKJOFSJ-UHFFFAOYSA-N C1CC2(CCC1C(C2)(CNC(=S)NC3=NC4=CC=CC=C4S3)O)N Chemical compound C1CC2(CCC1C(C2)(CNC(=S)NC3=NC4=CC=CC=C4S3)O)N SAQKPETWKJOFSJ-UHFFFAOYSA-N 0.000 description 1
- SKIRASZMSIKQIL-QGZVFWFLSA-N C1CCN(C1)C2=CN=C(C=N2)N3C[C@@]4(CN5CCC4CC5)OC3 Chemical compound C1CCN(C1)C2=CN=C(C=N2)N3C[C@@]4(CN5CCC4CC5)OC3 SKIRASZMSIKQIL-QGZVFWFLSA-N 0.000 description 1
- VXVWNMKBKSTPJL-UHFFFAOYSA-N C1CN2CCC1C3(C2C4=CC(=NC=C4)Br)CN=C(O3)N Chemical compound C1CN2CCC1C3(C2C4=CC(=NC=C4)Br)CN=C(O3)N VXVWNMKBKSTPJL-UHFFFAOYSA-N 0.000 description 1
- SAQYGPMWAZZHHP-UHFFFAOYSA-N C1CN2CCC1C3(C2C4=NC(=CC=C4)Br)CN=C(O3)N Chemical compound C1CN2CCC1C3(C2C4=NC(=CC=C4)Br)CN=C(O3)N SAQYGPMWAZZHHP-UHFFFAOYSA-N 0.000 description 1
- QNPHNKPYMLVKRS-OAHLLOKOSA-N C1CN2CCC1[C@@]3(C2)CN(CO3)C4=CC(=NC=N4)OCC(F)F Chemical compound C1CN2CCC1[C@@]3(C2)CN(CO3)C4=CC(=NC=N4)OCC(F)F QNPHNKPYMLVKRS-OAHLLOKOSA-N 0.000 description 1
- PZNILGXLFDNBAG-MRXNPFEDSA-N C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC5=CC=CC=C5S4 Chemical group C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC5=CC=CC=C5S4 PZNILGXLFDNBAG-MRXNPFEDSA-N 0.000 description 1
- NIUARHWCNQLFFD-LJQANCHMSA-N C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC=CC(=C4)C5=CC(=CN=C5)Cl Chemical compound C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC=CC(=C4)C5=CC(=CN=C5)Cl NIUARHWCNQLFFD-LJQANCHMSA-N 0.000 description 1
- XCIVLXAJFHPGHF-LJQANCHMSA-N C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC=CC(=C4)C5=CN=C(C=C5)F Chemical compound C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC=CC(=C4)C5=CN=C(C=C5)F XCIVLXAJFHPGHF-LJQANCHMSA-N 0.000 description 1
- XUPCLHWCGWUEJX-QGZVFWFLSA-N C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC=CC(=C4)C5=CSC=N5 Chemical compound C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC=CC(=C4)C5=CSC=N5 XUPCLHWCGWUEJX-QGZVFWFLSA-N 0.000 description 1
- QVTXHYPMFPBDFE-GOSISDBHSA-N C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC=NC(=C4)C5=CC(=CN=C5)F Chemical compound C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC=NC(=C4)C5=CC(=CN=C5)F QVTXHYPMFPBDFE-GOSISDBHSA-N 0.000 description 1
- ABVTYNSQOJGVAO-HSZRJFAPSA-N C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC=NC(=C4)C5=CC6=CC=CC=C6C=C5 Chemical compound C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC=NC(=C4)C5=CC6=CC=CC=C6C=C5 ABVTYNSQOJGVAO-HSZRJFAPSA-N 0.000 description 1
- HJQBFKNVTJVFIJ-GOSISDBHSA-N C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC=NC(=C4)C5=CN=C(C=C5)F Chemical compound C1CN2CCC1[C@@]3(C2)CN(CO3)C4=NC=NC(=C4)C5=CN=C(C=C5)F HJQBFKNVTJVFIJ-GOSISDBHSA-N 0.000 description 1
- NUOODNNPECZLHZ-OAHLLOKOSA-N CC(C)C1=CSC(=N1)N2C[C@@]3(CN4CCC3CC4)OC2 Chemical group CC(C)C1=CSC(=N1)N2C[C@@]3(CN4CCC3CC4)OC2 NUOODNNPECZLHZ-OAHLLOKOSA-N 0.000 description 1
- XSUVYZDDCKMAOX-LJQANCHMSA-N CC1=C2C=C(C=C(C2=CC(=N1)N3C[C@@]4(CN5CCC4CC5)OC3)F)F Chemical compound CC1=C2C=C(C=C(C2=CC(=N1)N3C[C@@]4(CN5CCC4CC5)OC3)F)F XSUVYZDDCKMAOX-LJQANCHMSA-N 0.000 description 1
- WWGFQAQTHQEOSH-UHFFFAOYSA-N CC1=CC2=C(C=C1)N(CC=N2)CC3=C(C=C(C=C3)OC)OC Chemical compound CC1=CC2=C(C=C1)N(CC=N2)CC3=C(C=C(C=C3)OC)OC WWGFQAQTHQEOSH-UHFFFAOYSA-N 0.000 description 1
- HLEYQFBQZKWEGE-UHFFFAOYSA-N CC1=CC2=C(C=C1)N=CCN2CC3=C(C=C(C=C3)OC)OC Chemical compound CC1=CC2=C(C=C1)N=CCN2CC3=C(C=C(C=C3)OC)OC HLEYQFBQZKWEGE-UHFFFAOYSA-N 0.000 description 1
- GTQOWPDTUOJWIZ-HXUWFJFHSA-N COC1=NC=C(C=C1)C2=CC(=NC=C2)N3C[C@@]4(CN5CCC4CC5)OC3 Chemical compound COC1=NC=C(C=C1)C2=CC(=NC=C2)N3C[C@@]4(CN5CCC4CC5)OC3 GTQOWPDTUOJWIZ-HXUWFJFHSA-N 0.000 description 1
- JTWIDFVKMVVAKU-UHFFFAOYSA-N CO[S+]1C(N)=NC2=C1C=CC=C2 Chemical compound CO[S+]1C(N)=NC2=C1C=CC=C2 JTWIDFVKMVVAKU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GNLJTYGGHWPVNJ-OAHLLOKOSA-N ClC=1C(=NC(=C(C1)Cl)C)N1CO[C@]2(CN3CCC2CC3)C1 Chemical compound ClC=1C(=NC(=C(C1)Cl)C)N1CO[C@]2(CN3CCC2CC3)C1 GNLJTYGGHWPVNJ-OAHLLOKOSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FFUSBSIMKLRXRM-UHFFFAOYSA-N N(=C=S)N1CC2=CC(=C(C=C2C=C1)C)C Chemical compound N(=C=S)N1CC2=CC(=C(C=C2C=C1)C)C FFUSBSIMKLRXRM-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- PWUBEALFLKCYFE-GOSISDBHSA-N N1=CC(=CC=C1)C=1N=CC(=NC1)N1CO[C@]2(CN3CCC2CC3)C1 Chemical compound N1=CC(=CC=C1)C=1N=CC(=NC1)N1CO[C@]2(CN3CCC2CC3)C1 PWUBEALFLKCYFE-GOSISDBHSA-N 0.000 description 1
- FZEPZXOYAQOKDM-UHFFFAOYSA-N NC1=NC(C=CC=C2)=C2[S+]1Cl Chemical compound NC1=NC(C=CC=C2)=C2[S+]1Cl FZEPZXOYAQOKDM-UHFFFAOYSA-N 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YGCODSQDUUUKIV-UHFFFAOYSA-N Zoxazolamine Chemical compound ClC1=CC=C2OC(N)=NC2=C1 YGCODSQDUUUKIV-UHFFFAOYSA-N 0.000 description 1
- DACWQSNZECJJGG-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CN=C21 DACWQSNZECJJGG-UHFFFAOYSA-N 0.000 description 1
- VTIVYUBSVCXRPI-UHFFFAOYSA-N [1,2]thiazolo[5,4-b]pyridine Chemical compound C1=CC=C2C=NSC2=N1 VTIVYUBSVCXRPI-UHFFFAOYSA-N 0.000 description 1
- OGWPHTRWLWDCOC-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridin-2-amine Chemical compound C1=CN=C2SC(N)=NC2=C1 OGWPHTRWLWDCOC-UHFFFAOYSA-N 0.000 description 1
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- 229950010850 acistrate Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000006934 amyloid beta 42 aggregation Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- XORXDJBDZJBCOC-UHFFFAOYSA-N azanium;acetonitrile;acetate Chemical compound [NH4+].CC#N.CC([O-])=O XORXDJBDZJBCOC-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- JBIDUFGTLLGTBI-UHFFFAOYSA-N bis(methylsulfanyl)methanimine Chemical compound CSC(=N)SC JBIDUFGTLLGTBI-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- OVBXTKIWZAHFAC-UHFFFAOYSA-N butane;pyrazine;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CN=CC=N1 OVBXTKIWZAHFAC-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- NDTCXABJQNJPCF-UHFFFAOYSA-N chlorocyclopentane Chemical compound ClC1CCCC1 NDTCXABJQNJPCF-UHFFFAOYSA-N 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
- 125000006402 chloropyridazinyl group Chemical group 0.000 description 1
- 125000006390 chloropyrimidinyl group Chemical group 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- DBPFRRFGLYGEJI-UHFFFAOYSA-N ethyl glyoxylate Chemical compound CCOC(=O)C=O DBPFRRFGLYGEJI-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- MXDFPKDNQYNZPK-UHFFFAOYSA-N ethyl n-(5-chloro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)carbamate Chemical compound N1=C(Cl)N=C2SC(NC(=O)OCC)=NC2=C1 MXDFPKDNQYNZPK-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- QGBPKJFJAVDUNC-UHFFFAOYSA-N methyl 4-methoxy-3-oxobutanoate Chemical compound COCC(=O)CC(=O)OC QGBPKJFJAVDUNC-UHFFFAOYSA-N 0.000 description 1
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 1
- 125000006399 methylpyrazinyl group Chemical group 0.000 description 1
- 125000006405 methylpyridazinyl group Chemical group 0.000 description 1
- 125000006393 methylpyrimidinyl group Chemical group 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- BIRKZPAWNVZXGA-UHFFFAOYSA-N n-(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)-1,1-bis(methylsulfanyl)methanimine Chemical compound C1=C(Cl)N=C2SC(N=C(SC)SC)=NC2=C1 BIRKZPAWNVZXGA-UHFFFAOYSA-N 0.000 description 1
- FUCCVTKQLLOEPO-UHFFFAOYSA-N n-(5-methoxy-[1,3]thiazolo[5,4-b]pyridin-2-yl)imidazole-1-carbothioamide Chemical compound S1C2=NC(OC)=CC=C2N=C1NC(=S)N1C=CN=C1 FUCCVTKQLLOEPO-UHFFFAOYSA-N 0.000 description 1
- WDINSPOQKMZCHQ-UHFFFAOYSA-N n-(5-phenyl-1,3-thiazol-2-yl)imidazole-1-carbothioamide Chemical compound C1=CN=CN1C(=S)NC(S1)=NC=C1C1=CC=CC=C1 WDINSPOQKMZCHQ-UHFFFAOYSA-N 0.000 description 1
- KQOOSJRLDUUAGK-UHFFFAOYSA-N n-(6-bromopyridin-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4h-1,3-oxazole]-2'-amine Chemical compound BrC1=CC=CC(NC=2OC3(C4CCN(CC4)C3)CN=2)=N1 KQOOSJRLDUUAGK-UHFFFAOYSA-N 0.000 description 1
- YPWKLBCTOUEZKE-UHFFFAOYSA-N n-(6-chloropyridin-2-yl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=CC(Cl)=N1 YPWKLBCTOUEZKE-UHFFFAOYSA-N 0.000 description 1
- HUBRSUQLBOOYKF-UHFFFAOYSA-N n-(7-methoxy-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)-1,1-bis(methylsulfanyl)methanimine Chemical compound COC1=NC=NC2=C1N=C(N=C(SC)SC)S2 HUBRSUQLBOOYKF-UHFFFAOYSA-N 0.000 description 1
- YJZQFLXZZGZDKK-UHFFFAOYSA-N n-[(2,4-dimethoxyphenyl)methyl]-6-methoxyquinoxalin-2-amine Chemical compound COC1=CC(OC)=CC=C1CNC1=CN=C(C=C(OC)C=C2)C2=N1 YJZQFLXZZGZDKK-UHFFFAOYSA-N 0.000 description 1
- NTKLQWVHHBNEPH-UHFFFAOYSA-N n-[(2,4-dimethoxyphenyl)methyl]-7-methoxyquinoxalin-2-amine Chemical compound COC1=CC(OC)=CC=C1CNC1=CN=C(C=CC(OC)=C2)C2=N1 NTKLQWVHHBNEPH-UHFFFAOYSA-N 0.000 description 1
- LRAMDZDYWGJMGU-UHFFFAOYSA-N n-[2-(imidazole-1-carbothioylamino)-1,3-benzothiazol-6-yl]acetamide Chemical compound S1C2=CC(NC(=O)C)=CC=C2N=C1NC(=S)N1C=CN=C1 LRAMDZDYWGJMGU-UHFFFAOYSA-N 0.000 description 1
- IFYDWYVPVAMGRO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)NCCCN(C)C IFYDWYVPVAMGRO-UHFFFAOYSA-N 0.000 description 1
- FBMCKFANBCCIFK-UHFFFAOYSA-N n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]imidazole-1-carbothioamide Chemical compound C1=CC(OC)=CC=C1C1=CSC(NC(=S)N2C=NC=C2)=N1 FBMCKFANBCCIFK-UHFFFAOYSA-N 0.000 description 1
- NPLRRFUPFJMICF-UHFFFAOYSA-N n-[4-(4-methoxyphenyl)-5-methyl-1,3-thiazol-2-yl]imidazole-1-carbothioamide Chemical compound C1=CC(OC)=CC=C1C1=C(C)SC(NC(=S)N2C=NC=C2)=N1 NPLRRFUPFJMICF-UHFFFAOYSA-N 0.000 description 1
- OESGJWFGVHFAAE-UHFFFAOYSA-N n-[4-(4-methoxyphenyl)-5-methyl-1,3-thiazol-2-yl]imidazole-1-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C)SC(NC(=O)N2C=NC=C2)=N1 OESGJWFGVHFAAE-UHFFFAOYSA-N 0.000 description 1
- LZNSBKRVTSLHIE-UHFFFAOYSA-N n-[5-(4-methoxyphenyl)-1,3-thiazol-2-yl]imidazole-1-carbothioamide Chemical compound C1=CC(OC)=CC=C1C(S1)=CN=C1NC(=S)N1C=NC=C1 LZNSBKRVTSLHIE-UHFFFAOYSA-N 0.000 description 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- GSWAOPJLTADLTN-UHFFFAOYSA-N oxidanimine Chemical compound [O-][NH3+] GSWAOPJLTADLTN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000007114 proinflammatory cascade Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- NWELCUKYUCBVKK-UHFFFAOYSA-N pyridin-2-ylhydrazine Chemical compound NNC1=CC=CC=N1 NWELCUKYUCBVKK-UHFFFAOYSA-N 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical compound C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 230000009151 sensory gating Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- MRTAVLDNYYEJHK-UHFFFAOYSA-M sodium;2-chloro-2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)(F)Cl MRTAVLDNYYEJHK-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LTXDXOMHOOIKAB-UHFFFAOYSA-N tert-butyl n-(6-chloropyrimidin-4-yl)-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)C1=CC(Cl)=NC=N1 LTXDXOMHOOIKAB-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- YYQKQPYPLADFMK-UHFFFAOYSA-N tributyl(1,3-thiazol-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CSC=N1 YYQKQPYPLADFMK-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- AVCVDUDESCZFHJ-UHFFFAOYSA-N triphenylphosphane;hydrochloride Chemical compound [Cl-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 AVCVDUDESCZFHJ-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
本開示は、全般的に、塩を含む式Iの化合物および組成物ならびに本化合物を使用する方法に関する。本化合物は、ニコチン性α7受容体に対するリガンド、アゴニストおよび部分アゴニストであり、中枢神経系の種々の障害、特に情動障害および神経変性障害の処置に有用であり得る。
本発明は、薬学的に許容される塩を含む式Iの化合物、および、これらの化合物を用いた組成物および処置方法を包含する。本化合物は、中枢神経系の種々の障害の処置に有用であり得る。
R1は、イソオキサゾリル、ピラゾリル、オキサゾリル、チアゾリル、イミダゾリル、オキサジアゾリル、チアジアゾリル、トリアゾリル、ピリジニル、ピラジニル、ピリダジニル、ピリミジニル、トリアジニル、キノリニル、イソキノリニル、テトラヒドロイソキノリニル、キノキサリニル、キナゾリニル、ナフチリジニル、インダゾリル、インドリル、2−インドロニル(indolonyl)、ベンゾイソオキサゾリル、ベンゾイソチアゾリル、ベンゾオキサゾリル、ベンゾチアゾリル、ベンゾイミダゾリル、フロピリジニル、チエノピリジニル、チエノピリミジニル、イソチアゾロピリジニル、チアゾロピリジニル、チアゾロピリジノニル、チアゾロピラジニル、チアゾロピリミジニル、トリアゾロピリジニル、トリアゾロピラジニル、ピロロトリアジニル、5,6−ジヒドロベンゾ[h]キナゾリニル、5H−クロメノ[4,3−d]ピリミジニル、6,7−ジヒドロ−5H−シクロペンタ[d]ピリミジニル、5,6,7,8−テトラヒドロキナゾリニル、7,8−ジヒドロキナゾリン−5(6H)−オニルおよびテトラヒドロベンゾチアゾリルからなる群から選択され、これらは、C1−4アルキル、C3−7シクロアルキル、C1−4ハロアルキル、C1−4アルコキシ、C1−4ハロアルコキシ、C3−7シクロアルコキシ、C1−4アルキルチオ、フェノキシ、ベンジルオキシ、ハロ、ヒドロキシ、シアノ、ニトロ、C1−4アルキルスルホニル、NR2R3、ピロリジノニル、メチレンジオキシ、フリル、チエニル、ピラゾリル、イミダゾリル、チアゾリル、トリアゾリル、ピラジニル、ピリミジニル、ナフチル、C1−4アルキルアミド、CONR2R3、ピリジル、フェニルおよびベンジルからなる群から独立して選択される0〜3個の置換基で置換されており、ここで、イミダゾリル、ピリジル、フェニルおよびベンジルは、ハロ、C1−4アルキル、C1−4アルコキシ、C1−4ハロアルキル、C1−4ハロアルコキシおよびNR2R3からなる群から独立して選択される0〜2個の置換基で置換されており;
R2は、水素、C1−4アルキル、C1−4ヒドロキシアルキルまたはC1−4アミノアルキルであって、
R3は、水素、C1−4アルキル、C1−4ヒドロキシアルキルまたはC1−4アミノアルキルであるか;
あるいは、R2およびR3は、それらが結合している窒素原子と一体となって、アゼチジニル、ピロリジニル、ピペリジニル、ピペラジニル、N−(C1−4アルキル)ピペラジニル、モルホリニルまたはホモピペリジニルである。]
の化合物もしくはその立体異性体またはそれらの薬学的に許容される塩である。
本化合物は、下記の方法および当技術分野の技術の範囲内の変形を含む、当技術分野で既知の方法によって合成され得る。幾つかの反応剤および中間体は、当技術分野で既知である。他の反応剤および中間体は、容易に入手可能な物質を用いて、当技術分野で既知の方法によって合成され得る。本化合物の合成を説明するために用いられる可変基(例えば番号付けされた“R”置換基)は、本化合物を合成する方法を説明することのみを意図しており、特許請求の範囲または本明細書の他の章で用いられる可変基と混同されるべきではない。下記の方法は、例示を目的とし、本発明の範囲を限定することを意図しない。
I) α7ニコチン性アセチルコリン受容体結合
ラットのα7ニコチン性アセチルコリン受容体(ラットα7nAChR)を安定に発現するHEK293細胞を用いて、結合のための膜を調製した。4℃で、10mM Tris(pH 7.4)、5mM EDTAおよびプロテアーゼ阻害剤からなる低浸透圧性溶解緩衝液中で、細胞をホモジナイズし、32000×gで20分間遠心分離した。50mM Tris(pH 7.4)、1mM EDTAおよびプロテアーゼ阻害剤からなる膜洗浄緩衝液中で、ペレットを1回洗浄し、32000×gで20分間遠心分離した。このペレットを、50mM KH2PO4(pH 7.4, 25℃)、1mM EDTA、0.005% Triton-X 100および0.1%(v/v) Sigma社製プロテアーゼ阻害剤カクテルからなるアッセイ緩衝液に再度懸濁した。アリコートをドライアイス/エタノール中で凍結し、アッセイの日まで−80℃で保存した。
概要: リード化合物を、哺乳動物のHEK 293細胞中で発現させたニコチン性ACh受容体イオンチャネルのα−7、α3β4、α4αβ2およびα1β1δ1εサブタイプへのアゴニスト活性について評価する。384ウェルFLIPR(蛍光画像プレートリーダー)を用いて行った動的蛍光Ca2+流入測定から、アゴニスト強度および有効性を測定する。創薬活動における細胞内二価カチオン濃度、特にCa2+の濃度変化を測定するための蛍光指示薬の有用性が詳細に記載されている(Rudiger, R., et al., Nature Reviews, 2003, 4:579-586; Gonzalez J.E., et al., Receptors and Channels, 2002, 8:283-295)。このアッセイにおいて、384ウェルアッセイプレートに播種したチャネル発現HEK細胞株に、510nmでの緑色の放出シグナルが細胞内Ca2+濃度の上昇に応答して増加する、膜透過性蛍光Ca2+指示色素を取り込ませる。細胞の基底蛍光をリアルタイムでモニターし、次に試験化合物を急性に添加する。化合物が非選択性カチオンチャネルのいずれかのアゴニストであれば、チャネルは開いて、細胞内Ca2+イオンの細胞質への移動が可能となり、それらはCa2+指示色素に結合して、蛍光アウトプットシグナルの増加を起こし、それが冷却CCD撮像カメラによって検出される。
オスのウィスターラットを、医薬(1〜10mg/kg)またはビークル(2ml/kg, 皮下)で処置した。処置後2時間で、ラットを素早く断頭し、目的の脳領域を氷上で摘出し、重量を量り、液体窒素で急速冷凍し、−80℃で保存する。核抽出物における脳組織のさらなる処理およびFos定量化は、市販のELISAベース化学発光検出キット(カタログ番号89860, EZ−検出c−Fosトランスキット, Pierce Biotechnology Inc., Rockford, IL)によって規定されたプロトコルに従って行う。
このアッセイは、Stefani et al. (Behavioral Neuroscience, 2003, 117: 728-737)によって記載されたプロトコルの修飾を用いる。このアッセイにおいて、MK−801誘発運動能力欠損(0.03mg/kg, 腹腔内, 1回投与)を逆転させる能力について、試験化合物を評価した。
式Iの化合物は、α7に結合し、情動障害および神経変性障害を処置するのに有用であり得る。従って、本発明の他の局面は、式Iの化合物またはその薬学的に許容される塩、および、薬学的に許容される担体を含む組成物である。
本発明の他の局面は、統合失調症またはアルツハイマー病を処置する医薬の製造における、式Iの化合物の使用である。
本発明の他の局面は、統合失調症またはアルツハイマー病を処置する方法であって、患者に、治療有効量の式Iの化合物を投与することを含む方法である。
本発明の他の局面は、アルツハイマー病を処置する方法であって、患者に、治療有効量の式Iの化合物を投与することを含む方法である。
本発明の他の局面は、関節リウマチを処置する方法であって、患者に、治療有効量の式Iの化合物を投与することを含む方法である。
本発明の他の局面は、潰瘍性大腸炎を処置する方法であって、患者に、治療有効量の式Iの化合物を投与することを含む方法である。
本発明の他の局面は、糖尿病を処置する方法であって、患者に、治療有効量の式Iの化合物を投与することを含む方法である。
“処置”、“治療”および関連の用語は、情動障害および神経変性障害の分野の従業者によって理解される通りに用いられる。
1H−NMRスペクトルを、Bruker 500、400または300 MHz装置で測定し、化学シフトを、テトラメチルシラン(δ=0.0)を参照としてppm(δ)で示した。全ての蒸発を減圧下で行った。特にことわらない限り、Shimadzu社の装置で、Phenomenex-Luna 4.6×50mm S 10 逆相カラムを用いて、流速4ml/分で、メタノール/水中0.1% TFAの濃度勾配[0〜100%, 3分, ランタイム4分]を用いて、UV検出器を220nmに設定して、あるいは、Gemini C18 4.6×50mm 5μ 逆相カラムで、流速5ml/分で、10mM 酢酸アンモニウム アセトニトリル/水の濃度勾配[5〜95%, 3分, ランタイム4分]を用いて、UV検出器を220nmに設定して、LC/MS分析を行った(陰イオンの質量分析)。特にことわらない限り、精製は、分取C-18カラムによって、0.1% トリフルオロ酢酸(TFA)を含むメタノール−水の濃度勾配を用いて、Shimadzu社の高速液体分取クロマトグラフィー系を用いて、XTERRA 30×100mm S5 カラムを用いて、流速40ml/分で、12分の濃度勾配で行った。
1H NMR (500 MHz, DMSO-d6) δ ppm 11.88 (s, 1 H), 10.30 (s, 1 H), 7.94 (d, J=7.63 Hz, 1 H), 7.55 - 7.74 (m, 1 H), 7.37 - 7.53 (m, J=7.32, 7.32 Hz, 1 H), 7.16 - 7.37 (m, J=7.63, 7.63 Hz, 1 H), 5.39 (s, 1 H), 3.85 (d, 2 H), 2.65 - 3.08 (m, 6 H), 1.99 - 2.22 (m, 1 H), 1.79 - 1.97 (m, 2 H), 1.66 - 1.79 (m, 1 H), 1.08 - 1.63 (m, 4 H). MS (LC/MS) R.T. = 3.40; [M+H]+ = 363.1。
1H NMR (500 MHz, DMSO-d6) δ ppm 9.09 (br. s., 1 H) 7.81 (d, J=7.63 Hz, 1 H) 7.63 (d, J=7.93 Hz, 1 H) 7.30 - 7.40 (m, 1 H) 7.15 - 7.24 (m, 1 H) 3.88 (d, J=10.38 Hz, 1 H) 3.77 (d, J=10.38 Hz, 1 H) 3.25 - 3.37 (m, 1 H) 3.17 (dd, J=14.95, 1.83 Hz, 1 H) 2.99 - 3.10 (m, 1 H) 2.79 - 2.98 (m, 3 H) 2.27 (br. s., 1 H) 1.98 - 2.11 (m, 1 H) 1.71 - 1.88 (m, 3 H) 1.45 (br. s., 3 H). MS (LC/MS) R.T. = 2.44; [M+H-BH3]+ = 315.1。
1H NMR (500 MHz, DMSO-d6) δ ppm 9.02 (br. s., 1 H) 7.79 (d, J=7.02 Hz, 1 H) 7.62 (d, J=7.63 Hz, 1 H) 7.29 - 7.38 (m, 1 H) 7.15 - 7.22 (m, 1 H) 3.90 (d, J=10.07 Hz, 1 H) 3.65 (d, J=10.07 Hz, 1 H) 2.98 - 3.10 (m, 2 H) 2.73 - 2.88 (m, 2 H) 2.67 (t, J=7.78 Hz, 2 H) 2.07 (br. s., 1 H) 1.93 (br. s., 1 H) 1.42 - 1.67 (m, 3 H). MS (LC/MS) R.T. = 1.15; [M+H]+ = 315.3。
(1a; S−異性体): 1H NMR (400 MHz, DMSO-d6) δ ppm 9.03 (br. s., 1 H) 7.78 (d, J=7.05 Hz, 1 H) 7.61 (d, J=7.55 Hz, 1 H) 7.27 - 7.37 (m, 1 H) 7.11 - 7.23 (m, 1 H) 3.89 (d, J=10.07 Hz, 1 H) 3.64 (d, J=10.07 Hz, 1 H) 2.96 - 3.09 (m, 2 H) 2.71 - 2.88 (m, 2 H) 2.66 (t, J=7.81 Hz, 2 H) 2.02 - 2.11 (m, 1 H) 1.85 - 1.97 (m, 1 H) 1.41 - 1.65 (m, 3 H). MS (LC/MS) R.T. = 1.15; [M+H]+ = 315.3. 旋光度(1.23 mg/mL, DMSO) = +5.20°。
(1b; R−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 9.02 (br. s., 1 H) 7.79 (d, J=7.32 Hz, 1 H) 7.62 (d, J=7.63 Hz, 1 H) 7.33 (t, J=7.63 Hz, 1 H) 7.18 (t, J=7.48 Hz, 1 H) 3.90 (d, J=10.07 Hz, 1 H) 3.65 (d, J=10.07 Hz, 1 H) 2.98 - 3.10 (m, 2 H) 2.73 - 2.87 (m, 2 H) 2.67 (t, J=7.63 Hz, 2 H) 2.08 (br. s., 1 H) 1.93 (br. s., 1 H) 1.42 - 1.67 (m, 3 H). MS (LC/MS) R.T. = 1.15; [M+H]+ = 315.3; 旋光度(3.9 mg/mL, DMSO) = -3.92°。
1H NMR (300 MHz, DMSO-d6) δ ppm 7.60 (1 H, d, J=8.42 Hz), 7.41 (2 H, s), 6.67 (1 H, d, J=8.78 Hz), 3.81 (3 H, s)。
MS (LC/MS) R.T. = 3.23; [M+H]+ = 392.1。
1H NMR (300 MHz, DMSO-d6) δ ppm 8.98 (1 H, s), 7.86 (1 H, d, J=8.78 Hz), 6.81 (1 H, d, J=8.42 Hz), 3.87 (3 H, s), 3.83 (1 H, s), 3.68 - 3.78 (1 H, m), 3.31 (1 H, s), 3.15 - 3.29 (1 H, m), 2.78 - 3.14 (4 H, m), 2.26 (1 H, br. s.), 2.04 (1 H, br. s.), 1.63 - 1.89 (3 H, m)。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.90 (1 H, br. s.), 7.82 - 7.86 (1 H, m), 6.80 (1 H, d, J=8.85 Hz), 3.84 - 3.89 (4 H, m), 3.61 (1 H, d, J=10.07 Hz), 3.03 (2 H, d, J=5.19 Hz), 2.73 - 2.86 (2 H, m), 2.66 (2 H, t, J=7.78 Hz), 2.07 (1 H, br. s.), 1.92 (1 H, br. s.), 1.45 - 1.65 (3 H, m). MS (LC/MS) R.T. = 1.29; [M+H]+ = 346.1。
(2a; S−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 8.89 (1 H, br. s.), 7.84 (1 H, d, J=8.85 Hz), 6.77 - 6.82 (1 H, m), 3.84 - 3.89 (4 H, m), 3.61 (1 H, d, J=10.07 Hz), 3.03 (2 H, d, J=5.19 Hz), 2.74 - 2.86 (2 H, m), 2.66 (2 H, t, J=7.63 Hz), 2.06 (1 H, br. s.), 1.92 (1 H, br. s.), 1.44 - 1.65 (3 H, m). MS (LC/MS) R.T. = 1.47; [M+H]+ = 346.2. 旋光度(3.57 mg/ml, DMSO) = -2.58°。
(2b; R−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 8.89 (1 H, br. s.), 7.84 (1 H, d, J=8.85 Hz), 6.79 (1 H, d, J=8.55 Hz), 3.82 - 3.90 (4 H, m), 3.61 (1 H, d, J=10.07 Hz), 3.03 (2 H, d, J=5.49 Hz), 2.74 - 2.86 (2 H, m), 2.66 (2 H, t, J=7.78 Hz), 2.06 (1 H, br. s.), 1.92 (1 H, br. s.), 1.42 - 1.67 (3 H, m). MS (LC/MS) R.T. = 1.30; [M+H]+ = 346.2. 旋光度(3.29 mg/ml, DMSO) = +2.43°。
1H NMR (500 MHz, DMSO-d6) δ ppm 11.95 (s, 1 H), 8.14 (s, 1 H), 7.61 - 7.77 (m, J=8.39, 1.98 Hz, 1 H), 7.46 - 7.63 (m, 1 H), 3.39 - 3.63 (m, 4 H), 1.74 - 2.00 (m, 4 H), 1.45 - 1.62 (m, 9 H). MS (LC/MS) R.T. = 3.40; [M+H]+ = 363.1。
1H NMR (400 MHz, DMSO-d6) δ ppm 7.86 (d, J=1.51 Hz, 1 H), 7.65 (s, 2 H), 7.35 - 7.46 (m, 1 H), 7.26 - 7.35 (m, 1 H), 3.41 - 3.57 (m, 4 H), 1.64 - 1.97 (m, 4 H). MS (LC/MS) R.T. = 1.39; [M+H]+ = 248.1。
1H NMR (400 MHz, DMSO-d6) δ ppm 9.05 (br. s., 1 H) 7.99 (d, J=1.76 Hz, 1 H) 7.60 (d, J=8.31 Hz, 1 H) 7.48 (dd, J=8.31, 1.76 Hz, 1 H) 3.90 (d, J=10.07 Hz, 1 H) 3.65 (d, J=10.07 Hz, 1 H) 3.42 - 3.52 (m, 4 H) 3.04 (s, 2 H) 2.75 - 2.87 (m, 2 H) 2.67 (t, J=7.81 Hz, 2 H) 2.08 (br. s., 1 H) 1.76 - 1.98 (m, 5 H) 1.41 - 1.65 (m, 3 H). MS (LC/MS) R.T. = 1.33; [M+H]+ = 412.2。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.63 (1 H, br. s.), 7.71 (1 H, s), 7.52 (2 H, d, J=7.32 Hz), 7.37 (2 H, t, J=7.78 Hz), 7.25 (1 H, t, J=7.32 Hz), 3.82 (1 H, d, J=10.07 Hz), 3.57 (1 H, d, J=9.77 Hz), 3.02 (2 H, d, J=4.27 Hz), 2.79 (2 H, t, J=7.63 Hz), 2.66 (2 H, t, J=7.63 Hz), 2.04 (1 H, br. s.), 1.92 - 1.97 (1 H, m), 1.44 - 1.65 (3 H, m). MS (LC/MS) R.T. = 1.52; [M+H]+ = 341.3。
(4a, S−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 8.69 (s, 1 H), 7.69 - 7.87 (m, 1 H), 7.52 - 7.66 (m, J=10.99 Hz, 2 H), 7.37 - 7.51 (m, 2 H), 7.21 - 7.38 (m, 2 H), 3.52 - 4.00 (m, 2 H), 2.98 - 3.23 (m, 2 H), 2.78 - 2.94 (m, 2 H), 2.64 - 2.78 (m, 2 H), 1.88 - 2.19 (m, J=60.43 Hz, 2 H), 1.40 - 1.77 (m, 3 H). MS (LC/MS) R.T. = 1.77; [M+H]+ = 341.1。
(4b, R−異性体):L 融点 187〜9℃. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.64 (s, 1 H), 7.62 - 7.84 (m, 1 H), 7.44 - 7.61 (m, 2 H), 7.33 - 7.46 (m, 2 H), 7.18 - 7.31 (m, 1 H), 3.50 - 3.99 (m, 2 H), 2.94 - 3.14 (m, 2 H), 2.74 - 2.91 (m, 2 H), 2.61 - 2.72 (m, 2 H), 2.05 (s, 1 H), 1.82 - 2.00 (m, 1 H), 1.34 - 1.72 (m, 3 H). MS (LC/MS) R.T. = 1.78; [M+H]+ = 341.1。
N−(6−メトキシベンゾ[d]チアゾール−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
工程A: N−(6−メトキシベンゾ[d]チアゾール−2−イル)−1H−イミダゾール−1−カルボチオアミド
LC/MS MH+ - BH3 = 345.2。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.88 (1 H, d, J=1.22 Hz), 7.48 - 7.52 (1 H, m), 7.40 (1 H, d, J=2.75 Hz), 6.92 (1 H, dd, J=8.70, 2.59 Hz), 3.87 (1 H, d, J=9.77 Hz), 3.77 (3 H, s), 3.61 (1 H, d, J=9.77 Hz), 3.03 (2 H, s), 2.75 - 2.86 (2 H, m), 2.67 (2 H, t, J=7.78 Hz), 2.06 (1 H, br. s.), 1.91 (1 H, br. s.), 1.41 - 1.65 (3 H, m). MS (LC/MS) R.T. = 1.44; [M+H]+ = 345.3。
(5a, S−異性体): 1H NMR (400 MHz, DMSO-d6) δ ppm 8.88 (1 H, br. s.), 7.50 (1 H, d, J=8.81 Hz), 7.40 (1 H, d, J=2.52 Hz), 6.92 (1 H, dd, J=8.81, 2.77 Hz), 3.87 (1 H, d, J=9.82 Hz), 3.77 (3 H, s), 3.58 - 3.65 (1 H, m), 3.02 (2 H, s), 2.74 - 2.86 (2 H, m), 2.66 (2 H, t, J=7.68 Hz), 2.03 - 2.08 (1 H, m), 1.91 (1 H, br. s.), 1.39 - 1.65 (3 H, m). MS (LC/MS) R.T. = 1.40; [M+H]+ = 345.2。
(5b, R−異性体): 1H NMR (400 MHz, DMSO-d6) δ ppm 8.88 (1 H, br. s.), 7.50 (1 H, d, J=8.56 Hz), 7.40 (1 H, d, J=2.52 Hz), 6.93 (1 H, dd, J=8.81, 2.52 Hz), 3.87 (1 H, d, J=10.07 Hz), 3.77 (3 H, s), 3.62 (1 H, d, J=10.07 Hz), 3.02 (2 H, s), 2.75 - 2.86 (2 H, m), 2.67 (2 H, t, J=7.68 Hz), 2.04 - 2.09 (1 H, m), 1.92 (1 H, br. s.), 1.42 - 1.66 (3 H, m). MS (LC/MS) R.T. = 1.70; [M+H]+ = 345.1。
1H NMR (500 MHz, DMSO-d6) δ ppm 11.93 (1 H, s), 7.74 (1 H, d, J=7.63 Hz), 7.22 - 7.26 (1 H, m), 7.19 (1 H, t, J=7.63 Hz), 3.75 - 3.93 (2 H, m), 2.72 - 2.95 (6 H, m), 2.56 (3 H, s), 2.03 - 2.14 (1 H, m), 1.95 (1 H, br. s.), 1.78 - 1.87 (1 H, m), 1.73 (1 H, ddd, J=13.81, 9.23, 5.04 Hz), 1.56 (1 H, td, J=9.99, 7.78 Hz), 1.38 (2 H, br. s.). (LC/MS) R.T. = 3.70; [M+H]+ = 375.2。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.90 (s, 1 H), 7.61 (d, J=7.63 Hz, 1 H), 7.13 - 7.17 (m, 1 H), 7.09 (t, J=7.48 Hz, 1 H), 3.90 (d, J=10.38 Hz, 1 H), 3.77 (d, J=10.38 Hz, 1 H), 3.32 (s, 3 H), 3.30 (d, J=1.53 Hz, 1 H), 3.13 - 3.20 (m, 2 H), 3.00 - 3.09 (m, 1 H), 2.85 - 2.94 (m, 4 H), 2.57 (s, 4 H), 2.28 (s, 1 H), 2.06 (s, 1 H), 1.75 - 1.83 (m, 4 H), 1.45 (s, 1 H). (LC/MS) R.T. = 2.73; [M+H]+ = 343.2。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.84 (s, 1 H), 7.60 (d, J=7.32 Hz, 1 H), 7.13 - 7.17 (m, 1 H), 7.08 (t, J=7.63 Hz, 1 H), 3.92 (d, J=10.07 Hz, 1 H), 3.66 (d, J=9.77 Hz, 1 H), 3.04 (s, 2 H), 2.76 - 2.85 (m, 2 H), 2.68 (t, J=7.48 Hz, 2 H), 2.56 (s, 3 H), 2.09 (s, 1 H), 1.93 (s, 1 H), 1.61 (d, J=3.05 Hz, 1 H), 1.60 (s, 1 H), 1.50 (dd, J=7.17, 2.59 Hz, 1 H). (LC/MS) R.T. = 1.76; [M+H]+ = 329.2。
(6a, S−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 8.83 (br. s., 1 H) 7.59 (d, J=7.63 Hz, 1 H) 7.11 - 7.18 (m, 1 H) 7.08 (t, J=7.63 Hz, 1 H) 3.92 (d, J=10.38 Hz, 1 H) 3.66 (d, J=9.77 Hz, 1 H) 3.04 (s, 2 H) 2.73 - 2.89 (m, 2 H) 2.61 - 2.72 (m, 2 H) 2.56 (s, 3 H) 2.09 (br. s., 1 H) 1.93 (br. s., 1 H) 1.43 - 1.71 (m, 3 H). MS (LC/MS) R.T. = 1.75; [M+H]+ = 329.1。
(6b, R−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 8.84 (br. s., 1 H) 7.59 (d, J=7.63 Hz, 1 H) 7.15 (d, J=7.20 Hz, 1 H) 7.08 (t, J=7.48 Hz, 1 H) 3.92 (d, J=9.77 Hz, 1 H) 3.66 (d, J=10.07 Hz, 1 H) 3.00 - 3.09 (m, 2 H) 2.73 - 2.87 (m, 2 H) 2.62 - 2.72 (m, 2 H) 2.56 (s, 3 H) 2.05 - 2.12 (m, 1 H) 1.93 (br. s., 1 H) 1.56 - 1.67 (m, 2 H) 1.45 - 1.55 (m, 1 H). MS (LC/MS) R.T. = 1.75; [M+H]+ = 329.1。
1H NMR (500 MHz, DMSO-d6) δ ppm 12.19 (s, 1 H) 9.72 (br. s., 1 H) 7.93 (d, J=7.93 Hz, 1 H) 7.51 (d, J=7.93 Hz, 1 H) 7.26 - 7.32 (m, 1 H) 5.32 (s, 1 H) 3.88 (dd, J=13.73, 4.88 Hz, 1 H) 3.75 (dd, J=13.73, 4.88 Hz, 1 H) 2.73 - 2.95 (m, 6 H) 2.08 (br. s., 1 H) 1.96 (br. s., 1 H) 1.79 - 1.89 (m, 1 H) 1.68 - 1.78 (m, 1 H) 1.52 - 1.61 (m, 1 H) 1.39 (br. s., 3 H)。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.95 (s, 1 H) 7.79 (d, J=7.93 Hz, 1 H) 7.42 (d, J=7.63 Hz, 1 H) 7.18 (t, J=7.93 Hz, 1 H) 3.92 (d, J=10.38 Hz, 1 H) 3.77 (d, J=10.38 Hz, 1 H) 3.26 - 3.38 (m, 1 H) 3.19 (dd, J=15.26, 1.53 Hz, 1 H) 3.01 - 3.11 (m, 1 H) 2.81 - 3.00 (m, 3 H) 2.31 (br. s., 1 H) 2.03 - 2.15 (m, 1 H) 1.70 - 1.89 (m, 3 H) 1.45 (br. s., 3 H)。
1H NMR(500 MHz, DMSO-d6) δ ppm 8.90 (br. s., 1 H) 7.77 (dd, J=7.78, 1.07 Hz, 1 H) 7.41 (dd, J=7.78, 1.07 Hz, 1 H) 7.17 (t, J=7.78 Hz, 1 H) 3.94 (d, J=10.07 Hz, 1 H) 3.67 (d, J=10.07 Hz, 1 H) 3.00 - 3.11 (m, 2 H) 2.76 - 2.88 (m, 2 H) 2.68 (t, J=7.63 Hz, 2 H) 2.11 (br. s., 1 H) 1.91 - 2.00 (m, 1 H) 1.47 - 1.67 (m, 3 H). MS (LC/MS) R.T. = 2.11; [M+H]+ = 349.1。
(7a, S−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 8.90 (br. s., 1 H) 7.77 (d, J=7.32 Hz, 1 H) 7.41 (d, J=7.93 Hz, 1 H) 7.17 (t, J=7.93 Hz, 1 H) 3.94 (d, J=10.07 Hz, 1 H) 3.67 (d, J=10.07 Hz, 1 H) 3.00 - 3.11 (m, 2 H) 2.76 - 2.90 (m, 2 H) 2.68 (t, J=7.78 Hz, 2 H) 2.11 (br. s., 1 H) 1.91 - 2.01 (m, 1 H) 1.47 - 1.68 (m, 3 H). MS (LC/MS) R.T. = 2.06; [M+H]+ = 349.1。
(7b, R−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 8.89 (br. s., 1 H) 7.77 (d, J=7.93 Hz, 1 H) 7.40 (d, J=7.93 Hz, 1 H) 7.16 (t, J=7.93 Hz, 1 H) 3.94 (d, J=10.07 Hz, 1 H) 3.67 (d, J=10.07 Hz, 1 H) 2.99 - 3.11 (m, 2 H) 2.74 - 2.88 (m, 2 H) 2.68 (t, J=7.78 Hz, 2 H) 2.11 (br. s., 1 H) 1.90 - 2.01 (m, 1 H) 1.44 - 1.68 (m, 3 H). MS (LC/MS) R.T. = 2.07; [M+H]+ = 349.1。
1H NMR (500 MHz, DMSO-d6) δ ppm 11.41 (s, 1 H), 11.16 (s, 1 H), 7.43 (d, J=3.05 Hz, 3 H), 7.13 (ddd, J=9.46, 3.81, 3.51 Hz, 3 H), 5.36 (s, 1 H), 4.01-4.07 (m, 3 H), 3.79 (dd, J=13.28, 4.12 Hz, 1 H), 2.83-2.92 (m, 6 H), 2.71 (d, J=14.04 Hz, 2 H), 2.04-2.13 (m, 2 H), 1.89-1.94 (m, 3 H), 1.74 (td, J=9.46, 5.49 Hz, 2 H), 1.51-1.59 (m, 2 H), 1.38 (s, 2 H), 1.31 (s, 1 H)。
LC/MSにより、本LC/MS条件でBH3が無い生成物を確認した:保持時間 2.75 (M+1-BH3 = 332.2)。
1H NMR (500 MHz, DMSO-d6) δ ppm 7.29 (s, 1 H), 6.99 - 7.05 (m, 2 H), 3.90 (t, J=9.77 Hz, 1 H), 3.75 (d, J=10.38 Hz, 1 H), 3.26 - 3.35 (m, 1 H), 3.13 (dd, J=14.95, 1.53 Hz, 1 H), 2.98 - 3.06 (m, 1 H), 2.84 - 2.92 (m, 3 H), 2.22 (s, 1 H), 1.98 - 2.05 (m, 1 H), 1.72 - 1.82 (m, 3 H), 1.45 (s, 1 H)。
LC/MSにより、本LC/MS条件でBH3が無い生成物を確認した:保持時間 2.29 (M+1-BH3 = 298.2)。
1H NMR (500 MHz, DMSO-d6) δ ppm 11.45 (s, 1 H), 9.20 (s, 1 H), 7.32 (s, 1 H), 7.00 (dd, J=5.65, 2.90 Hz, 4 H), 3.91 (d, J=10.07 Hz, 2 H), 3.64 (d, J=10.07 Hz, 2 H), 2.98 - 3.05 (m, 4 H), 2.73 - 2.82 (m, 4 H), 2.67 (t, J=7.63 Hz, 4 H), 2.03 (d, J=2.75 Hz, 2 H), 1.85 - 1.92 (m, 2 H), 1.54 - 1.63 (m, 4 H), 1.44 - 1.51 (m, 2 H). MS (LC/MS) R.T. = 1.30; [M+H]+ = 298.2。
(8a; R−異性体): 融点 255℃(分解). 1H NMR (500 MHz, DMSO-d6) δ ppm 11.43 (br. s., 1 H) 9.16 (br. s., 1 H) 7.14 - 7.53 (m, 2 H) 6.82 - 7.09 (m, 2 H) 3.91 (d, J=9.77 Hz, 1 H) 3.64 (d, J=10.07 Hz, 1 H) 2.96 - 3.09 (m, 2 H) 2.71 - 2.87 (m, 2 H) 2.62 - 2.73 (m, 2 H) 2.01 - 2.08 (m, 1 H) 1.81 - 1.97 (m, 1 H) 1.54 - 1.66 (m, 2 H) 1.40 - 1.53 (m, 1 H). MS (LC/MS) R.T. = 1.26; [M+H]+ = 298.2。
(8b; S−異性体): 1H NMR(500 MHz, DMSO-d6) δ ppm 11.43 (br. s., 1 H) 9.20 (br. s., 1 H) 7.10 - 7.60 (m, 2 H) 6.83 - 7.11 (m, 2 H) 3.91 (d, J=9.77 Hz, 1 H) 3.64 (d, J=9.77 Hz, 1 H) 2.94 - 3.16 (m, 2 H) 2.71 - 2.86 (m, 2 H) 2.59 - 2.72 (m, 2 H) 1.97 - 2.09 (m, 1 H) 1.81 - 1.95 (m, 1 H) 1.53 - 1.71 (m, 2 H) 1.41 - 1.53 (m, 1 H). MS (LC/MS) R.T. = 1.28; [M+H]+ = 298.2。
1H NMR (500 MHz, DMSO-d6) δ ppm 11.92 (br. s., 1 H) 9.89 (br. s., 1 H) 8.08 (br. s., 1 H) 7.62 (br. s., 1 H) 7.40 - 7.50 (m, 1 H) 5.40 (br. s., 1 H) 3.88 (d, J=10.20 Hz, 1 H) 3.76 (d, J=10.20 Hz, 1 H) 2.67 - 3.02 (m, 6 H) 2.08 (br. s., 1 H) 1.80 - 1.95 (m, 2 H) 1.73 (br. s., 1 H) 1.01 - 1.63 (m, 4 H). MS (LC/MS) R.T. = 3.87; [M+H]+ = 395.1。
1H NMR (500 MHz, DMSO-d6) δ ppm 9.10 (br. s., 1 H) 7.95 (d, J=2.14 Hz, 1 H) 7.60 (d, J=8.55 Hz, 1 H) 7.36 (dd, J=8.55, 2.14 Hz, 1 H) 3.88 (d, J=10.38 Hz, 1 H) 3.76 (d, J=10.38 Hz, 1 H) 3.26 - 3.37 (m, 1 H) 3.17 (dd, J=14.95, 1.83 Hz, 1 H) 3.00 - 3.11 (m, 1 H) 2.80 - 2.97 (m, 3 H) 2.28 (br. s., 1 H) 2.00 - 2.11 (m, 1 H) 1.69 - 1.88 (m, 3 H) 1.46 (br. s., 3 H). LC/MS: 保持時間 2.94 (M+1-BH3 = 349.1)。
1H NMR (500 MHz, DMSO-d6) δ ppm 9.03 (br. s., 1 H) 7.93 (d, J=2.14 Hz, 1 H) 7.58 (d, J=8.55 Hz, 1 H) 7.35 (dd, J=8.55, 2.14 Hz, 1 H) 3.90 (d, J=10.07 Hz, 1 H) 3.65 (d, J=10.07 Hz, 1 H) 2.99 - 3.11 (m, 2 H) 2.73 - 2.89 (m, 2 H) 2.67 (t, J=7.63 Hz, 2 H) 2.08 (br. s., 1 H) 1.82 - 1.99 (m, 1 H) 1.43 - 1.67 (m, 3 H). MS (LC/MS) R.T. = 2.07; [M+H]+ = 349.1。
(9a; S−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 9.02 (br. s., 1 H) 7.93 (d, J=2.14 Hz, 1 H) 7.58 (d, J=8.55 Hz, 1 H) 7.35 (dd, J=8.55, 2.14 Hz, 1 H) 3.90 (d, J=10.07 Hz, 1 H) 3.65 (d, J=10.07 Hz, 1 H) 2.97 - 3.11 (m, 2 H) 2.73 - 2.89 (m, 2 H) 2.67 (t, J=7.48 Hz, 2 H) 2.08 (br. s., 1 H) 1.93 (br. s., 1 H) 1.43 - 1.69 (m, 3 H). MS (LC/MS) R.T. = 2.05; [M+H]+ = 349.1. 旋光度 = + 4.00°。
(9b; R−異性体): 1H NMR(500 MHz, DMSO-d6) δ ppm 9.02 (br. s., 1 H) 7.93 (d, J=2.14 Hz, 1 H) 7.58 (d, J=8.55 Hz, 1 H) 7.35 (dd, J=8.55, 2.44 Hz, 1 H) 3.90 (d, J=10.07 Hz, 1 H) 3.65 (d, J=10.07 Hz, 1 H) 2.93 - 3.13 (m, 2 H) 2.72 - 2.91 (m, 2 H) 2.62 - 2.73 (m, 2 H) 2.08 (br. s., 1 H) 1.93 (d, J=1.22 Hz, 1 H) 1.44 - 1.68 (m, 3 H). MS (LC/MS) R.T. = 2.04; [M+H]+ = 349.1. 旋光度 = -3.74°。
1H NMR (400 MHz, DMSO-d6) δ ppm 9.36 (br. s., 1 H) 7.34 - 7.44 (m, 1 H) 7.26 - 7.34 (m, 1 H) 7.00 - 7.12 (m, 2 H) 3.90 (d, J=10.32 Hz, 1 H) 3.77 (d, J=10.32 Hz, 1 H) 3.57 (s, 3 H) 3.28 (dd, J=14.86, 2.27 Hz, 1 H) 3.13 (dd, J=14.86, 1.51 Hz, 1 H) 2.95 - 3.08 (m, 1 H) 2.75 - 2.95 (m, 3 H) 2.22 (br. s., 1 H) 1.96 - 2.11 (m, 1 H) 1.67 - 1.89 (m, 3 H) 1.43 (br. s., 3 H). LC/MS : 保持時間 2.37 (M+1-BH3 = 312.2)。
1H NMR (400 MHz, DMSO-d6) δ ppm 9.24 - 9.39 (m, 1 H) 7.33 - 7.42 (m, 1 H) 7.25 - 7.33 (m, 1 H) 6.99 - 7.10 (m, 2 H) 3.92 (d, J=10.07 Hz, 1 H) 3.66 (d, J=10.07 Hz, 1 H) 3.57 (s, 3 H) 2.97 - 3.08 (m, 2 H) 2.78 (t, J=7.81 Hz, 2 H) 2.67 (t, J=7.81 Hz, 2 H) 2.01 - 2.09 (m, 1 H) 1.80 - 1.96 (m, 1 H) 1.40 - 1.66 (m, 3 H). MS (LC/MS) R.T. = 1.49; [M+H]+ = 312.2。
(10a, R−異性体): 1H NMR(500 MHz, DMSO-d6) δ ppm 9.31 (br. s., 1 H) 7.35 - 7.45 (m, 1 H) 7.26 - 7.34 (m, 1 H) 7.00 - 7.15 (m, 2 H) 3.93 (d, J=10.10 Hz, 1 H) 3.67 (d, J=10.10 Hz, 1 H) 3.59 (s, 3 H) 2.93 - 3.13 (m, 2 H) 2.74 - 2.89 (m, 2 H) 2.61 - 2.74 (m, 2 H) 2.05 (br. s., 1 H) 1.91 (br. s., 1 H) 1.38 - 1.68 (m, 3 H). MS (LC/MS) R.T. = 1.37; [M+H]+ = 312.2. 旋光度 = - 16.02°。
(10b; S−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 9.31 (br. s., 1 H) 7.33 - 7.43 (m, 1 H) 7.25 - 7.33 (m, 1 H) 6.93 - 7.11 (m, 2 H) 3.93 (dd, J=9.92, 3.20 Hz, 1 H) 3.67 (dd, J=9.92, 3.20 Hz, 1 H) 3.58 (s, 3 H) 2.94 - 3.13 (m, 2 H) 2.74 - 2.85 (m, 2 H) 2.59 - 2.72 (m, 2 H) 2.04 (br. s., 1 H) 1.90 (br. s., 1 H) 1.37 - 1.70 (m, 3 H). MS (LC/MS) R.T. = 1.37; [M+H]+ = 312.2. 旋光度 = + 35.99°。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.89 (1 H, br. s.), 7.50 (1 H, d, J=8.81 Hz), 7.38 (1 H, d, J=2.52 Hz), 6.91 (1 H, dd, J=8.81, 2.52 Hz), 4.03 (2 H, q, J=7.05 Hz), 3.87 (1 H, d, J=10.07 Hz), 3.62 (1 H, d, J=10.07 Hz), 3.02 (2 H, s), 2.78 (2 H, t, J=7.81 Hz), 2.66 (2 H, t, J=7.68 Hz), 2.05 (1 H, br. s.), 1.91 (1 H, br. s.), 1.42 - 1.67 (3 H, m), 1.33 (3 H, t, J=7.05 Hz). MS (LC/MS) R.T. = 1.60; [M+H]+ = 359.0。
(11a; S−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 8.87 (1 H, br. s.), 7.49 (1 H, d, J=8.55 Hz), 7.38 (1 H, d, J=2.44 Hz), 6.91 (1 H, dd, J=8.85, 2.44 Hz), 4.03 (2 H, q, J=7.02 Hz), 3.87 (1 H, d, J=10.07 Hz), 3.61 (1 H, d, J=10.07 Hz), 3.02 (2 H, s), 2.72 - 2.85 (2 H, m), 2.66 (2 H, t, J=7.63 Hz), 2.05 (1 H, br. s.), 1.91 (1 H, br. s.), 1.43 - 1.64 (3 H, m), 1.33 (3 H, t, J=7.02 Hz). MS (LC/MS) R.T. = 1.81; [M+H]+ = 359.1。
(11b; R−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 8.86 (1 H, br. s.), 7.48 (1 H, d, J=8.85 Hz), 7.37 (1 H, d, J=2.44 Hz), 6.91 (1 H, d, J=2.75 Hz), 4.02 (2 H, q, J=7.02 Hz), 3.86 (1 H, d, J=9.77 Hz), 3.61 (1 H, d, J=9.77 Hz), 3.01 (2 H, s), 2.72 - 2.85 (2 H, m), 2.62 - 2.69 (2 H, m), 2.04 (1 H, d, J=2.44 Hz), 1.90 (1 H, d, J=4.27 Hz), 1.42 - 1.63 (3 H, m), 1.29 - 1.35 (3 H, m). MS (LC/MS) R.T. = 1.52; [M+H]+ = 359.1。
MS (LC/MS) R.T. = 3.71; [M+H]+ = 375.2。
1H NMR (500 MHz, DMSO-d6) δ ppm 9.03 (1 H, br. s.), 7.59 (1 H, s), 7.51 (1 H, d, J=8.24 Hz), 7.15 (1 H, d, J=8.24 Hz), 3.86 (1 H, d, J=10.38 Hz), 3.74 (1 H, d, J=10.38 Hz), 3.29 (1 H, dd, J=15.26, 1.83 Hz), 3.14 (1 H, d, J=15.26 Hz), 2.99 - 3.09 (1 H, m), 2.80 - 2.95 (3 H, m), 2.36 (3 H, s), 2.25 (1 H, br. s.), 2.03 (1 H, t, J=10.22 Hz), 1.70 - 1.85 (3 H, m). MS (LC/MS) R.T. = 2.78; [M+H]+ = 343.2。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.96 (1 H, br. s.), 7.57 (1 H, s), 7.49 (1 H, d, J=8.24 Hz), 7.13 (1 H, d, J=8.24 Hz), 3.88 (1 H, d, J=10.07 Hz), 3.63 (1 H, d, J=9.77 Hz), 2.98 - 3.04 (2 H, m), 2.72 - 2.85 (2 H, m), 2.66 (2 H, t, J=7.63 Hz), 2.36 (3 H, s), 2.05 (1 H, d, J=2.14 Hz), 1.91 (1 H, br. s.), 1.53 - 1.64 (2 H, m), 1.42 - 1.53 (1 H, m). MS (LC/MS) R.T. = 1.79; [M+H]+ = 329.2。
(12a; R−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 8.95 (s, 1 H), 7.57 (s, 2 H), 7.48 (d, J=8.24 Hz, 2 H), 7.13 (d, J=8.24 Hz, 2 H), 3.89 (d, J=10.38 Hz, 2 H), 3.63 (d, J=10.38 Hz, 2 H), 2.99 - 3.06 (m, 4 H), 2.75 - 2.84 (m, 4 H), 2.67 (t, J=7.63 Hz, 4 H), 2.37 (s, 7 H), 2.06 (s, 2 H), 1.92 (s, 2 H), 1.55 - 1.64 (m, 4 H), 1.49 (dd, J=9.77, 2.44 Hz, 2 H). MS (LC/MS) R.T. = 1.80; [M+H]+ = 329.2. 旋光度 = -4.52。
(12b; S−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 8.96 (s, 1 H), 7.58 (s, 1 H), 7.49 (d, J=8.24 Hz, 1 H), 7.14 (d, J=8.24 Hz, 1 H), 3.89 (d, J=10.07 Hz, 1 H), 3.63 (d, J=10.07 Hz, 1 H), 3.03 (d, J=2.44 Hz, 2 H), 2.75 - 2.84 (m, 2 H), 2.67 (t, J=7.78 Hz, 2 H), 2.37 (s, 3 H), 2.06 (s, 1 H), 1.92 (s, 1 H), 1.55 - 1.64 (m, 2 H), 1.49 (dd, J=9.77, 2.75 Hz, 1 H). MS (LC/MS) R.T. = 1.80; [M+H]+ = 329.2. 旋光度 = + 10.08。
MS (LC/MS) R.T. = 2.56; [M+H]+ = 388.9。
MS (LC/MS) R.T. = 3.60; [M+H-BH3]+ = 445.2。
1H NMR (500 MHz, DMSO-d6) δ ppm 9.36 (1 H, br. s.), 8.85 (1 H, br. s.), 7.41 (1 H, d, J=8.85 Hz), 7.12 (1 H, d, J=2.44 Hz), 6.78 (1 H, dd, J=8.85, 2.44 Hz), 3.86 (1 H, d, J=10.07 Hz), 3.61 (1 H, d, J=10.07 Hz), 2.96 - 3.06 (2 H, m), 2.71 - 2.85 (2 H, m), 2.66 (2 H, t, J=7.78 Hz), 2.04 (1 H, br. s.), 1.90 (1 H, br. s.), 1.43 - 1.64 (3 H, m). MS (LC/MS) R.T. = 1.03; [M+H]+ = 331.29。
(13a, S−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 9.36 (1 H, br. s.), 8.84 (1 H, br. s.), 7.41 (1 H, d, J=8.55 Hz), 7.12 (1 H, d, J=2.44 Hz), 6.78 (1 H, dd, J=8.55, 2.44 Hz), 3.86 (1 H, d, J=9.77 Hz), 3.61 (1 H, d, J=10.07 Hz), 2.96 - 3.05 (2 H, m), 2.72 - 2.84 (2 H, m), 2.65 (2 H, t, J=7.63 Hz), 2.04 (1 H, br. s.), 1.90 (1 H, br. s.), 1.52 - 1.64 (2 H, m), 1.43 - 1.52 (1 H, m). MS (LC/MS) R.T. = 1.30; [M+H]+ = 331.4。
(13b, R−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 7.40 (1 H, d, J=8.55 Hz), 7.11 (1 H, d, J=2.44 Hz), 6.77 (1 H, dd, J=8.55, 2.44 Hz), 3.86 (1 H, d, J=10.07 Hz), 3.60 (1 H, d, J=10.07 Hz), 3.01 (2 H, s), 2.73 - 2.84 (2 H, m), 2.65 (2 H, t, J=7.78 Hz), 2.04 (1 H, br. s.), 1.90 (1 H, br. s.), 1.54 - 1.62 (2 H, m), 1.43 - 1.52 (1 H, m). MS (LC/MS) R.T. = 1.43; [M+H]+ = 331.4。
1H NMR (500 MHz, DMSO-D6) δ ppm 11.46 (s, 1 H), 5.26 (s, 1 H), 3.89 (dd, J=13.58, 5.34 Hz, 1 H), 3.68 (dd, J=13.73, 4.88 Hz, 1 H), 2.55 - 2.94 (m, 8 H), 2.06 (dd, J=9.31, 3.20 Hz, 1 H), 1.66 - 1.90 (m, 6 H), 1.21 - 1.59 (m, 4 H); [M+H]+ = 365.1。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.26 - 8.86 (m, 1 H), 3.78 (d, J=9.46 Hz, 1 H), 3.66 (d, J=9.77 Hz, 1 H), 3.19 - 3.30 (m, J=14.95, 2.14 Hz, 1 H), 2.96 - 3.12 (m, 2 H), 2.78 - 2.94 (m, 3 H), 2.54 - 2.65 (m, 4 H), 2.19 (s, 1 H), 2.00 (s, 1 H), 1.66 - 1.85 (m, 7 H), 1.43 (m, 3 H). MS (LC/MS) R.T. = 2.50; [M+H-BH3]+ = 319.1。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.30 - 8.75 (br.s, 1 H), 3.79 (d, J=9.44 Hz , 1 H), 3.55 (d, J=9.76 Hz , 1 H), 2.90 - 3.03 (m, 2 H), 2.54 - 2.84 (m, 8 H), 2.00 (s, 1 H), 1.81 - 1.93 (m, 1 H), 1.75 (d, J=2.44 Hz, 4 H), 1.36 - 1.67 (m, 3 H). MS (LC/MS) R.T. = 1.39; [M+H]+ = 319.1。
(14a, S−異性体): 1H NMR (500 MHz, DMSO-D6) δ ppm 8.29 - 8.89 (br.s, 1 H), 3.80 (d, J=9.46 Hz, 1 H), 3.54 (d, J=9.77 Hz, 1 H), 2.94 - 3.04 (m, 2 H), 2.55 - 2.85 (m, 8 H), 2.00 (s, 1 H), 1.85 - 1.94 (m, 1 H), 1.70 - 1.81 (m, J=2.43 Hz , 4 H), 1.39 - 1.65 (m, 3 H). MS (LC/MS) R.T. = 1.54; [M+H]+ = 319.1。
(14b, R−異性体): 1H NMR (500 MHz, DMSO-D6) δ ppm 8.24 - 8.96 (br.s, 1 H), 3.79 (d, J=9.46 Hz, 1 H), 3.52 (d, J=9.76 Hz, 1 H), 2.95 - 3.08 (m, 2 H), 2.55 - 2.80 (m, 8 H), 2.00 (s, 1 H), 1.85 - 1.90 (m, 1 H), 1.70 - 1.79 (m, J=2.42 Hz , 4 H), 1.39 - 1.63 (m, 3 H); [M+H]+ = 319.1。
1H NMR (500 MHz, DMSO-d6) δ ppm 11.62 (s, 1 H), 6.70 (s, 1 H), 5.31 (s, 1 H), 3.58 - 3.96 (m, 2 H), 2.63 - 3.11 (m, 7 H), 2.00 - 2.22 (m, 1 H), 1.65 - 1.97 (m, 3 H), 1.16 - 1.61 (m, 10 H). MS (LC/MS) R.T. = 3.43; [M+H]+ = 353.2。
1H NMR (500 MHz, DMSO-d6) δ ppm 6.55 (s, 1 H), 3.75 (m, 2 H), 3.20 - 3.31 (m, 1 H), 2.96 - 3.15 (m, 2 H), 2.77 - 2.97 (m, 4 H), 2.22 (s, 1 H), 2.01 (s, 1 H), 1.68 - 1.90 (m, 3 H), 1.43 (s, 3 H), 1.21 (d, J=7.02 Hz, 6 H). MS (LC/MS) R.T. = 2.36; [M+H-BH3]+ = 307.2。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.20 - 8.91 (m, 1 H), 6.52 (s, 1 H), 3.83 (d, J=9.46 Hz, 1 H), 3.57 (d, J=9.46 Hz, 1 H), 2.99 (s, 2 H), 2.58 - 2.92 (m, 5 H), 2.02 (s, 1 H), 1.82 - 1.96 (m, 1 H), 1.38 - 1.66 (m, 3 H), 1.20 (d, J=7.02 Hz, 6 H). MS (LC/MS) R.T. = 1.27; [M+H]+ = 307.1。
(15a, S−異性体): 1H NMR (500 MHz, DMSO-D6) δ ppm 8.35 - 8.95 (m, 1 H), 6.52 (s, 1 H), 3.82 (d, J=9.41 Hz , 1 H), 3.57 (d, J=9.46 Hz, 1 H), 2.99 (s, 2 H), 2.60 - 2.88 (m, 5 H), 2.02 (s, 2 H), 1.82 - 1.96 (m, 1 H), 1.38 - 1.65 (m, 3 H), 1.20 (d, J=6.71 Hz, 6 H). MS (LC/MS) R.T. = 1.38; [M+H]+ = 307.1。
(15b, R−異性体): 1H NMR (500 MHz, DMSO-D6) δ ppm 8.35 - 8.91 (m, 1 H), 6.52 (s, 1 H), 3.82 (d, J=9.44 Hz , 1 H), 3.57 (d, J=9.46 Hz, 1 H), 2.99 (s, 2 H), 2.60 - 2.90 (m, 5 H), 2.02 (s, 2 H), 1.82 - 1.96 (m, 1 H), 1.38 - 1.62 (m, 3 H), 1.20 (d, J=6.78 Hz, 6 H). MS (LC/MS) R.T. = 1.49; [M+H]+ = 307.3。
1H NMR (500 MHz, DMSO-d6) δ ppm 11.64 (s, 1 H), 7.42 (d, J=3.36 Hz, 1 H), 7.14 (m, 1 H), 5.32 (s, 1 H), 3.78 (dd, 2 H), 2.59 - 3.02 (m, 6 H), 1.99 - 2.18 (m, 1 H), 1.79 - 1.92 (m, 2 H), 1.64 - 1.80 (m, 1 H), 1.19 - 1.65 (m, 4 H). MS (LC/MS) R.T. = 2.73; [M+H]+ = 311.1。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.37 - 9.14 (m, 1 H), 7.32 (d, J=3.66 Hz, 1 H), 7.04 (d, J=3.66 Hz, 2 H), 3.79 (d, J=10.07 Hz, 1 H), 3.67 (d, J=10.07 Hz, 1 H), 3.20 - 3.29 (m, J=14.95, 2.14 Hz, 1 H), 2.97 - 3.15 (m, 2 H), 2.78 - 2.94 (m, 3 H), 2.22 (s, 1 H), 1.95 - 2.08 (m, 1 H), 1.66 - 1.85 (m, 3 H), 1.43 (s, 3 H). MS (LC/MS) R.T. = 1.57; [M+H-BH3]+ = 265.1。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.64 (s, 1 H), 7.24 (d, J=3.74 Hz, 2 H), 7.01 (d, J=3.75 Hz, 2 H), 3.78 (d, J=9.80 Hz, 2 H), 3.53 (d, J=9.80 Hz, 2 H), 2.97 - 3.05 (m, 4 H), 2.74 - 2.86 (m, 4 H), 2.65 (t, J=7.84 Hz, 4 H), 2.01 (s, 2 H), 1.88 (s, 2 H), 1.53 - 1.64 (m, 4 H), 1.45 - 1.56 (m, 2 H). MS (LC/MS) R.T. = 0.28; [M+H]+ = 265.1。
(16a, S−異性体): 1H NMR (400 MHz, DMSO-d6) δ ppm 8.64 (s, 1 H), 7.26 (d, J=3.75 Hz, 2 H), 7.00 (d, J=3.77 Hz, 2 H), 3.78 (d, J=9.81 Hz, 2 H), 3.54 (d, J=9.82 Hz, 2 H), 2.95 - 3.10 (m, 4 H), 2.75 - 2.82 (m, 4 H), 2.65 (t, J=7.80 Hz, 4 H), 2.01 (s, 2 H), 1.88 (s, 2 H), 1.53 - 1.60 (m, 4 H), 1.42 - 1.51 (m, 2 H). MS (LC/MS) R.T. = 0.32; [M+H]+ = 265.1。
(16b, R−異性体): 1H NMR (400 MHz, DMSO-d6) δ ppm 8.64 (s, 1 H), 7.25 (d, J=3.74 Hz, 2 H), 7.00 (d, J=3.76 Hz, 2 H), 3.78 (d, J=9.80 Hz, 2 H), 3.53 (d, J=9.80 Hz, 2 H), 2.95 - 3.08 (m, 4 H), 2.75 - 2.84 (m, 4 H), 2.65 (t, J=7.80 Hz, 4 H), 2.01 (s, 2 H), 1.88 (s, 2 H), 1.54 - 1.62 (m, 4 H), 1.43 - 1.53 (m, 2 H). MS (LC/MS) R.T. = 0.28; [M+H]+ = 265.3。
1H NMR (500 MHz, DMSO-D6) δ ppm 7.59 (d, J=7.63 Hz, 2 H), 6.98 (d, J=8.55 Hz, 2 H), 3.80 (s, 4 H), 3.67 (s, 1 H), 3.24 - 3.31 (m, 1 H), 3.13 (s, 1 H), 3.03 (s, 1 H), 2.83 - 2.92 (m, 3 H), 2.39 (s, 3 H), 2.23 (s, 1 H), 2.07 (s, 1 H), 1.73 - 1.82 (m, 2 H), 1.44 (s, 1 H). MS (LC/MS) R.T. = 2.88; [M+H]+ = 399.34。
1H NMR (500 MHz, DMSO-D6) δ ppm 7.58 (d, J=8.24 Hz, 2 H), 6.98 (d, J=8.55 Hz, 2 H), 3.83 (d, J=9.16 Hz, 1 H), 3.80 (s, 3 H), 3.56 (d, J=9.46 Hz, 1 H), 3.00 (s, 2 H), 2.74 - 2.83 (m, 2 H), 2.66 (t, J=7.63 Hz, 2 H), 2.38 (s, 3 H), 2.03 (s, 1 H), 1.91 (s, 1 H), 1.54 - 1.62 (m, 2 H), 1.48 (d, J=7.02 Hz, 1 H). MS (LC/MS) R.T. = 2.04; [M+H]+ = 385.28。
1H NMR (500 MHz, MeOD-d4) δ ppm 8.56 - 8.70 (m, 1 H), 8.24 - 8.36 (m, 1 H), 8.08 - 8.16 (m, 1 H), 7.32 - 7.48 (m, 1 H), 4.02 - 4.18 (m, 1 H), 3.67 - 3.77 (m, 1 H), 3.53 - 3.62 (m, 1 H), 2.88 - 3.11 (m, 3 H), 2.70 - 2.88 (m, 1 H), 2.15 - 2.29 (m, 1 H), 1.92 - 2.12 (m, 2 H), 1.73 - 1.89 (m, 1 H), 1.54 - 1.69 (m, 2 H). MS (LC/MS) R.T. = 1.00; [MH+-BH3] = 293.10。
1H NMR (500 MHz, MeOD) δ ppm 8.34 - 8.60 (m, 1 H), 8.16 (d, J=4.27 Hz, 1 H), 7.59 - 7.96 (m, 1 H), 7.35 (dd, J=8.24, 4.88 Hz, 1 H), 3.89 (br. s., 1 H), 3.65 (d, J=9.46 Hz, 1 H), 3.16 - 3.23 (m, 1 H), 3.04 - 3.16 (m, 1 H), 2.85 - 3.04 (m, 2 H), 2.23 (br. s., 1 H), 1.74 - 1.97 (m, 4 H), 1.36 - 1.70 (m, 2 H). MS (LC/MS) R.T. = 0.65; [M+H-BH3]+ = 259.21。
1H NMR (500 MHz, MeOD-d4) δ ppm 8.39 (br. s., 1 H), 8.14 (d, J=4.27 Hz, 1 H), 7.72 (br. s., 1 H), 7.34 (dd, J=8.24, 4.88 Hz, 1 H), 3.89 (d, J=9.77 Hz, 1 H), 3.57 (d, J=10.38 Hz, 1 H), 3.14 - 3.27 (m, 1 H), 3.00 - 3.13 (m, 1 H), 2.70 - 3.00 (m, 4 H), 1.97 - 2.22 (m, 2 H), 1.54 - 1.84 (m, 3 H). MS (LC/MS) R.T. = 0.26; [M+H]+ = 259.16。
1H NMR (500 MHz, CDCl3) δ ppm 7.50 - 7.62 (m, 1 H), 7.34 - 7.43 (m, 1 H), 6.91 - 7.11 (m, 1 H). MS (LC/MS) R.T. = 1.92; [M+H]+ = 216.86。
MS (LC/MS) R.T. = 1.04; [M+H]+ = 373.01。
MS (LC/MS) R.T. = 0.65; [M+H]+ = 337.0。
1H NMR (500 MHz, MeOD) δ ppm 8.13 - 8.33 (m, 1 H), 7.57 - 7.72 (m, 1 H), 6.83 - 7.04 (m, 2 H), 3.97 (d, J=10.07 Hz, 1 H), 3.66 (d, J=10.07 Hz, 1 H), 3.18 - 3.27 (m, 1 H), 3.03 - 3.14 (m, 1 H), 2.94 (t, J=7.63 Hz, 2 H), 2.70 - 2.90 (m, 2 H), 2.06 - 2.24 (m, 2 H), 1.57 - 1.87 (m, 3 H). MS (LC/MS) R.T. = 1.76; [M+H]+ = 259.25。
1H NMR (500 MHz, DMSO-d6) δ ppm 11.74 (s, 1 H), 7.91 (d, J=8.55 Hz, 2 H), 7.43 (s, 1 H), 6.97 (d, J=8.85 Hz, 2 H), 5.50 (s, 1 H), 3.62 - 3.98 (m, 5 H), 2.70 - 3.10 (m, 6 H), 2.13 (s, 1 H), 1.94 (s, 1 H), 1.66 - 1.91 (m, 2 H), 1.11 - 1.62 (m, 4 H). MS (LC/MS) R.T. = 3.54; [M+H]+ = 417.1。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.65 (s, 1 H), 7.89 (d, J=7.32 Hz, 2 H), 7.15 - 7.43 (m, 1 H), 6.95 (d, J=8.85 Hz, 2 H), 3.64 - 3.93 (m, 5 H), 3.23 - 3.31 (m, J=1.53 Hz, 1 H), 3.09 - 3.21 (m, 1 H), 2.99 - 3.09 (m, 1 H), 2.79 - 2.97 (m, 3 H), 2.25 (s, 1 H), 1.96 - 2.16 (m, 1 H), 1.68 - 1.91 (m, 3 H), 1.45 (s, 3 H). MS (LC/MS) R.T. = 2.80; [M+H-BH3]+ = 371.1。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.56 (s, 1 H), 7.77 - 8.00 (m, J=8.55 Hz, 2 H), 7.27 (s, 1 H), 6.80 - 7.08 (m, 2 H), 3.87 (d, J=9.77 Hz, 1 H), 3.79 (s, 3 H), 3.61 (d, J=9.77 Hz, 1 H), 3.02 (s, 3 H), 2.60 - 2.92 (m, 4 H), 2.06 (s, 2 H), 1.82 - 2.00 (m, 1 H), 1.39 - 1.70 (m, 3 H). MS (LC/MS) R.T. = 1.95; [M+H]+ = 371.2。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.56 (1 H, br. s.), 7.86 (2 H, d, J=8.55 Hz), 7.25 (1 H, s), 6.93 - 6.96 (2 H, m), 3.86 (1 H, d, J=9.77 Hz), 3.78 (3 H, s), 3.60 (1 H, d, J=9.46 Hz), 3.01 (2 H, s), 2.72 - 2.84 (2 H, m), 2.62 - 2.71 (2 H, m), 2.05 (1 H, br. s.), 1.91 (1 H, br. s.), 1.55 - 1.64 (2 H, m), 1.44 - 1.52 (1 H, m). MS (LC/MS) R.T. = 2.03; [M+H]+ = 371.3。
(21b, R−異性体): 1H NMR (500 MHz, DMSO-d6) δ ppm 8.58 (1 H, br. s.), 7.87 (2 H, d, J=8.55 Hz), 7.26 (1 H, s), 6.92 - 6.97 (2 H, m), 3.86 (1 H, d, J=9.77 Hz), 3.78 (3 H, s), 3.60 (1 H, d, J=9.77 Hz), 3.01 (2 H, s), 2.73 - 2.85 (2 H, m), 2.63 - 2.71 (2 H, m), 2.05 (1 H, br. s.), 1.91 (1 H, br. s.), 1.54 - 1.64 (2 H, m), 1.43 - 1.53 (1 H, m). MS (LC/MS) R.T. = 2.03; [M+H]+ = 371.3。
1H NMR (400 MHz, CDCl3) δ ppm 7.30 - 7.43 (5 H, m), 5.27 (1 H, br. s.), 5.12 (2 H, s), 3.36 (2 H, d, J=6.04 Hz), 2.76 - 3.21 (6 H, m), 2.21 (1 H, br. s.), 1.97 (1 H, br. s.), 1.71 - 1.86 (2 H, m)。
旋光度: +28.2, c = クロロホルム中2.9。
カラムの二番目のピークは、明るい琥珀色の油状物として、(S)−(3−((ベンジルオキシカルボニルアミノ)メチル)−3−ヒドロキシ−1−アンモニオビシクロ[2.2.2]オクタン−1−イル)トリヒドロボレートであった(46.82g, 153mmol)。
旋光度: 27.4, c = クロロホルム中2.5。
1H NMR (500 MHz, DMSO-d6) δ ppm 10.93 (1 H, br. s.), 8.24 (3 H, br. s.), 6.02 (1 H, s), 3.26 (1 H, d, J=13.43 Hz), 2.99 - 3.22 (5 H, m), 2.10 - 2.19 (2 H, m), 1.81 - 1.90 (1 H, m), 1.72 - 1.81 (1 H, m), 1.60 - 1.72 (1 H, m). 旋光度: [α]20 D = -50.9°(c = 6.4, 水)。
1H NMR (300 MHz, DMSO-d6) δ ppm 9.98 (1 H, s), 8.93 (1 H, br. s.), 8.12 (1 H, d, J=1.83 Hz), 7.52 (1 H, d, J=8.42 Hz), 7.38 (1 H, dd, J=8.60, 2.01 Hz), 3.88 (1 H, d, J=9.88 Hz), 3.62 (1 H, d, J=9.88 Hz), 3.02 (2 H, s), 2.74 - 2.85 (2 H, m), 2.66 (2 H, t, J=7.68 Hz), 2.05 (4 H, s), 1.91 (1 H, br. s.), 1.41 - 1.64 (3 H, m). MS (LC/MS) R.T. = 1.55; [M+H]+ = 372.2。
融点 223〜5℃. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.99 (1 H, br. s.), 7.69 (1 H, d, J=2.75 Hz), 7.61 (1 H, d, J=8.55 Hz), 7.02 - 7.34 (2 H, m), 3.89 (1 H, d, J=10.07 Hz), 3.64 (1 H, d, J=9.77 Hz), 3.03 (2 H, d, J=2.44 Hz), 2.73 - 2.86 (2 H, m), 2.62 - 2.70 (2 H, m), 2.07 (1 H, br. s.), 1.92 (1 H, br. s.), 1.54 - 1.65 (2 H, m), 1.44 - 1.53 (1 H, m). MS (LC/MS) R.T. = 1.43; [M+H]+ = 381.1。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.49 (1 H, d, J=5.79 Hz), 6.95 (1 H, d, J=5.79 Hz), 3.92 (3 H, s). MS (LC/MS) R.T. = 3.15; [M+H]+ = 168.1。
融点 186〜8℃. 1H NMR (400 MHz, MeOD) δ ppm 8.40 (1 H, s), 6.17 (1 H, br. s.), 3.92 - 4.04 (1 H, m), 3.89 (3 H, s), 3.68 (1 H, d, J=10.32 Hz), 3.12 - 3.23 (1 H, m), 2.98 - 3.12 (1 H, m), 2.67 - 2.97 (4 H, m), 2.11 (2 H, br. s.), 1.48 - 1.82 (3 H, m). MS (LC/MS) R.T. = 0.82; [M+H]+ = 290.3。
1H NMR (300 MHz, DMSO-d6) δ ppm 12.03 (1 H, br. s.), 11.37 (1 H, br. s.), 8.53 (1 H, br. s.), 8.11 (1 H, d, J=2.93 Hz), 7.50 (1 H, dd, J=8.97, 3.11 Hz), 4.22 (2 H, q, J=7.07 Hz), 3.84 (3 H, s), 1.26 (3 H, t, J=7.14 Hz). MS (LC/MS) R.T. = 2.40; [M+H]+ = 256.1。
1H NMR (300 MHz, DMSO-d6) δ ppm 8.30 (1 H, d, J=1.83 Hz), 7.24 - 7.32 (1 H, m), 7.16 - 7.23 (1 H, m), 5.82 (2 H, br. s.), 3.78 (3 H, s). MS (LC/MS) R.T. = 0.53; [M+H]+ = 165.2。
1H NMR (300 MHz, DMSO-d6) δ ppm 8.29 (1 H, d, J=2.20 Hz), 7.24 - 7.30 (1 H, m), 7.15 - 7.22 (1 H, m), 5.79 (2 H, s), 3.78 (3 H, s)。
1H NMR (300 MHz, CDCl3) δ ppm 8.03 (1 H, d, J=2.20 Hz), 7.54 (1 H, d, J=9.88 Hz), 7.34 (1 H, dd, J=9.51, 2.56 Hz), 3.88 (3 H, s)。
1H NMR (500 MHz, CDCl3) δ ppm 8.51 (1 H, br. s.), 8.08 (1 H, d, J=2.44 Hz), 7.35 (1 H, d, J=9.77 Hz), 7.18 (1 H, dd, J=9.46, 2.44 Hz), 3.92 (1 H, d, J=8.85 Hz), 3.84 (3 H, s), 3.58 (1 H, d, J=8.85 Hz), 3.36 - 3.41 (1 H, m), 2.72 - 3.05 (4 H, m), 2.18 - 2.26 (1 H, m, J=13.26, 9.98, 3.66, 3.49, 3.49 Hz), 2.13 (1 H, br. s.), 1.79 (1 H, br. s.), 1.67 - 1.76 (1 H, m, J=13.96, 9.84, 4.27, 4.27 Hz), 1.45 - 1.63 (2 H, m). MS (LC/MS) R.T. = 0.86; [M+H]+ = 329.2。
1H NMR (400 MHz, CDCl3) δ ppm 8.32 (1 H, s), 7.99 (1 H, d, J=1.26 Hz), 5.02 (2 H, br. s.). MS (LC/MS) R.T. = 1.56; [M+H]+ = 164.03。
1H NMR (400 MHz, CDCl3) δ ppm 9.08 (1 H, br. s.), 8.35 (1 H, s), 8.32 (1 H, s), 3.95 (1 H, d, J=9.57 Hz), 3.61 (1 H, d, J=9.57 Hz), 3.30 (1 H, dd, J=14.86, 1.76 Hz), 2.65 - 2.99 (5 H, m), 2.05 - 2.16 (2 H, m), 1.64 - 1.74 (1 H, m), 1.42 - 1.57 (2 H, m). MS (LC/MS) R.T. = 1.06; [M+H]+ = 328.30。
1H NMR (500 MHz, DMSO-D6) δ ppm 11.42 (s, 1 H), 7.70 (dd, J=8.55, 5.49 Hz, 1 H), 6.97 (dd, J=10.07, 1.83 Hz, 1 H), 6.72 - 6.79 (m, 1 H), 5.40 (s, 2 H). MS (LC/MS) R.T. = 0.61; [M+H]+ = 152.11。
1H NMR (500 MHz, DMSO-D6) δ ppm 13.39 (s, 1 H), 7.78 (dd, J=8.85, 4.88 Hz, 1 H), 7.41 (dd, J=9.31, 1.68 Hz, 1 H), 7.14 (td, J=9.16, 1.83 Hz, 1 H). MS (LC/MS) R.T. = 3.69; [M+H]+ = 194.07。
1H NMR (500 MHz, DMSO-D6) δ ppm 12.16 (s, 1 H), 8.00 (s, 1 H), 7.59 - 7.67 (m, 1 H), 7.09 (dd, J=9.77, 2.14 Hz, 1 H), 6.81 - 6.88 (m, 1 H), 3.81 (d, J=9.16 Hz, 1 H), 3.56 (d, J=8.85 Hz, 1 H), 3.00 (s, 2 H), 2.78 (s, 2 H), 2.67 (t, J=7.32 Hz, 2 H), 2.01 (d, J=2.44 Hz, 1 H), 1.92 (s, 1 H), 1.59 (d, J=5.80 Hz, 2 H), 1.46 (s, 1 H). MS (LC/MS) R.T. = 1.44; [M+H]+ = 316.16。
MS (LC/MS) R.T. = 0.51; [M+H]+ = 135.02。
1H NMR (400 MHz, MeOD) δ ppm 8.08 (1 H, d, J=5.79 Hz), 7.69 (1 H, d, J=2.01 Hz), 6.99 - 7.13 (2 H, m), 4.00 (1 H, d, J=10.07 Hz), 3.69 (1 H, d, J=10.07 Hz), 3.19 - 3.26 (1 H, m), 3.05 - 3.13 (1 H, m), 2.93 (2 H, t, J=7.43 Hz), 2.73 - 2.87 (2 H, m), 2.08 - 2.24 (2 H, m), 1.52 - 1.82 (3 H, m). MS (LC/MS) R.T. = 0.68; [M+H]+ = 299.19。
1H NMR (500 MHz, CDCl3) δ ppm 8.17 - 8.42 (m, 1 H), 8.02 - 8.20 (m, 1 H), 7.32 - 7.62 (m, 4 H), 7.25 (s, 1 H), 7.06 - 7.20 (m, 1 H). MS (LC/MS) R.T. = 0.91; [M+H]+ = 171.09。
1H NMR (500 MHz, MeOD-d4) δ ppm 8.40 (br. s., 2 H), 7.66 (d, J=7.32 Hz, 2 H), 7.46 - 7.56 (m, 3 H), 7.43 (d, J=7.32 Hz, 1 H), 3.79 - 4.02 (m, 1 H), 3.51 - 3.68 (m, 1 H), 3.22 (d, J=14.95 Hz, 1 H), 3.02 - 3.15 (m, 1 H), 2.72 - 2.99 (m, 3 H), 2.14 (br. s., 2 H), 1.76 (dd, J=9.31, 4.12 Hz, 3 H), 1.12 - 1.35 (m, 1 H). MS (LC/MS) R.T. = 0.90; [M+H]+ = 335.17。
(R)−N−(2−フェニルピリジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, MeOD) δ ppm 8.38 (d, J=5.49 Hz, 1 H), 7.88 (d, J=7.93 Hz, 2 H), 7.71 - 7.84 (m, 1 H), 7.48 (d, J=7.63 Hz, 3 H), 7.19 - 7.36 (m, 1 H), 3.94 - 4.09 (m, 1 H), 3.61 - 3.79 (m, 1 H), 3.17 - 3.27 (m, 1 H), 3.00 - 3.14 (m, 1 H), 2.74 - 3.00 (m, 4 H), 2.05 - 2.23 (m, 2 H), 1.55 - 1.86 (m, 3 H). MS (LC/MS) R.T. = 0.86; [M+H]+ = 335.23。
(R)−N−(6−フェニルピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, MeOD-d4) δ ppm 7.91 (d, J=7.63 Hz, 2 H), 7.71 (t, J=7.78 Hz, 1 H), 7.32 - 7.55 (m, 5 H), 4.04 (d, J=10.07 Hz, 1 H), 3.72 (d, J=9.77 Hz, 1 H), 3.23 (d, J=1.22 Hz, 1 H), 3.12 (s, 1 H), 2.95 (s, 2 H), 2.84 (s, 2 H), 2.16 (br. s., 2 H), 1.58 - 1.85 (m, 3 H). MS (LC/MS) R.T. = 0.75; [M+H]+ = 335.23。
1H NMR (500 MHz, DMSO-d6) δ ppm 7.70 (d, J=8.55 Hz, 1 H), 7.14 (s, 1 H), 6.73 (d, J=8.55 Hz, 1 H), 5.49 (s, 1 H), 3.70 (s, 3 H)。
1H NMR (500 MHz, DMSO-d6) δ ppm 7.64 (d, J=8.55 Hz, 1 H), 7.28 (d, J=5.19 Hz, 1 H), 6.83 (dd, J=8.55, 1.83 Hz, 1 H), 3.88 (s, 3 H), 3.77 - 3.84 (m, 1 H), 3.51 - 3.64 (m, 1 H), 3.00 (s, 2 H), 2.72 - 2.84 (m, 2 H), 2.67 (t, J=7.48 Hz, 2 H), 2.02 (br. s., 1 H), 1.85 - 1.98 (m, 1 H), 1.59 (d, J=5.80 Hz, 2 H), 1.36 - 1.53 (m, 1 H), 1.09 (d, J=6.41 Hz, 1 H). MS (LC/MS) R.T. = 1.04; [M+H]+ = 378.19。
1H NMR (400 MHz, DMSO-d6) δ ppm 9.14 (d, J=2.76 Hz, 1 H), 8.68 (dd, J=9.03, 2.76 Hz, 1 H), 7.98 (s, 0.5 H), 7.62 (s, 0.5 H), 7.34 (d, J=9.03 Hz, 1 H)。
1H NMR (400 MHz, MeOD-d4) δ ppm 7.60 (d, J=2.76 Hz, 1 H), 7.37 (s, 0.5 H), 7.15 (dd, J=8.66, 2.89 Hz, 1 H), 7.00 (s, 0.5 H), 6.71 (d, J=8.78 Hz, 1 H)。
1H NMR (400 MHz, DMSO-d6) δ ppm 7.64 - 7.81 (m, 2 H), 6.92 (d, J=8.53 Hz, 1 H). MS (LC/MS) R.T. = 1.66; [M+H]+ = 218.10。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.77 (d, J=4.77 Hz, 1 H), 8.06 (d, J=8.53 Hz, 1 H), 8.01 (s, 1 H), 7.72 (s, 1 H), 7.54 (s, 1 H), 6.94 - 7.13 (m, 1 H)。
1H NMR (400 MHz, DMSO-d6) δ ppm 7.99 (d, J=8.78 Hz, 1 H), 7.68 (s, 1 H), 7.03 (d, J=8.53 Hz, 1 H), 3.87 (d, J=10.04 Hz, 1 H), 3.62 (d, J=10.04 Hz, 1 H), 3.03 (d, J=5.02 Hz, 2 H), 2.80 (d, J=9.03 Hz, 2 H), 2.65 (t, J=7.65 Hz, 2 H), 2.08 (br. s., 1 H), 1.83 - 1.99 (m, 1 H), 1.43 - 1.68 (m, 3 H). MS (LC/MS) R.T. = 1.73; [M+H]+ = 382.20。
(R)−N−(6−イソプロポキシベンゾ[d]チアゾール−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, DMSO-d6) δ ppm 7.49 (d, J=8.78 Hz, 1 H), 7.38 (d, J=2.51 Hz, 1 H), 6.90 (dd, J=8.78, 2.51 Hz, 1 H), 4.50 - 4.68 (m, 1 H), 3.87 (d, J=10.04 Hz, 1 H), 3.62 (d, J=9.79 Hz, 1 H), 2.79 (d, J=9.03 Hz, 2 H), 2.66 (t, J=7.78 Hz, 2 H), 2.06 (br. s., 1 H), 1.85 - 1.96 (m, 1 H), 1.42 - 1.67 (m, 3 H), 1.17 - 1.34 (m, 6 H), 0.96 - 1.19 (m, 2 H)。
1H NMR (400 MHz, DMSO-d6) δ ppm 7.52 (1 H, d, J=1.51 Hz), 7.36 (1 H, d, J=1.76 Hz), 5.21 (2 H, s), 3.24 - 3.29 (4 H, m), 1.90 (4 H, ddd, J=6.48, 3.53, 3.34 Hz). MS (LC/MS) R.T. = 0.52; [M+H]+ = 165.29。
1H NMR (500 MHz, CDCl3) δ ppm 8.51 (1 H, br. s.), 8.02 (1 H, s), 7.44 (1 H, d, J=0.92 Hz), 3.84 (1 H, d, J=9.16 Hz), 3.51 (1 H, d, J=8.85 Hz), 3.39 - 3.45 (4 H, m), 3.31 (1 H, dd, J=14.80, 1.07 Hz), 2.69 - 3.04 (5 H, m), 2.15 - 2.25 (1 H, m), 2.09 (1 H, br. s.), 1.98 - 2.02 (4 H + HOD, m), 1.64 - 1.74 (1 H, m), 1.42 - 1.61 (2 H, m). MS (LC/MS) R.T. = 0.76; [M+H]+ = 329.40。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.74 (1 H, d, J=1.51 Hz), 7.69 (1 H, d, J=1.51 Hz), 6.20 (2 H, s), 3.84 (2 H, t, J=7.05 Hz), 2.49 (2 H, t, J=7.93 Hz), 2.04 (2 H, dq, J=7.68, 7.51 Hz). MS (LC/MS) R.T. = 0.48; [M+H]+ = 179.27。
1H NMR (500 MHz, CDCl3) δ ppm 9.20 (1 H, d, J=1.22 Hz), 8.91 (1 H, br. s.), 8.13 (1 H, s), 4.02 (2 H, t, J=7.02 Hz), 3.92 (1 H, d, J=9.46 Hz), 3.58 (1 H, d, J=9.16 Hz), 3.33 (1 H, dd, J=14.95, 1.53 Hz), 2.71 - 3.01 (5 H, m), 2.63 (2 H, t, J=8.09 Hz), 2.08 - 2.23 (4 H, m), 1.66 - 1.76 (1 H, m), 1.42 - 1.61 (2 H, m). MS (LC/MS) R.T. = 0.67; [M+H]+ = 343.30。
1H NMR (400 MHz, アセトン) δ ppm 9.13 (1 H, d, J=1.51 Hz), 8.54 (1 H, d, J=1.26 Hz), 8.50 (1 H, dd, J=4.78, 1.51 Hz), 8.22 - 8.28 (1 H, m), 8.07 (1 H, d, J=1.26 Hz), 7.39 (1 H, ddd, J=7.87, 4.72, 0.76 Hz), 6.05 (2 H, br. s.). MS (LC/MS) R.T. = 0.58; [M+H]+ = 173.20。
1H NMR (400 MHz, CDCl3) δ ppm 9.12 (1 H, dd, J=2.27, 0.76 Hz), 9.08 (1 H, br. s.), 8.59 (1 H, dd, J=4.78, 1.76 Hz), 8.55 (1 H, d, J=1.51 Hz), 8.45 (1 H, d, J=1.26 Hz), 8.25 (1 H, dt, J=7.99, 1.92 Hz), 7.38 (1 H, ddd, J=8.06, 4.78, 0.76 Hz), 3.97 (1 H, d, J=9.57 Hz), 3.63 (1 H, d, J=9.32 Hz), 3.36 (1 H, dd, J=14.86, 1.76 Hz), 2.69 - 3.06 (5 H, m), 2.14 - 2.24 (1 H, m), 2.12 (1 H, br. s.), 1.66 - 1.77 (1 H, m, J=13.94, 9.66, 4.31, 4.31 Hz), 1.44 - 1.62 (2 H, m). MS (LC/MS) R.T. = 0.65; [M+H]+ = 337.30。
(R)−N−(5−(6−メトキシピリジン−3−イル)ピラジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, CDCl3) δ ppm 9.04 (1 H, br. s.), 8.66 (1 H, d, J=2.01 Hz), 8.46 (1 H, d, J=1.51 Hz), 8.41 (1 H, d, J=1.01 Hz), 8.15 (1 H, dd, J=8.81, 2.52 Hz), 6.82 (1 H, d, J=8.31 Hz), 3.97 (3 H, s), 3.95 (1 H, d, J=9.57 Hz), 3.61 (1 H, d, J=9.32 Hz), 3.35 (1 H, dd, J=14.86, 1.51 Hz), 2.68 - 3.07 (5 H, m), 2.14 - 2.24 (1 H, m, J=13.27, 9.93, 3.53, 3.38, 3.38 Hz), 2.11 (1 H, br. s.), 1.67 - 1.77 (1 H, m), 1.45 - 1.61 (2 H, m). MS (LC/MS) R.T. = 0.81; [M+H]+ = 367.40。
MS (LC/MS) R.T. = 0.68; [M+H]+ = 177.10。
1H NMR (400 MHz, CDCl3) δ ppm 8.69 (s, 1 H), 7.88 (d, J=9.32 Hz, 1 H), 7.43 (dd, J=9.32, 2.77 Hz, 1 H), 7.37 (d, J=2.77 Hz, 1 H), 3.95 (s, 3 H)。
1H NMR (400 MHz, CDCl3) δ ppm 8.13 (1 H, s), 7.59 - 7.63 (1 H, m), 7.30 (1 H, d, J=8.31 Hz), 7.21 - 7.24 (2 H, m), 6.47 (1 H, d, J=2.27 Hz), 6.42 (1 H, dd, J=8.31, 2.27 Hz), 5.10 (1 H, t, J=5.92 Hz), 4.61 (2 H, d, J=5.79 Hz), 3.88 (3 H, s), 3.84 (3 H, s), 3.78 (3 H, s). MS (LC/MS) R.T. = 1.95; [M+H]+ = 326.23。
1H NMR (400 MHz, CDCl3) δ ppm 8.27 (1 H, s), 7.54 - 7.58 (1 H, m), 7.25 - 7.29 (2 H, m), 4.71 (2 H, br. s.), 3.90 (3 H, s). MS (LC/MS) R.T. = 0.86; [M+H]+ = 176.23。
1H NMR (400 MHz, CDCl3) δ ppm 9.61 (1 H, br. s.), 8.57 (1 H, s), 7.62 (1 H, d, J=9.06 Hz), 7.23 - 7.32 (2 H, m), 4.01 (1 H, d, J=9.32 Hz), 3.90 (3 H, s), 3.66 (1 H, d, J=9.32 Hz), 3.37 (1 H, dd, J=14.86, 1.51 Hz), 2.68 - 3.08 (5 H, m), 2.15 - 2.25 (1 H, m), 2.10 - 2.14 (1 H, m), 1.67 - 1.77 (1 H, m), 1.42 - 1.63 (2 H, m). MS (LC/MS) R.T. = 0.81; [M+H]+ = 340.30。
MS (LC/MS) R.T. = 1.32; [M+H]+ = 181.14。
1H NMR (400 MHz, MeO-d4) δ ppm 8.46 (2 H, s), 6.85 (1 H, t), 4.02 (1 H, d, J=10.07 Hz), 3.73 (1 H, d, J=10.32 Hz), 3.28 (1 H, d, J=1.01 Hz), 3.16 (1 H, d), 2.81 - 3.05 (4 H, m), 2.08 - 2.25 (2 H, m), 1.46 - 1.89 (3 H, m). MS (LC/MS) R.T. = 0.53; [M+H]+ = 326.30。
1H NMR (400 MHz, DMSO-d6) δ ppm 7.89 (1 H, s), 6.19 (2 H, s), 2.18 (3 H, s), 1.99 (3 H, s). MS (LC/MS) R.T. = 0.56; [M+H]+ = 124.20。
1H NMR (400 MHz, MeOD-d4) δ ppm 8.22 (1 H, s), 4.01 (1 H, d, J=10.07 Hz), 3.73 (1 H, d, J=10.32 Hz), 3.40 (1 H, d), 3.25 (1 H, d), 2.91 - 3.12 (4 H, m), 2.41 (3 H, s), 2.09 - 2.28 (5 H, m), 1.62 - 1.97 (3 H, m). MS (LC/MS) R.T. = 0.47; [M+H]+ = 288.31。
MS (LC/MS) R.T. = 0.99; [M+H]+ = 172.23。
1H NMR (400 MHz, MeOD-d4) δ ppm 9.54 (1 H, d, J=1.01 Hz), 8.75 - 8.86 (2 H, m), 8.18 - 8.28 (3 H, m), 8.00 (1 H, br. s.), 4.70 (1 H, d, J=10.32 Hz), 4.43 (1 H, d, J=10.58 Hz), 3.72 - 3.88 (2 H, m), 3.41 - 3.63 (4 H, m), 2.63 - 2.87 (2 H, m), 2.18 - 2.48 (3 H, m). MS (LC/MS) R.T. = 1.36; [M+H]+ = 336.24。
(R)−N−(6−(4−メトキシフェニル)ピリミジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD-d4) δ ppm 8.72 (1 H, d, J=1.26 Hz), 7.90 - 8.00 (2 H, m), 7.16 (1 H, br. s.), 6.96 - 7.05 (2 H, m), 4.04 (1 H, d, J=10.07 Hz), 3.84 (3 H, s), 3.73 (1 H, d, J=10.07 Hz), 3.22 (1 H, d), 3.09 (1 H, d), 2.73 - 2.98 (4 H, m), 2.02 - 2.21 (2 H, m), 1.51 - 1.85 (3 H, m). MS (LC/MS) R.T. = 1.44; [M+H]+ = 366.28。
(R)−N−(6−(6−メトキシピリジン−3−イル)ピリミジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD-d4) δ ppm 8.79 (2 H, dd, J=19.01, 1.89 Hz), 8.27 (1 H, dd, J=8.56, 2.52 Hz), 7.18 (1 H, br. s.), 6.89 (1 H, d, J=8.81 Hz), 4.05 (1 H, d, J=10.32 Hz), 3.96 (3 H, s), 3.74 (1 H, d, J=10.32 Hz), 3.23 (1 H, d), 3.10 (1 H, d), 2.73 - 2.99 (4 H, m), 2.02 - 2.21 (2 H, m), 1.53 - 1.84 (3 H, m). MS (LC/MS) R.T. = 1.34; [M+H]+ = 367.25。
(R)−N−(6−(ナフタレン−2−イル)ピリミジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD-d4) δ ppm 8.83 (1 H, s), 8.56 (1 H, s), 7.83 - 8.13 (4 H, m), 7.49 - 7.58 (2 H, m), 7.37 (1 H, br. s.), 4.06 (1 H, d, J=10.32 Hz), 3.76 (1 H, d, J=10.32 Hz), 3.23 (1 H, s), 3.12 (1 H, d), 2.75 - 3.00 (4 H, m), 2.02 - 2.24 (2 H, m), 1.56 - 1.84 (3 H, m). MS (LC/MS) R.T. = 1.93; [M+H]+ = 386.31。
MS (LC/MS) R.T. = 0.19; [M+H]+ = 141.20。
1H NMR (400 MHz, CDCl3) δ ppm 8.88 (1 H, d, J=1.01 Hz), 7.52 (1 H, d, J=1.01 Hz), 4.53 (2 H, s), 3.50 (3 H, s). MS (LC/MS) R.T. = 0.98; [M+H]+ = 159.10。
1H NMR (400 MHz, CDCl3) δ ppm 8.47 (1 H, s), 6.55 (1 H, s), 5.12 (2 H, br. s.), 4.38 (2 H, s), 3.45 (3 H, s). MS (LC/MS) R.T. = 0.42; [M+H]+ = 140.20。
1H NMR (400 MHz, CDCl3) δ ppm 8.91 (1 H, d, J=1.26 Hz), 7.19 (1 H, d, J=1.01 Hz), 4.52 (2 H, s), 3.49 (3 H, s). MS (LC/MS) R.T. = 1.39; [M+H]+ = 182.10。
1H NMR (400 MHz, MeOD-d4) δ ppm 8.65 (1 H, d, J=1.01 Hz), 6.92 (1 H, br. s.), 4.40 (3 H, s), 4.03 (1 H, d, J=10.32 Hz), 3.72 (1 H, d, J=10.32 Hz), 3.44 (2 H, s), 3.18 - 3.26 (1 H, m), 3.06 - 3.13 (1 H, m), 2.69 - 2.96 (4 H, m), 1.94 - 2.19 (2 H, m), 1.45 - 1.86 (3 H, m). MS (LC/MS) R.T. = 0.76; [M+H]+ = 304.30。
MS (LC/MS) R.T. = 2.32; [M+H]+ = 199.23。
1H NMR (400 MHz, DMSO-d6) δ ppm 7.99 (2 H, s), 6.18 (2 H, s), 4.54 - 4.75 (1 H, m), 1.30 - 1.91 (8 H, m). MS (LC/MS) R.T. = 1.47; [M+H]+ = 180.24。
1H NMR (400 MHz, MeOD-d4) δ ppm 8.24 (2 H, s), 4.76 - 4.86 (1 H, m), 3.98 (1 H, d, J=10.07 Hz), 3.69 (1 H, d, J=10.07 Hz), 3.33 (1 H, d), 3.20 (1 H, d), 2.77 - 3.08 (4 H, m), 2.04 - 2.26 (2 H, m), 1.49 - 2.03 (11 H, m). MS (LC/MS) R.T. = 1.56; [M+H]+ = 344.32。
MS (LC/MS) R.T. = 2.78; [M+H]+ = 213.12。
MS (LC/MS) R.T. = 1.16; [M+H]+ = 194.07。
1H NMR (400 MHz, CDCl3) δ ppm 9.30 (1 H, br. s.), 8.39 (1 H, s), 6.38 (1 H, br. s.), 4.59 - 4.84 (2 H, m), 3.94 (1 H, d, J=9.32 Hz), 3.59 (1 H, d, J=9.57 Hz), 3.33 (1 H, d, J=16.62 Hz), 2.61 - 3.01 (5 H, m), 1.97 - 2.25 (2 H, m), 1.37 - 1.81 (3 H, m). MS (LC/MS) R.T. = 1.42; [M+H]+ = 358.33。
1H NMR (400 MHz, DMSO-d6) d ppm 8.10 (1 H, d, J=5.04 Hz), 6.45 (3 H, d, J=5.04 Hz), 2.59 - 2.80 (1 H, m), 1.15 (6 H, d, J=7.05 Hz). MS (LC/MS) R.T. = 0.76; [M+H]+ = 138.12。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.21 (1 H, s), 6.75 (2 H, s), 3.10 - 3.23 (1 H, m), 1.14 (6 H, d, J=6.80 Hz). MS (LC/MS) R.T. = 2.58; [M]+ = 216.09。
1H NMR (400 MHz, MeOD-d4) δ ppm 8.49 (1 H, s), 4.02 (1 H, d, J=10.07 Hz), 3.72 (1 H, d, J=10.07 Hz), 3.34 - 3.44 (1 H, m), 3.23 (1 H, s), 3.06 - 3.15 (1 H, m), 2.95 (2 H, t, J=7.55 Hz), 2.75 - 2.89 (2 H, m), 2.00 - 2.21 (2 H, m), 1.52 - 1.83 (3 H, m), 1.24 (6 H, d, J=6.80 Hz). MS (LC/MS) R.T. = 1.84; [M+H]+ = 382.24。
(R)−N−(5−ブロモ−4−(ピリジン−3−イル)ピリミジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD-d4) δ ppm 8.92 (1 H, d, J=1.51 Hz), 8.73 (1 H, s), 8.64 (1 H, dd, J=4.91, 1.64 Hz), 8.23 (1 H, dt, J=8.06, 1.89 Hz), 7.56 (1 H, dd, J=7.93, 4.91 Hz), 4.00 (1 H, d, J=10.07 Hz), 3.69 (1 H, d, J=10.07 Hz), 3.22 (1 H, d), 3.07 (1 H, d), 2.60 - 2.99 (4 H, m), 2.00 - 2.21 (2 H, m), 1.50 - 1.83 (3 H, m). MS (LC/MS) R.T. = 0.76; [M+H]+ = 416.30。
MS (LC/MS) R.T. = 1.64; [M+H]+ = 180.22。
1H NMR (400 MHz, MeOD-d4) δ ppm 8.37 (1 H, s), 6.16 (1 H, br. s.), 5.27 (1 H, br. s.), 3.98 (1 H, d, J=10.32 Hz), 3.67 (1 H, d, J=10.32 Hz), 3.15 - 3.24 (1 H, m), 3.02 - 3.12 (1 H, m), 2.71 - 2.97 (4 H, m), 2.01 - 2.14 (2 H, m), 1.87 - 2.00 (3 H, m), 1.49 - 1.84 (8 H, m). MS (LC/MS) R.T. = 1.96; [M+H]+ = 344.34。
(R)−N−(6−イソプロポキシピリミジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD-d4) δ ppm 8.37 (1 H, s), 6.13 (1 H, br. s.), 5.09 - 5.30 (1 H, m), 3.98 (1 H, d, J=10.32 Hz), 3.67 (1 H, d, J=10.32 Hz), 3.13 - 3.24 (1 H, m), 3.01 - 3.09 (1 H, m), 2.68 - 2.98 (4 H, m), 1.98 - 2.17 (2 H, m), 1.49 - 1.83 (3 H, m), 1.30 (6 H, d, J=6.04 Hz). MS (LC/MS) R.T. = 1.36; [M+H]+ = 318.24。
(R)−N−(6−(2,2−ジフルオロエトキシ)ピリミジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
融点 83〜8℃. 1H NMR (400 MHz, MeOD-d4) δ ppm 8.42 (1 H, s), 5.93 - 6.37 (2 H, m), 4.52 (2 H, td, J=13.98, 3.78 Hz), 3.99 (1 H, d, J=10.32 Hz), 3.68 (1 H, d, J=10.32 Hz), 3.19 (1 H, d), 3.07 (1 H, d), 2.67 - 2.97 (4 H, m), 1.99 - 2.19 (2 H, m), 1.51 - 1.82 (3 H, m). MS (LC/MS) R.T. = 0.99; [M+H]+ = 340.26。
(R)−N−(ピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, MeOD-d4) δ ppm 8.26 (d, J=4.88 Hz, 1 H), 7.58 - 7.74 (m, 1 H), 6.85 - 7.02 (m, 2 H), 4.00 (d, J=10.07 Hz, 1 H), 3.70 (d, J=10.07 Hz, 1 H), 3.26 - 3.35 (m, 1 H), 3.14 - 3.21 (m, 1 H), 3.02 (d, J=8.24 Hz, 2 H), 2.84 - 2.97 (m, 2 H), 2.11 - 2.25 (m, 2 H), 1.58 - 1.92 (m, 3 H). MS (LC/MS) R.T. = 0.30; [M+H]+ = 259.16。
(R)−N−(ピリジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, MeOD-d4) δ ppm 8.31 (d, J=6.41 Hz, 2 H), 7.39 (d, J=3.97 Hz, 2 H), 4.01 (d, J=12.21 Hz, 1 H), 3.70 (d, J=11.90 Hz, 1 H), 3.37 (s, 1 H), 3.29 (s, 1 H), 3.18 (d, J=1.83 Hz, 1 H), 3.15 (d, J=2.14 Hz, 1 H), 2.86 - 3.09 (m, 3 H), 2.02 - 2.20 (m, 1 H), 1.59 - 1.88 (m, 3 H). MS (LC/MS) R.T. = 0.22; [M+H]+ = 259.16。
1H NMR (400 MHz, CDCl3) δ ppm 7.70 (d, J=8.78 Hz, 1 H) 7.48 (d, J=7.28 Hz, 2 H) 7.39 (t, J=7.28 Hz, 2 H) 7.30 - 7.36 (m, 1 H) 6.78 (d, J=8.78 Hz, 1 H) 5.39 (s, 2 H) 5.14 (br. s., 2 H)。
1H NMR (400 MHz, CDCl3) δ ppm 8.02 (d, J=8.78 Hz, 1 H) 7.51 (d, J=7.28 Hz, 2 H) 7.38 - 7.45 (m, 2 H) 7.32 - 7.38 (m, 1 H) 6.89 (d, J=8.53 Hz, 1 H) 5.46 (s, 2 H) 2.65 (s, 6 H)。
1H NMR (500 MHz, CDCl3) δ ppm 9.18 (br. s., 1 H) 7.76 (d, J=8.85 Hz, 1 H) 7.50 (d, J=7.32 Hz, 2 H) 7.41 (t, J=7.32 Hz, 2 H) 7.32 - 7.37 (m, 1 H) 5.42 (s, 2 H) 4.02 (d, J=9.46 Hz, 1 H) 3.68 (d, J=9.46 Hz, 1 H) 3.37 - 3.44 (m, 1 H) 2.75 - 3.06 (m, 5 H) 2.13 - 2.25 (m, 2 H) 1.73 - 1.82 (m, 1 H) 1.49 - 1.70 (m, 3 H). MS (LC/MS) R.T. = 1.69; [M+H]+ = 421.98。
(R)−2−(4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−イルアミノ)チアゾロ[5,4−b]ピリジン−5(4H)−オン
融点 245℃(分解). 1H NMR (400 MHz, DMSO-d6) δ ppm 9.99 (br. s., 1 H) 9.05 (br. s., 1 H) 7.81 (d, J=8.53 Hz, 1 H) 6.65 (d, J=8.78 Hz, 1 H) 3.96 (d, J=10.29 Hz, 1 H) 3.82 (d, J=10.54 Hz, 1 H) 3.63 - 3.78 (m, 2 H) 3.36 - 3.47 (m, 1 H) 3.16 - 3.34 (m, 3 H) 2.43 (br. s., 1 H) 2.16 (br. s., 1 H) 1.76 - 2.07 (m, 3 H). MS (LC/MS) R.T. = 0.50; [M+H]+ = 332.15。
LCMS R.T. = 1.28; [M+H]+ = 201.98。
LCMS R.T. = 2.91; [M+H]+ = 244.03。
融点 80〜5℃. 1H NMR (400 MHz, MeOD) δ ppm 8.77 (1 H, s), 7.47 - 7.58 (2 H, m), 7.39 (1 H, t), 7.20 (1 H, br. s.), 7.04 (1 H, dd), 4.05 (1 H, d), 3.85 (3 H, s), 3.74 (1 H, d), 3.23 (1 H, d), 3.10 (1 H, d), 2.71 - 3.00 (4 H, m), 2.03 - 2.22 (2 H, m), 1.53 - 1.85 (3 H, m). MS (LC/MS) R.T. = 1.58; [M+H]+ = 366.15。
LCMS R.T. = 2.47; [M+H]+ = 187.23。
融点 196〜200℃. 1H NMR (400 MHz, MeOD) δ ppm 9.00 (1 H, s), 7.92 (1 H, d), 7.71 (1 H, d), 7.59 (1 H, t), 7.20 - 7.45 (2 H, m), 3.96 (1 H, d), 3.65 (1 H, d), 3.22 (1 H, d), 3.08 (1 H, d), 2.66 - 3.00 (4 H, m), 2.05 - 2.23 (2 H, m), 1.50 - 1.86 (3 H, m). R.T. = 1.37; [M+H]+ = 309.31。
LCMS R.T. = 1.37; [M+H]+ = 197.95。
LCMS R.T. = 2.78; [M+H]+ = 229.94。
1H NMR (500 MHz, MeOD) δ ppm 8.43 (1 H, s), 7.47 (2 H, t), 7.30 (1 H, t), 7.16 (2 H, d), 6.21 (1 H, br. s.), 4.03 (1 H, d), 3.72 (1 H, d), 3.22 (1 H, d), 3.11 (1 H, d), 2.73 - 2.99 (4 H, m), 2.00 - 2.18 (2 H, m), 1.54 - 1.88 (3 H, m). LCMS R.T. = 1.46; [M+H]+ = 352.19。
1H NMR (400 MHz, CDCl3) δ ppm 8.00 (1 H, s), 7.70 (1 H, d, J=8.81 Hz), 7.29 (1 H, d, J=8.31 Hz), 7.05 (1 H, d, J=2.77 Hz), 6.97 (1 H, dd, J=9.06, 2.77 Hz), 6.47 (1 H, d, J=2.27 Hz), 6.43 (1 H, dd, J=8.18, 2.39 Hz), 5.22 (1 H, t, J=5.29 Hz), 4.63 (2 H, d, J=5.54 Hz), 3.91 (3 H, s), 3.83 (3 H, s), 3.78 (3 H, s). LCMS: RT = 1.91分, MH+ = 326.15。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.10 (1 H, s), 7.63 (1 H, d, J=9.07 Hz), 6.95 (1 H, dd, J=9.06, 2.77 Hz), 6.89 (1 H, d, J=2.77 Hz), 6.85 (2 H, br. s.), 3.84 (3 H, s). LCMS: RT = 1.04 分, MH+ = 176.14。
LCMS: RT = 2.49分, MH+ = 218.06。
1H NMR (400 MHz, CDCl3) δ ppm 9.73 (1 H, br. s.), 8.45 (1 H, s), 7.80 (1 H, d, J=9.07 Hz), 7.12 (1 H, dd, J=9.06, 2.77 Hz), 7.03 (1 H, d, J=2.52 Hz), 4.02 (1 H, d, J=9.32 Hz), 3.90 (3 H, s), 3.67 (1 H, d, J=9.32 Hz), 3.36 (1 H, dd, J=14.86, 1.51 Hz), 2.69 - 3.06 (5 H, m), 2.10 - 2.26 (2 H, m), 1.66 - 1.80 (1 H, m), 1.43 - 1.63 (2 H, m). LCMS: RT = 0.835分, MH- = 338.2, MH+ = 340.1。
1H NMR (400 MHz, CDCl3) δ ppm 8.12 (1 H, s), 7.60 (1 H, s), 7.59 (1 H, d, J=5.79 Hz), 7.38 (1 H, dd, J=8.56, 1.76 Hz), 7.30 (1 H, d, J=8.31 Hz), 6.46 (1 H, d, J=2.27 Hz), 6.42 (1 H, dd, J=8.18, 2.39 Hz), 5.20 (1 H, t, J=5.41 Hz), 4.62 (2 H, d, J=5.54 Hz), 3.83 (3 H, s), 3.77 (3 H, s), 2.46 (3 H, s). LCMS: RT = 1.93分, MH+ = 310.20。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.24 (1 H, s), 7.55 (1 H, s), 7.34 - 7.45 (2 H, m), 6.82 (2 H, s), 2.41 (3 H, s). LCMS: RT = 1.07 分, MH+ = 160.12。
LCMS: RT = 2.59分, MH+ = 202.04。
1H NMR (400 MHz, CDCl3) δ ppm 9.75 (1 H, br. s.), 8.57 (1 H, s), 7.71 (1 H, s), 7.60 (1 H, d, J=8.56 Hz), 7.42 (1 H, dd, J=8.44, 1.89 Hz), 4.01 (1 H, d, J=9.57 Hz), 3.68 (1 H, d, J=9.32 Hz), 3.38 (1 H, dd, J=14.86, 1.01 Hz), 2.73 - 3.08 (5 H, m), 2.50 (3 H, s), 2.16 - 2.26 (1 H, m), 2.14 (1 H, br. s.), 1.67 - 1.79 (1 H, m), 1.45 - 1.65 (2 H, m). LCMS: RT = 0.838分, MH- = 322.2, MH+ = 324.2。
1H NMR (400 MHz, CDCl3) δ ppm 8.08 (1 H, s), 7.70 (1 H, d, J=8.31 Hz), 7.49 (1 H, s), 7.30 (1 H, d, J=8.06 Hz), 7.17 (1 H, dd, J=8.31, 2.01 Hz), 6.47 (1 H, d, J=2.52 Hz), 6.42 (1 H, dd, J=8.31, 2.52 Hz), 5.23 (1 H, t, J=5.16 Hz), 4.63 (2 H, d, J=5.79 Hz), 3.83 (3 H, s), 3.78 (3 H, s), 2.48 (3 H, s). LCMS: RT = 1.93分, MH+ = 310.20。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.20 (1 H, s), 7.64 (1 H, d, J=8.31 Hz), 7.28 (1 H, s), 7.15 (1 H, dd, J=8.31, 1.76 Hz), 6.89 (2 H, s), 2.42 (3 H, s). LCMS: RT = 1.07分, MH+ = 160.12。
LCMS: RT = 2.58分, MH+ = 202.04。
1H NMR (400 MHz, CDCl3) δ ppm 9.80 (1 H, br. s.), 8.53 (1 H, s), 7.81 (1 H, d, J=8.31 Hz), 7.50 (1 H, s), 7.31 (1 H, dd, J=8.56, 1.76 Hz), 4.01 (1 H, d, J=9.57 Hz), 3.66 (1 H, d, J=9.32 Hz), 3.36 (1 H, d, J=14.86 Hz), 2.70 - 3.04 (5 H, m), 2.50 (3 H, s), 2.15 - 2.24 (1 H, m), 2.13 (1 H, br. s.), 1.66 - 1.79 (1 H, m), 1.44 - 1.63 (2 H, m). LCMS: RT = 8.67分, MH- = 322.6, MH+ = 324.1。
LCMS R.T. = 0.31; [M+H]+ = 173.11。
1H NMR (400 MHz, MeOD) δ ppm 9.13 - 9.21 (1 H, m), 8.82 (1 H, d), 8.63 (1 H, dd), 8.44 (1 H, dt), 7.56 (1 H, dd), 7.31 (1 H, s), 4.06 (1 H, d), 3.76 (1 H, d), 3.20 - 3.28 (1 H, m), 3.08 - 3.16 (1 H, m), 2.72 - 3.01 (4 H, m), 2.00 - 2.24 (2 H, m), 1.52 - 1.83 (3 H, m). LCMS R.T. = 0.72; [M+H]+ = 337.2。
LCMS R.T. = 0.53; [M+H]+ = 204.11。
LCMS R.T. = 2.29; [M+H]+ = 246.03。
1H NMR (400 MHz, MeOD) δ ppm 9.19 (2 H, s), 8.80 (1 H, d), 7.24 (1 H, br. s.), 4.00 - 4.09 (4 H, m), 3.76 (1 H, d), 3.23 (1 H, s), 3.08 - 3.15 (1 H, m), 2.72 - 3.04 (4 H, m), 1.97 - 2.22 (2 H, m), 1.38 - 1.85 (3 H, m). R.T. = 1.22; [M+H]+ = 368.22。
LCMS R.T. = 0.30; [M+H]+ = 173.11。
LCMS R.T. = 1.46; [M+H]+ = 215.09。
1H NMR (400 MHz, MeOD) δ ppm 8.85 (1 H, d), 8.67 (2 H, dd), 8.04 (2 H, dd), 7.34 (1 H, br. s.), 4.06 (1 H, d), 3.76 (1 H, d), 3.23 (1 H, d), 3.10 (1 H, d), 2.70 - 2.99 (4 H, m), 2.01 - 2.22 (2 H, m), 1.53 - 1.86 (3 H, m). LCMS R.T. = 0.42; [M+H]+ = 337.14。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.36 (d, J=8.24 Hz, 1 H), 7.39 (d, J=8.24 Hz, 1 H), 2.65 (s, 3 H). MS (LC/MS) R.T. = 2.09; [M+H]+ = 176.0。
1H NMR (500 MHz, DMSO-D6) δ ppm 9.11 (s, 1 H), 7.87 (d, J=7.93 Hz, 2 H), 6.69 (s, 1 H), 3.89 (d, J=10.38 Hz, 2 H), 3.63 (d, J=10.38 Hz, 3 H), 3.00 (s, 5 H), 2.72 - 2.80 (m, 4 H), 2.64 - 2.69 (m, 5 H), 2.60 (s, 7 H), 2.00 (d, J=2.14 Hz, 3 H), 1.91 (s, 1 H), 1.87 (s, 2 H), 1.58 (s, 5 H), 1.42 - 1.50 (m, 2 H). MS (LC/MS) R.T. = 0.48; [M+H]+ = 298.13。
1H NMR (500 MHz, DMSO-D6) δ ppm 7.37 (s, 1 H), 2.63 (s, 3 H). MS (LC/MS) R.T. = 2.40; [M+H]+ = 190。
1H NMR (500 MHz, DMSO-D6) δ ppm 9.08 (s, 1 H), 6.60 (s, 1 H), 3.88 (d, J=10.38 Hz, 1 H), 3.61 (d, J=10.38 Hz, 1 H), 2.98 (s, 2 H), 2.70 - 2.79 (m, 2 H), 2.63 - 2.69 (m, 2 H), 2.55 - 2.60 (m, 4 H), 2.31 - 2.39 (m, 4 H), 1.99 (s, 1 H), 1.89 (s, 1 H), 1.54 - 1.62 (m, 2 H), 1.41 - 1.49 (m, 1 H). MS (LC/MS) R.T. = 0.78; [M+H]+ = 312.1。
LCMS: RT = 2.17分, MH+ = 214.06。
1H NMR (400 MHz, CDCl3) δ ppm 9.61 (1 H, br. s.), 7.95 - 7.99 (2 H, m), 7.74 (1 H, d, J=9.32 Hz), 7.39 - 7.52 (3 H, m), 7.22 (1 H, partial d), 3.97 (1 H, d, J=9.32 Hz), 3.64 (1 H, d, J=9.32 Hz), 3.37 (1 H, dd, J=14.73, 1.38 Hz), 2.69 - 3.06 (5 H, m), 2.16 - 2.26 (1 H, m), 2.14 (1 H, br. s.), 1.66 - 1.79 (1 H, m), 1.45 - 1.60 (2 H, m)
1H NMR (400 MHz, MeOD) δ ppm 7.87 - 8.02 (3 H, m), 7.44 - 7.55 (3 H, m), 7.13 - 7.29 (1 H, m), 4.05 (1 H, d, J=9.82 Hz), 3.74 (1 H, d, J=10.07 Hz), 3.17 (2 H, dd, J=49.35, 14.60 Hz), 2.73 - 3.04 (4 H, m), 2.16 (2 H, br. s.), 1.55 - 1.85 (3 H, m)
LCMS: RT = 0.82分, MH- = 334.2, MH+ = 336.2。
LCMS R.T. = 0.91; [M+H]+ = 141.89。
LCMS R.T. = 2.65; [M+H]+ = 184.02。
融点 155〜60℃. 1H NMR (400 MHz, MeOD) δ ppm 8.13 (1 H, d), 8.06 (1 H, s), 3.96 (1 H, d), 3.66 (1 H, d), 3.20 (1 H, d), 3.08 (1 H, d), 2.87 - 2.96 (2 H, m), 2.72 - 2.82 (2 H, m), 2.52 (3 H, s), 2.00 - 2.19 (2 H, m), 1.51 - 1.81 (3 H, m). LCMS R.T. = 1.01; [M+H]+ = 306.12。
1H NMR (500 MHz, CDCl3) δ ppm 8.17 (s, 1 H), 7.96 (s, 1 H), 7.72 (s, 1 H), 1.31 (s, 10 H). MS (LC/MS) R.T. = 1.85; [M+H]+ = 248.8。
1H NMR (500 MHz, CDCl3) δ ppm 7.44 (d, J=8.55 Hz, 1 H), 6.36 (d, J=8.24 Hz, 1 H), 4.58 (s, 2 H). MS (LC/MS) R.T. = 1.28; [M+H]+ = 164.8。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.26 (d, J=8.55 Hz, 1 H), 7.47 (d, J=8.24 Hz, 1 H). MS (LC/MS) R.T. = 2.83; [M+H]+ = 204.8。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.31 (d, J=1.22 Hz, 1 H), 7.84 (s, 1 H), 6.80 (s, 1 H), 3.85 (d, J=10.07 Hz, 1 H), 3.57 (d, J=10.38 Hz, 2 H), 2.98 (s, 3 H), 2.69 - 2.78 (m, 3 H), 2.65 (t, J=7.78 Hz, 3 H), 2.00 (s, 2 H), 1.86 (s, 2 H), 1.58 (dd, J=7.48, 2.90 Hz, 2 H), 1.56 (s, 1 H), 1.41 - 1.49 (m, 2 H). MS (LC/MS) R.T. = 0.81; [M+H]+ = 327.1。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.81 (s, 1 H), 8.32 (d, J=6.10 Hz, 1 H), 7.03 (s, 1 H), 3.83 (d, J=9.46 Hz, 1 H), 3.57 (d, J=9.77 Hz, 1 H), 2.98 (s, 2 H), 2.71 - 2.79 (m, 2 H), 2.65 (t, J=7.78 Hz, 2 H), 1.99 (s, 1 H), 1.86 (s, 1 H), 1.53 - 1.61 (m, 2 H), 1.41 - 1.49 (m, 1 H). MS (LC/MS) R.T. = 0.78; [M+H]+ = 327.0。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.45 (s, 1 H), 7.47 (s, 1 H), 2.37 (s, 3 H). LC/MS RT=2.79; [M+H]+ = 184.9。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.79 (s, 1 H), 8.08 - 8.15 (m, 2 H), 6.78 (s, 1 H), 3.82 (d, J=8.55 Hz, 2 H), 3.55 (d, J=10.38 Hz, 2 H), 2.93 - 3.02 (m, 5 H), 2.71 - 2.80 (m, 5 H), 2.66 (t, J=7.63 Hz, 4 H), 2.23 - 2.29 (m, 7 H), 1.94 - 2.02 (m, 2 H), 1.92 (s, 1 H), 1.86 (s, 2 H), 1.53 - 1.62 (m, 5 H), 1.41 - 1.49 (m, J=12.55, 9.88, 7.02, 2.29 Hz, 2 H). MS (LC/MS) R.T. = 0.72; [M+H]+ = 307.1。
LCMS: RT = 1.25分, MH+ = 172.00。
1H NMR (400 MHz, CDCl3) δ ppm 9.27 (1 H, br. s.), 7.28 (1 H, d, J=9.07 Hz), 7.10 (1 H, d, J=9.07 Hz), 3.95 (1 H, d, J=9.57 Hz), 3.62 (1 H, d, J=9.57 Hz), 3.34 (1 H, dd, J=14.98, 1.64 Hz), 2.67 - 3.04 (5 H, m), 2.14 - 2.21 (1 H, m), 2.12 (1 H, br. s.), 1.65 - 1.79 (1 H, m), 1.45 - 1.61 (2 H, m). LCMS: RT = 0.62分, MH- = 292.1, MH+ = 294.1。
LCMS: RT = 1.34分, MH+ = 215.92。
1H NMR (400 MHz, CDCl3) δ ppm 9.23 (1 H, br. s.), 7.37 (1 H, d, J=9.07 Hz), 6.97 (1 H, d, J=9.07 Hz), 3.92 (1 H, d, J=9.57 Hz), 3.59 (1 H, d, J=9.82 Hz), 3.29 (1 H, dd, J=14.98, 1.64 Hz), 2.63 - 2.99 (5 H, m), 2.04 - 2.19 (2 H, m), 1.59 - 1.74 (1 H, m), 1.39 - 1.58 (2 H, m). LCMS: RT= 0.64分, MH- 336.1, MH+ 338.0。
LCMS R.T. = 1.42; [M+2H]+ = 207.91。
LCMS R.T. = 2.82; [M]+ = 248.03。
1H NMR (400 MHz, CDCl3) δ ppm 9.54 (1 H, br. s.), 8.83 (1 H, d), 7.89 - 8.04 (2 H, m), 7.41 - 7.54 (2 H, m), 7.33 (1 H, br. s.), 4.02 (1 H, d), 3.71 (1 H, d), 3.42 (1 H, d), 2.73 - 3.15 (5 H, m), 2.10 - 2.31 (2 H, m), 1.46 - 1.89 (3 H, m). LCMS R.T. = 1.92; [M]+ = 370.35。
LCMS R.T. = 1.45; [M+2H]+ = 208.05。
LCMS R.T. = 2.15; [M]+ = 248.31。
1H NMR (400 MHz, MeOD) δ ppm 8.82 (1 H, d), 8.05 (1 H, d), 7.93 (1 H, ddd), 7.43 - 7.52 (2 H, m), 7.35 (1 H, br. s.), 4.13 (1 H, d), 3.93 (1 H, d), 3.63 - 3.81 (2 H, m), 3.42 - 3.53 (1 H, m), 3.30 - 3.40 (3 H, m), 2.46 (1 H, d), 2.26 - 2.40 (1 H, m), 1.88 - 2.16 (3 H, m). LCMS R.T. = 1.90; [M]+ = 370.28。
1H NMR (500 MHz, CDCl3) δ ppm 2.63 (s, 6H), 2.50 (s, 3H). LCMS R.T. 1.66分; [M+H] = 203.91。
1H NMR (500 MHz, MeOD) δ ppm 4.05 (d, 1H), 3.74 (d, 1H), 3.25 (d, 1H), 3.15 (d, 1H), 2.94 (m, 2H), 2.85 (m, 2H), 2.43 (s, 3H), 2.19(m, 1H), 2.10 (m, 1H), 1.6-1.8 (m, 3H). MS (LCMS) [M+H] = 264.05. R.T. 0.16分。
1H NMR (500 MHz, CDCl3) δ ppm 2.67 (s), 2.62 (s). MS [M+H] = 219.85。
1H NMR (500 MHz, MeOD) δ ppm 4.01-3.99 (d, 1H), 3.72-3.70 (d, 1H), 3.27 (d, 1H), 3.16 (d, 1H), 3.01-2.9 (m, 2H), 2.86-2.83 (m, 2H), 2.43 (s, 3H), 2.21-2.0(m, 2H), 1.81-1.75(m, 1H), 1.75-1.70 (m, 2H). MS (LCMS) [M+H] = 279.99; R.T. = 0.2分。
MS (LCMS) [M+H] = 203.91; R.T. = 1.84分。
生成物を次の工程に直接用いた。
1H NMR (500 MHz, MeOD) δ ppm 4.1-4.0 (d, 1H), 3.8-3.7 (d, 1H), 3.4-3.2 (d, 1H), 3.2-3.1 (d, 1H), 3.0-2.9 (m, 2H), 2.9-2.8 (m, 2H), 2.27 (s, 3H), 2.2 (m, 1H), 2.2-2.0 (m, 1H), 1.9-1.6 (m, 3H). MS (LCMS) [M+H] = 264.05; R.T. = 0.26分。
LCMS R.T. = 2.39; [M+H]+ = 234.08。
1H NMR (400 MHz, CDCl3) δ ppm 9.43 (1 H, br. s.), 8.55 (1 H, d), 6.78 (1 H, br. s.), 3.98 (1 H, d), 3.64 (1 H, d), 3.37 (1 H, dd), 2.72 - 3.06 (5 H, m), 2.51 (3 H, s), 2.08 - 2.24 (2 H, m), 1.69 - 1.81 (1 H, m), 1.41 - 1.64 (2 H, m). LCMS R.T. = 0.93; [M+H]+ = 306.29。
1H NMR (500 MHz, DMSO) δ ppm 8.09 (s, 1H), 7.55 (s, 1H), 7.13 (s, 1H)。
1H NMR (500 MHz, DMSO) δ ppm 8.05-8.0 (m, 1H), 7.44-7.40 (m, 1H), 7.08-7.0 (m, 1H), 6.74-6.70 (m, 1H), 6.35 (s, 2H). MS (LCMS) [M+H] = 134.98; R.T. = 0.1分。
1H NMR (500 MHz, CDCl3) δ ppm 8.17 (d, 1H), 7.7 (d, 1H), 7.24-7.22 (t, 1H), 6.84-6.80 (t, 1H), 2.71-2.68 (d, 6H). MS (LCMS) [M+H] = 238.94; R.T. = 1.26分。
1H NMR (500 MHz, CDCl3) δ ppm 8.2-8.1 (d, 1H), 7.6-7.5 (d, 1H), 7.2-7.1 (t, 1H), 6.7-6.6 (t, 1H), 4.1-4.0 (d, 1H), 3.7-3.6 (d, 1H), 3.5-3.4 (m, 1H), 3.1-2.7 (m, 5H), 2.4-2.2 (m, 2H), 1.8-1.7 (m, 1H), 1.7-1.5(m, 2H). MS (LCMS) [M+H] = 299.3; R.T. = 1.22分。
1H NMR (400 MHz, CDCl3) δ ppm 8.63 (s, 1 H) 2.68 (s, 6 H)。
1H NMR (400 MHz, CDCl3) δ ppm 9.39 (br. s., 1 H) 8.48 (s, 1 H) 4.05 (d, J=9.79 Hz, 1 H) 3.72 (d, J=9.79 Hz, 1 H) 3.42 (dd, J=15.06, 1.76 Hz, 1 H) 2.73 - 3.08 (m, 5 H) 2.10 - 2.22 (m, 2 H) 1.73 - 1.84 (m, J=14.09, 9.94, 4.17, 4.17 Hz, 1 H) 1.52 - 1.65 (m, 2 H). MS (LC/MS) R.T. = 1.29; [M+H]+ = 394.99。
(R)−N−(6−(メチルチオ)チアゾロ[5,4−b]ピラジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, CDCl3) δ ppm 9.39 (br. s., 1 H) 8.31 (s, 1 H) 4.03 (d, J=9.77 Hz, 1 H) 3.70 (d, J=9.77 Hz, 1 H) 3.41 (dd, J=14.95, 1.83 Hz, 1 H) 2.73 - 3.10 (m, 5 H) 2.63 (s, 3 H) 2.10 - 2.25 (m, 2 H) 1.47 - 1.86 (m, 3 H). MS (LC/MS) R.T. = 1.04; [M+H]+ = 363.04。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.43 (s, 1 H) 7.81 (s, 2 H) 3.90 (s, 3 H). MS (LC/MS) R.T. = 0.73; [M+H]+ = 183.03。
1H NMR (400 MHz, CDCl3) δ ppm 8.90 (s, 1 H) 4.09 (s, 3 H) 2.66 (s, 6 H)。
1H NMR (500 MHz, CDCl3) δ ppm 9.12 (br. s., 1 H) 8.63 (s, 1 H) 3.95 - 4.18 (m, 4 H) 3.71 (d, J=9.77 Hz, 1 H) 3.41 (d, J=15.26 Hz, 1 H) 2.74 - 3.10 (m, 5 H) 2.11 - 2.27 (m, 2 H) 1.71 - 1.86 (m, 1 H) 1.50 - 1.70 (m, 2 H). MS (LC/MS) R.T. = 1.66; [M+H]+ = 347.0。
1H NMR (500 MHz, CDCl3) δ ppm 2.86-2.83 (q, 2H), 2.63 (s, 6H), 1.39-1.35 (t, 3H). MS (LCMS) [M+H] = 217.95; R.T. = 1.93分。
1H NMR (500 MHz, MeOD) δ ppm 4.05 (d, 1H), 3.74 (d, 1H), 3.3-3.2 (d, 1H), 3.2-3.1(d, 1H), 3.0-2.9(m, 2H), 2.9-2.8 (m, 5H), 2.2 (s, 1H), 2.15-2.0 (m, 1H), 1.9-1.6 (m, 3H), 1.4-1.3 ( t, 3H). (m, 2H). MS (LCMS) [M+H] = 278.09; R.T. = 0.48分。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.50 (t, J=2.59 Hz, 1 H), 8.45 (t, J=2.59 Hz, 1 H). MS (LC/MS) R.T. = 2.07; [M+H]+ = 204.8。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.91 (s, 1 H), 8.11 - 8.17 (m, 1 H), 7.97 (d, J=2.44 Hz, 1 H), 3.84 (d, J=9.77 Hz, 1 H), 3.59 (d, J=9.77 Hz, 1 H), 2.95 - 3.04 (m, 2 H), 2.72 - 2.81 (m, 2 H), 2.66 (t, J=7.63 Hz, 2 H), 2.01 (s, 1 H), 1.89 (s, 1 H), 1.54 - 1.62 (m, 2 H), 1.42 - 1.50 (m, 1 H). MS (LC/MS) R.T. = 0.78; [M+]+ = 326.1。
1H NMR (400 MHz, CDCl3) δ ppm 8.04 (d, J=8.53 Hz, 1 H) 7.38 (d, J=8.53 Hz, 1 H) 2.66 (s, 6 H)。
1H NMR (400 MHz, DMSO-d6) δ ppm 9.13 (br. s., 1 H) 7.93 (d, J=8.53 Hz, 1 H) 7.45 (d, J=8.28 Hz, 1 H) 3.92 (d, J=10.29 Hz, 1 H) 3.67 (d, J=10.29 Hz, 1 H) 3.00 - 3.14 (m, 2 H) 2.77 - 2.93 (m, 2 H) 2.69 (t, J=7.65 Hz, 2 H) 2.12 (br. s., 1 H) 1.95 (br. s., 1 H) 1.43 - 1.72 (m, 3 H). MS (LC/MS) R.T. = 1.10; [M+H]+ = 350.10。
(R)−N 5 ,N 5 −ジメチル−N 2 −(4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−イル)チアゾロ[5,4−d]ピリミジン−2,5−ジアミン
1H NMR (400 MHz, DMSO-d6) δ ppm 12.64 (s, 1 H) 9.05 (s, 1 H) 4.31 (q, J=7.19 Hz, 2 H) 1.32 (t, J=7.15 Hz, 3 H)。
1H NMR (400 MHz, DMSO-d6) δ ppm 11.97 (s, 1 H) 8.67 (s, 1 H) 4.26 (q, J=7.03 Hz, 2 H) 3.17 (s, 6 H) 1.16 - 1.40 (m, 3 H). MS (LC/MS) R.T. = 1.88; [M+H]+ = 268.09。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.27 (s, 1 H) 7.44 (s, 2 H) 3.10 (s, 6 H)。
1H NMR (400 MHz, CDCl3) δ ppm 8.75 (s, 1 H) 3.26 (s, 6 H) 2.64 (s, 6 H)。
1H NMR (400 MHz, CDCl3) δ ppm 9.07 (br. s., 1 H) 8.50 (s, 1 H) 4.01 (d, J=9.54 Hz, 1 H) 3.67 (d, J=9.54 Hz, 1 H) 3.39 (dd, J=14.93, 1.63 Hz, 1 H) 3.23 (s, 6 H) 2.71 - 3.10 (m, 5 H) 2.10 - 2.24 (m, 2 H) 1.68 - 1.84 (m, 1 H) 1.46 - 1.68 (m, 2 H). MS (LC/MS) R.T. = 0.87; [M+H]+ = 360.23。
MS (LCMS) [M+H] = 135.96; R.T. = 0.21分。
1H NMR (500 MHz, CDCl3) δ ppm 9.2 (2, 1H), 8.5 (d, 1H), 8.2 (d, 1H), 2.67 (s, 6H). MS (LCMS) [M+H] = 239.92. [M+Na] = 261.89; R.T. = 1.55分。
1H NMR (500 MHz, MeOD) δ ppm 9.0 (m, 1H), 8.71-8.70 (m, 1H), 8.15-8.10 (m, 1H), 4.15-4.0 (d, 1H), 3.85-3.8 (d, 1H), 3.6-3.5 (d, 1H), 3.4-3.3 (d, 1H), 3.3-3.0 (m, 4H), 2.4-2.2 (m, 2H), 2.0-1.8 (m, 3H). MS (LCMS) [M+H] = 300.06; R.T. = 0.2分。
1H NMR (500 MHz, CDCl3) δ ppm 8.47 (d, J=4.58 Hz, 1 H) 8.11 (dd, J=8.24, 1.53 Hz, 1 H) 7.37 (dd, J=8.24, 4.88 Hz, 1 H) 2.66 (s, 6 H)。
1H NMR (400 MHz, CDCl3) δ ppm 9.30 (br. s., 1 H) 8.37 (dd, J=4.77, 1.51 Hz, 1 H) 7.82 (dd, J=8.03, 1.51 Hz, 1 H) 7.28 (dd, J=8.03, 4.77 Hz, 1 H) 4.05 (d, J=9.54 Hz, 1 H) 3.70 (d, J=9.54 Hz, 1 H) 3.42 (dd, J=15.06, 1.76 Hz, 1 H) 2.75 - 3.07 (m, 5 H) 2.14 - 2.26 (m, 2 H) 1.71 - 1.84 (m, J=13.99, 9.79, 4.17, 4.17 Hz, 1 H) 1.48 - 1.68 (m, 2 H). MS (LC/MS) R.T. = 0.64; [M+H]+ = 316.15。
(R)−N−(チアゾロ[5,4−b]ピラジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, CDCl3) δ ppm 9.50 (br. s., 1 H) 8.41 (d, J=2.76 Hz, 1 H) 8.27 (d, J=2.76 Hz, 1 H) 4.06 (d, J=9.79 Hz, 1 H) 3.72 (d, J=9.79 Hz, 1 H) 3.43 (dd, J=15.06, 1.76 Hz, 1 H) 2.74 - 3.09 (m, 5 H) 2.12 - 2.25 (m, 2 H) 1.71 - 1.86 (m, 1 H) 1.49 - 1.67 (m, 2 H). MS (LC/MS) R.T. = 0.75; [M+H]+ = 317.13。
1H NMR (400 MHz, DMSO-d6) δ ppm 12.70 (br. s., 1 H) 4.30 (q, J=7.19 Hz, 2 H) 2.69 (s, 3 H) 1.30 (t, J=7.15 Hz, 3 H)。
1H NMR (400 MHz, DMSO-d6) δ ppm 7.71 (s, 2 H) 3.98 (s, 3 H) 2.52 (s, 3 H)。
1H NMR (400 MHz, CDCl3) δ ppm 4.17 (s, 3 H) 2.71 (s, 3 H) 2.64 (s, 6 H)。
1H NMR (400 MHz, CDCl3) δ ppm 9.10 (br. s., 1 H) 4.14 (s, 3 H) 4.03 (d, J=9.54 Hz, 1 H) 3.68 (d, J=9.54 Hz, 1 H) 3.39 (dd, J=14.93, 1.63 Hz, 1 H) 2.74 - 3.07 (m, 5 H) 2.68 (s, 3 H) 2.04 - 2.28 (m, 2 H) 1.70 - 1.86 (m, 1 H) 1.44 - 1.67 (m, 2 H). MS (LC/MS) R.T. = 1.10; [M+H]+ = 361.32。
1H NMR (400 MHz, CDCl3) δ ppm 8.60 (s, 1 H) 4.20 (s, 3 H) 2.65 (s, 6 H)。
1H NMR (400 MHz, CDCl3) δ ppm 9.12 (br. s., 1 H) 8.52 (s, 1 H) 4.16 (s, 3 H) 4.05 (d, J=9.54 Hz, 1 H) 3.70 (d, J=9.54 Hz, 1 H) 3.40 (dd, J=14.93, 1.88 Hz, 1 H) 2.70 - 3.07 (m, 5 H) 2.08 - 2.27 (m, 2 H) 1.68 - 1.85 (m, 1 H) 1.48 - 1.66 (m, 2 H). MS (LC/MS) R.T. = 0.90; [M+H]+ = 347.34。
(R)−2−(4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−イルアミノ)チアゾール−5−カルボニトリル
1H NMR (500 MHz, DMSO-D6) δ ppm 9.05 (s, 1 H), 8.13 (s, 1 H), 3.86 (d, J=10.38 Hz, 1 H), 3.61 (d, J=10.38 Hz, 1 H), 3.01 - 3.10 (m, 2 H), 2.83 (t, J=7.63 Hz, 2 H), 2.62 - 2.71 (m, 2 H), 2.09 (s, 1 H), 1.90 - 1.97 (m, 2 H), 1.54 - 1.62 (m, 3 H). MS (LC/MS) R.T. = 0.52; [M+H]+ = 290.0。
(R)−N−(7−ブロモピロロ[1,2−f][1,2,4]トリアジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 8.13 (1 H, s), 7.04 (1 H, d, J=4.53 Hz), 6.77 (1 H, d, J=4.53 Hz), 4.09 (1 H, d, J=10.32 Hz), 3.79 (1 H, d, J=10.58 Hz), 3.24 (1 H, d), 3.12 (1 H, d), 2.70 - 3.00 (4 H, m), 2.06 - 2.25 (2 H, m), 1.52 - 1.86 (3 H, m). MS (LC/MS) R.T. = 1.62; [M+H]+ = 377.2。
(R)−N−(1,6−ナフチリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 8.99 (1 H, s), 8.48 (1 H, d, J=6.04 Hz), 8.20 (1 H, d, J=8.56 Hz), 7.77 (1 H, d, J=6.04 Hz), 7.12 (1 H, d, J=8.81 Hz), 4.12 (1 H, d, J=10.32 Hz), 3.82 (1 H, d, J=10.32 Hz), 3.36 (1 H, d), 3.21 (1 H, d), 2.79 - 3.09 (4 H, m), 2.08 - 2.30 (2 H, m), 1.56 - 1.95 (3 H, m). (LC/MS) R.T. = 0.38; [M+H]+ = 310.3。
(R)−N−(キナゾリン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 9.27 (1 H, s), 7.72 - 7.99 (3 H, m), 7.47 (1 H, dd, J=7.55, 3.78 Hz), 4.07 (1 H, d, J=10.07 Hz), 3.76 (1 H, d, J=10.07 Hz), 3.26 (1 H, br. s.), 3.13 (1 H, d), 2.70 - 3.03 (4 H, m), 2.17 (2 H, br. s.), 1.50 - 1.88 (3 H, m). (LC/MS) R.T. = 1.11; [M+H]+ = 310.3。
1H NMR (500 MHz, DMSO-D6) δ ppm 7.27 - 7.70 (m, 3 H), 4.77 (s, 1 H), 4.14 - 4.35 (m, 2 H), 3.45 - 3.68 (m, 4 H), 1.09 - 1.29 (m, 6 H). LC/MS RT=2.03; [M+H]+ = 304.9。
1H NMR (400 MHz, DMSO-D6) δ ppm 8.99 (s, 1 H), 7.64 - 7.73 (m, 1 H), 7.30 (d, J=2.01 Hz, 1 H), 6.61 (s, 1 H), 6.43 (s, 2 H). MS (LC/MS) R.T. = 1.40; [M+H]+ = 213.1。
1H NMR (500 MHz, DMSO-D6) δ ppm 9.42 (s, 1 H), 8.16 (d, J=1.83 Hz, 1 H), 8.02 (d, J=2.14 Hz, 1 H), 7.92 (s, 1 H). MS (LC/MS) R.T. = 3.63; [M+H]+ = 255.0。
1H NMR (400 MHz, DMSO-D6) δ ppm 9.23 (s, 1 H), 8.71 - 8.83 (m, 1 H), 7.90 - 8.00 (m, 1 H), 7.57 - 7.67 (m, 1 H), 7.13 - 7.24 (m, 1 H), 3.79 - 3.90 (m, 1 H), 3.53 - 3.64 (m, 1 H), 2.93 - 3.04 (m, 2 H), 2.72 - 2.82 (m, 2 H), 2.61 - 2.70 (m, 2 H), 1.99 (s, 1 H), 1.90 (s, 1 H), 1.59 (d, J=4.78 Hz, 2 H), 1.40 - 1.50 (m, 1 H). MS (LC/MS) R.T. = 1.68; [M+H]+ = 377.1。
1H NMR (500 MHz, CDCl3) δ ppm 7.45 (m, 1 H), 7.40 (m, 1 H), 7.19 (dd, J=8.09, 1.98 Hz, 1 H), 4.94 (s, 1 H), 4.43 (s, 2 H), 3.47 - 3.77 (m, 4 H), 1.41 - 1.79 (m, 6 H). LC/MS RT=2.15; [M+H]+ = 305.1。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.90 (s, 1 H), 8.83 (s, 1 H), 8.12 (s, 1 H), 7.89 (s, 1 H), 7.84 (d, J=8.54 Hz, 1 H), 7.28 (d, J=8.85 Hz, 1 H), 6.83 (s, 1 H), 6.58 (s, 1 H), 6.48 (s, 2 H), 6.25 (s, 2 H). MS (LC/MS) R.T. = 1.59; [M+H]+ = 213.0。
5,6−ジクロロ−3−イソチオシアナトイソキノリン: 1H NMR (500 MHz, CDCl3) δ ppm 9.10 (s, 1 H), 7.87 (d, J=8.85 Hz, 1 H), 7.82 (s, 1 H), 7.66 (d, J=8.55 Hz, 1 H). MS (LC/MS) R.T. = 3.63; [M+H]+ = 255.0。
6,7−ジクロロ−3−イソチオシアナトイソキノリン: 1H NMR (500 MHz, CDCl3) δ ppm 9.04 (s, 1 H), 8.11 (s, 1 H), 7.94 (s, 1 H), 7.37 (s, 1 H). MS (LC/MS) R.T. = 3.42; [M+H]+ = 255.0。
1H NMR (500 MHz, CDCl3) δ ppm 9.03 (s, 1 H), 8.87 (s, 1 H), 7.96 (s, 1 H), 7.83 (s, 1 H), 7.24 (s, 1 H), 3.88 - 4.06 (m, 1 H), 3.60 - 3.74 (m, 1 H), 3.42 (d, J=14.65 Hz, 1 H), 2.82 - 3.15 (m, 5 H), 2.23 - 2.34 (m, 1 H), 2.18 (s, 1 H), 1.72 - 1.87 (m, 1 H), 1.48 - 1.70 (m, 2 H). MS (LC/MS) R.T. = 1.63; [M+H]+ = 377.1。
(R)−N−(5,6−ジクロロイソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, CDCl3) δ ppm 9.09 (s, 1 H), 8.93 (s, 1 H), 7.63 - 7.82 (m, 2 H), 7.40 (d, J=8.55 Hz, 1 H), 3.99 (d, J=9.16 Hz, 1 H), 3.78 (d, J=8.85 Hz, 1 H), 3.51 (d, J=14.65 Hz, 1 H), 3.30 (d, J=14.65 Hz, 1 H), 2.90 - 3.23 (m, 4 H), 2.33 - 2.48 (m, 1 H), 2.29 (s, 1 H), 1.83 - 1.94 (m, 1 H), 1.62 - 1.83 (m, J=42.12 Hz, 2 H). MS (LC/MS) R.T. = 1.57; [M+H]+ = 377.1。
(R)−N−(3,4−ジクロロピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-D6) δ ppm 9.10 (s, 1 H), 8.08 (d, J=5.49 Hz, 1 H), 7.13 (d, J=5.49 Hz, 1 H), 3.86 (d, J=9.77 Hz, 1 H), 3.60 (d, J=9.77 Hz, 1 H), 2.96 - 3.05 (m, 2 H), 2.77 (t, J=7.63 Hz, 2 H), 2.66 (t, J=7.78 Hz, 2 H), 1.97 - 2.05 (m, 1 H), 1.86 - 1.94 (m, 1 H), 1.54 - 1.63 (m, 2 H), 1.43 - 1.51 (m, 1 H). MS (LC/MS) R.T. = 0.78; [M+H]+ = 327.0。
(R)−N−(3−クロロピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-D6) δ ppm 9.06 (s, 1 H), 8.14 - 8.19 (m, 1 H), 7.74 - 7.79 (m, J=7.78, 1.83, 1.83, 1.68 Hz, 1 H), 6.86 - 6.91 (m, 1 H), 3.81 - 3.89 (m, 1 H), 3.55 - 3.63 (m, 1 H), 2.96 - 3.04 (m, 2 H), 2.78 (t, J=7.63 Hz, 2 H), 2.67 (t, J=7.63 Hz, 2 H), 1.96 - 2.02 (m, 1 H), 1.86 - 1.92 (m, J=5.65, 3.20 Hz, 1 H), 1.54 - 1.63 (m, J=6.87, 3.66, 3.51 Hz, 2 H), 1.42 - 1.49 (m, 1 H). MS (LC/MS) R.T. = 0.26; [M+H]+ = 293.0。
(R)−N−(5−クロロ−3−フルオロピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-D6) δ ppm 8.81 (s, 1 H), 8.05 (s, 1 H), 7.79 (d, J=10.07 Hz, 1 H), 3.83 (d, J=9.46 Hz, 1 H), 3.58 (d, J=9.46 Hz, 1 H), 2.99 (s, 2 H), 2.71 - 2.80 (m, 2 H), 2.61 - 2.70 (m, 2 H), 2.00 (s, 1 H), 1.83 - 1.92 (m, 1 H), 1.53 - 1.62 (m, 2 H), 1.41 - 1.50 (m, 1 H). MS (LC/MS) R.T. = 0.52; [M+]+ = 311.0。
(R)−N−(6−クロロピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-D6) δ ppm 8.33 - 8.42 (m, 1 H), 7.60 - 7.68 (m, 1 H), 6.94 (d, J=7.02 Hz, 1 H), 6.72 - 6.81 (m, 1 H), 3.86 (d, J=9.46 Hz, 1 H), 3.57 (d, J=10.07 Hz, 1 H), 2.97 (s, 2 H), 2.69 - 2.78 (m, 2 H), 2.63 - 2.68 (m, J=7.63, 7.63 Hz, 2 H), 1.95 - 2.03 (m, 1 H), 1.83 - 1.92 (m, 1 H), 1.53 - 1.62 (m, 2 H), 1.41 - 1.49 (m, 1 H). MS (LC/MS) R.T. = 0.43; [M+H]+ = 293.0。
(R)−N−(4,6−ジクロロピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-D6) δ ppm 8.43 (s, 1 H), 7.13 (s, 1 H), 6.84 (s, 1 H), 3.86 (d, J=9.77 Hz, 1 H), 3.59 (d, J=10.07 Hz, 1 H), 2.98 (s, 2 H), 2.58 - 2.86 (m, 4 H), 1.94 - 2.13 (m, 1 H), 1.78 - 1.95 (m, 1 H), 1.36 - 1.65 (m, 3 H). MS (LC/MS) R.T. = 0.87; [M+H]+ = 327.0。
1H NMR (500 MHz, DMSO-D6) δ ppm 8.67 (d, J=2.44 Hz, 1 H), 8.26 (dd, J=4.88, 1.53 Hz, 1 H), 8.15 (dd, J=8.24, 2.44 Hz, 1 H), 7.89 (dd, J=7.32, 1.53 Hz, 1 H), 7.48 (d, J=8.24 Hz, 1 H), 7.15 (dd, J=7.32, 4.88 Hz, 1 H), 3.91 (s, 3 H). MS (LC/MS) R.T. = 2.87; [M+H]+ = 244.9。
1H NMR (500 MHz, DMSO-D6) δ ppm 9.07 (s, 1 H), 8.43 (s, 1 H), 8.17 (dd, J=4.73, 1.68 Hz, 1 H), 7.79 (d, J=7.32 Hz, 2 H), 7.10 (dd, J=7.32, 4.88 Hz, 1 H), 6.79 - 6.92 (m, 1 H), 3.76 - 3.97 (m, 4 H), 3.51 - 3.66 (m, 1 H), 2.92 - 3.09 (m, 2 H), 2.59 - 2.82 (m, 4 H), 1.85 - 2.03 (m, 2 H), 1.53 - 1.71 (m, 2 H), 1.35 - 1.49 (m, 1 H). MS (LC/MS) R.T. = 1.05; [M+H]+ = 366.1。
1H NMR (400 MHz, CDCl3) δ ppm 6.20 (br. s., 2 H) 7.02 - 7.11 (m, 1 H) 7.17 - 7.22 (m, 1 H) 7.29 (d, J=7.53 Hz, 1 H) 7.36 (d, J=7.03 Hz, 1 H ). MS (LC/MS) R.T. = 1.05; [M+H]+ = 134.96。
1H NMR (400 MHz, CDCl3) δ ppm 2.70 (s, 6 H) 7.24 - 7.34 (m, 2 H) 7.45 - 7.50 (m, 1 H) 7.66 - 7.74 (m, 1 H). MS (LC/MS) R.T. = 1.76, [M+H]+ = 238.96。
10mlのバイアルに、(S)−3−(アミノメチル)キヌクリジン−3−オール 二塩酸塩(69.5mg, 0.361mmol)、DMF(2ml)、DIEA(0.063ml, 0.361mmol)およびCs2CO3(235mg, 0.722mmol)を室温で入れ、次にベンゾ[d]オキサゾール−2−イルカルボンイミドジチオ酸ジメチル(86mg, 0.361mmol)を入れた。得られた懸濁液を室温で1時間撹拌した。LC/MSにより、出発物質が消費されたことが示された。混合物をMeOHで希釈し、分取HPLCによって精製し、予測された生成物である(R)−N−(ベンゾ[d]オキサゾール−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミンを黄褐色のゴム状物質として得た(101.5mg, 0.323mmol, 収率90%)。
1H NMR (400 MHz, アセトン-d6) δ ppm 2.07 - 2.14 (m, 2 H) 2.20 (ddd, J=8.78, 5.27, 3.26 Hz, 2 H) 2.33 - 2.45 (m, 1 H) 2.62 (d, J=2.26 Hz, 1 H) 3.34 - 3.47 (m, 3 H) 3.48 - 3.58 (m, 1 H) 3.75 - 3.88 (m, 2 H) 4.15 (d, J=10.54 Hz, 1 H) 4.32 (d, J=10.54 Hz, 1 H) 7.13 - 7.26 (m, 2 H) 7.41 (td, J=3.70, 1.63 Hz, 1 H) 9.24 (br, s, 1H). MS (LC/MS) R.T. = 0.792, [M+H]+ = 299.17。
1H NMR (400 MHz, DMSO-d6) δ ppm 2.69 (s, 6 H) 7.37 (dd, J=8.53, 2.26 Hz, 1 H) 7.66 (d, J=9.03 Hz, 1 H) 7.75 (d, J=1.76 Hz, 1 H). MS (LC/MS) R.T. = 1.44; [M+H]+ = 272.9。
1H NMR (400 MHz, アセトン-d6) δ ppm 2.08 - 2.30 (m, 3 H) 2.35 - 2.48 (m, 1 H) 2.60 - 2.73 (m, 1 H) 3.48 (qd, J=7.53, 7.28 Hz, 3 H) 3.54 - 3.68 (m, 1 H) 3.79 - 4.00 (m, 2 H) 4.18 (d, J=10.54 Hz, 1 H) 4.35 (d, J=10.54 Hz, 1 H) 7.19 (dd, J=8.53, 2.01 Hz, 1 H) 7.30 - 7.47 (m, 2 H) 9.10 (br. s., 1 H). MS(LC/MS) R.T. = 1.56; [M+H]+ = 333.13。
MS(LC/MS) R.T. = 0.235; [M+H]+ = 136.09。
1H NMR (400 MHz, CDCl3) δ ppm 2.71 (s, 6 H) 7.22 (dd, J=8.03, 5.02 Hz, 1 H) 7.72 (dd, J=8.03, 1.25 Hz, 1 H) 8.49 (dd, J=5.02, 1.51 Hz, 1 H). MS (LC/MS) R.T. = 1.358; [M+H] = 240.04。
1H NMR (400 MHz, アセトン-d6) δ ppm 1.54 - 1.60 (m, 1 H) 1.71 - 1.77 (m, 2 H) 2.16 - 2.24 (m, 1 H) 2.77 - 2.82 (m, 2 H) 2.89 (t, J=7.91 Hz, 4 H) 3.13 - 3.25 (m, 2 H) 3.90 (d, J=10.29 Hz, 1 H) 4.22 (d, J=10.29 Hz, 1 H) 7.13 (dd, J=8.03, 5.02 Hz, 1 H) 7.70 (dd, J=7.91, 1.13 Hz, 1 H) 8.27 (dd, J=5.14, 1.13 Hz, 1 H) 9.11 (br. s., 1 H). MS (LC/MS) R.T. = 0.443; [M+H]+ = 300.16。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.73 (s, 1 H), 7.69 (d, J=8.28 Hz, 1 H), 7.29 (s, 1 H), 7.00 (d, J=8.28 Hz, 1 H), 5.81 (s, 1 H), 2.40 (s, 3 H). MS (LC/MS) R.T. = 1.37; [M+H]+ = 159.10。
1H NMR (400 MHz, CDCl3) δ ppm 9.03 (s, 1 H), 7.88 (d, J=8.24 Hz, 1 H), 7.56 (s, 1 H), 7.46 (dd, J=8.24, 1.53 Hz, 1 H) , 7.39 (s, 1 H) 2.57 (s, 3 H). MS (LC/MS) R.T. = 1.92; [M+H]+ = 201.13。
1H NMR (400 MHz, MeOD) δ ppm 9.11 (s, 1 H), 8.02 (d, J=8.53 Hz, 1 H), 7.80 (s, 1 H), 7.74 (s, 1 H), 7.47 (d, J=8.53 Hz, 1 H), 4.47 (d, J=10.54 Hz, 1 H), 4.31 (d, J=10.54 Hz, 1 H), 4.10 (d, J=14.81 Hz, 1 H), 3.92 (d, J=14.81 Hz, 1 H), 3.53 - 3.71 (m, 2 H), 3.27 - 3.51 (m, 3 H), 2.84 (br.s, 1 H), 2.55 (s, 3H), 2.48 (m, 1 H), ) 2.10 - 2.30 (m, 3H). MS (LC/MS) R.T. = 1.24; [M+H]+ = 323.2。
1H NMR (400 MHz, CDCl3) δ ppm 7.47 (2 H, d, J=8.56 Hz), 7.23 (2 H, d, J=8.06 Hz), 6.76 (1 H, br. s.), 5.31 (1 H, br. s.), 4.94 (1 H, br. s.), 4.45 (2 H, br. s.), 3.47 - 3.77 (4 H, m), 1.26 (6 H, t, J=7.05 Hz). LCMS:R.T. = 2.12; [M+2]+ = 317.2。
LCMS:R.T. = 1.62; [M+2]+ = 225.1。
R.T. = 2.54; [M+H]+ = 267.04。
1H NMR (400 MHz, MeOD) δ ppm 9.04 (1 H, s), 7.80 - 8.05 (2 H, m), 7.55 (1 H, dd, J=8.81, 1.76 Hz), 7.37 (1 H, br. s.), 4.10 (1 H, d, J=10.58 Hz), 3.87 (1 H, d, J=10.83 Hz), 3.68 - 3.77 (1 H, m), 3.56 - 3.67 (1 H, m), 3.29 - 3.49 (4 H, m), 2.45 (1 H, br. s.), 2.28 - 2.41 (1 H, m), 1.86 - 2.15 (3 H, m). LCMS:R.T. = 1.76; [M+]+ = 387.21。
LCMS: R.T. = 2.11; [M+2]+ = 317.06。
LCMS:R.T. = 1.56; [M+2]+ = 225.1。
混合物をそのまま次の工程に用いた。
1H NMR (400 MHz, アセトン) δ ppm 9.19 (1 H, s), 8.41 (1 H, s), 7.86 - 8.02 (2 H, m), 7.76 (1 H, s). R.T. = 4.28; [M+H]+ = 267.04。
1H NMR (400 MHz, アセトン) δ ppm 9.24 (1 H, s), 8.23 (1 H, d), 8.15 (1 H, d), 7.81 (1 H, s), 7.64 (1 H, t). LCMS:R.T. = 4.61; [M+H]+ = 267.04。
1H NMR (400 MHz, MeOD) δ ppm 8.96 (1 H, s), 8.12 (1 H, s), 7.66 (2 H, s), 7.32 (1 H, s), 4.01 (1 H, d), 3.73 (1 H, d), 3.35 - 3.42 (1 H, m), 3.22 - 3.29 (1 H, m), 2.84 - 3.17 (4 H, m), 2.13 - 2.35 (2 H, m), 1.62 - 1.96 (3 H, m). LCMS:R.T. = 1.76; [M+]+ = 387.21。
((R)−N−(5−ブロモイソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 8.99 (1 H, s), 7.91 (2 H, dd), 7.55 (1 H, br. s.), 7.28 (1 H, t), 3.96 (1 H, d), 3.65 (1 H, d), 3.17 - 3.26 (1 H, m), 3.03 - 3.13 (1 H, m), 2.70 - 2.99 (4 H, m), 2.03 - 2.30 (2 H, m), 1.47 - 1.87 (3 H, m). LCMS:R.T. = 1.69; [M+2]+ = 389.21。
1H NMR (400 MHz, MeOD) δ ppm 8.82 (s, 1 H), 7.17 (s, 1 H), 6.90 (s, 1 H), 6.72 (s, 1 H), 2.61 (s, 3 H), 2.37 (s, 3 H). MS (LC/MS) R.T. = 0.77; [M+H]+ = 173.15。
1H NMR (400 MHz, CDCl3) δ ppm 9.20 (s, 1 H), 7.36 - 7.44 (m, 2 H), 7.23 (s, 1 H), 2.75 (s, 3 H), 2.51 (s, 3 H). MS (LC/MS) R.T. = 2.03; [M+H]+ = 215.1。
1H NMR (400 MHz, MeOD) δ ppm 9.29 (s, 1 H), 7.54 (s, 1 H), 7.43 (s, 1 H), 7.34 (s, 1 H), 4.38 (d, J=11.04 Hz, 1 H), 4.17 (d, J=11.04 Hz, 1 H), 3.94- 4.10 (m, 1 H), 3.86 (dd, J=15.06, 2.26 Hz, 1 H), 3.51 - 3.67 (m, 1 H), 3.37 - 3.51 (m, 3 H), 2.77 (s, 3 H), 2.73 (d, J=3.51 Hz, 1 H), 2.48 - 2.57 (m, 3 H), 2.30 - 2.46 (m, 1 H), 1.94 - 2.28 (m, 3 H). MS (LC/MS) R.T. = 0.90; [M+H]+ = 337.38。
(R)−N−(3,4'−ビピリジン−2'−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.95 (br. s., 2 H), 8.66 (d, J=4.6 Hz, 1 H), 8.31 (d, J=5.5 Hz, 1 H), 8.14 (br. s., 1 H), 7.54 (d, J=7.6 Hz, 1 H), 7.26 (br. s., 2 H), 3.85 (br. s., 1 H), 3.58 (s, 1 H), 3.00 (br. s., 2 H), 2.67 (br. s., 4 H), 1.90 (br. s., 2 H), 1.59 (br. s., 2 H), 1.45 (br. s., 1 H). MS (LC/MS) R.T. = 0.12; [M+H]+ = 336.18。
(R)−N−(5−クロロ−3,4'−ビピリジン−2'−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.92 (s, 2 H), 8.71 (d, J=2.1 Hz, 1 H), 8.19 - 8.39 (m, 2 H), 7.30 (d, J=4.3 Hz, 2 H), 3.77 - 3.95 (m, 1 H), 3.59 (d, J=10.1 Hz, 1 H), 3.01 (d, J=4.9 Hz, 2 H), 2.61 - 2.86 (m, 4 H), 2.00 (s, 1 H), 1.83 - 1.96 (m, 1 H), 1.55 - 1.68 (m, 2 H), 1.40 - 1.54 (m, 1 H). MS (LC/MS) R.T. = 0.91; [M+H]+ = 370.09。
(R)−N−(6−メトキシ−3,4'−ビピリジン−2'−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.79 - 9.21 (m, 1 H), 8.46 - 8.66 (m, 1 H), 8.26 (s, 1 H), 7.97 - 8.14 (m, 1 H), 6.99 - 7.27 (m, 2 H), 6.83 - 6.99 (m, 1 H), 3.92 (s, 4 H), 3.49 - 3.62 (m, 1 H), 2.99 (d, J=4.3 Hz, 2 H), 2.66 (d, J=7.6 Hz, 4 H), 1.79 - 2.05 (m, 2 H), 1.33 - 1.63 (m, 3 H). MS (LC/MS) R.T. = 0.98; [M+H]+ = 366.17。
(R)−N−(6−フルオロ−3,4'−ビピリジン−2'−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.90 - 9.17 (m, 1 H), 8.57 - 8.71 (m, 1 H), 8.31 (d, J=5.5 Hz, 2 H), 7.31 - 7.40 (m, 1 H), 7.01 - 7.29 (m, 2 H), 3.76 - 3.95 (m, 1 H), 3.59 (d, J=10.4 Hz, 1 H), 3.01 (br. s., 2 H), 2.68 (br. s., 4 H), 1.95 - 2.05 (m, 1 H), 1.81 - 1.95 (m, 1 H), 1.59 (br. s., 2 H), 1.37 - 1.53 (m, 1 H). MS (LC/MS) R.T. = 0.68; [M+H]+ = 354.09。
(R)−N−(4−(3−クロロ−4−フルオロ−フェニル)ピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.92 - 9.16 (m, 1 H), 8.28 (d, J=5.2 Hz, 1 H), 7.88 - 8.09 (m, 1 H), 7.66 - 7.81 (m, 1 H), 7.43 - 7.63 (m, 1 H), 7.19 - 7.30 (m, 1 H), 6.99 - 7.17 (m, 1 H), 3.77 - 3.94 (m, 1 H), 3.53 - 3.66 (m, 1 H), 2.99 (br. s., 2 H), 2.67 (br. s., 4 H), 1.82 - 2.03 (m, 2 H), 1.52 - 1.66 (m, 2 H), 1.37 - 1.53 (m, 1 H). MS (LC/MS) R.T. = 1.65; [M+H]+ = 387.10。
(R)−N−(4−m−トリルピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.86 - 9.25 (m, 1 H), 8.26 (d, J=5.5 Hz, 1 H), 7.45 - 7.57 (m, 2 H), 7.39 (t, J=7.5 Hz, 1 H), 7.27 (d, J=7.3 Hz, 1 H), 7.18 (d, J=4.3 Hz, 2 H), 3.76 - 3.98 (m, 1 H), 3.58 (d, J=10.4 Hz, 1 H), 2.99 (d, J=5.8 Hz, 2 H), 2.72 - 2.85 (m, 2 H), 2.67 (t, J=7.6 Hz, 2 H), 2.39 (s, 3 H), 1.83 - 2.05 (m, 2 H), 1.52 - 1.64 (m, 2 H), 1.36 - 1.51 (m, 1 H). MS (LC/MS) R.T. = 1.54; [M+H]+ = 349.19。
(R)−N−(4−フェニルピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.91 - 9.29 (m, 1 H), 8.27 (d, J=5.5 Hz, 1 H), 7.73 (d, J=7.3 Hz, 2 H), 7.38 - 7.58 (m, 3 H), 6.92 - 7.27 (m, 2 H), 3.78 - 3.94 (m, 1 H), 3.59 (d, J=10.4 Hz, 1 H), 2.91 - 3.08 (m, 2 H), 2.59 - 2.87 (m, 4 H), 1.82 - 2.05 (m, 2 H), 1.59 (br. s., 2 H), 1.36 - 1.53 (m, 1 H). MS (LC/MS) R.T. = 1.24; [M+H]+ = 335.15。
(R)−N−(4−(1−メチル−1H−ピラゾール−4−イル)ピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.80 - 9.17 (m, 1 H), 8.26 (s, 1 H), 8.14 (d, J=5.2 Hz, 1 H), 7.94 (br. s., 1 H), 7.06 (d, J=4.3 Hz, 2 H), 3.88 (s, 4 H), 3.56 (d, J=9.8 Hz, 1 H), 2.98 (br. s., 2 H), 2.60 - 2.86 (m, 4 H), 1.79 - 2.07 (m, 2 H), 1.58 (br. s., 2 H), 1.46 (dd, J=9.6, 2.6 Hz, 1 H). MS (LC/MS) R.T. = 0.7; [M+H]+ = 339.18。
(R)−N−(4−チアゾール−4−イル)ピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 9.25 (d, J=1.8 Hz, 2 H), 8.40 (s, 1 H), 8.27 (d, J=5.5 Hz, 1 H), 7.23 - 7.53 (m, 2 H), 3.85 (br. s., 1 H), 3.58 (d, J=10.4 Hz, 1 H), 3.00 (d, J=6.7 Hz, 2 H), 2.73 - 2.85 (m, 2 H), 2.68 (t, J=7.8 Hz, 2 H), 1.84 - 2.04 (m, 2 H), 1.53 - 1.68 (m, 2 H), 1.47 (d, J=7.0 Hz, 1 H). MS (LC/MS) R.T. = 0.78; [M+H]+ = 342.17。
(R)−N−(6−ニトロ−3,4'−ビピリジン−2'−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 9.06 (br. s., 2 H), 8.52 - 8.67 (m, 1 H), 8.31 - 8.46 (m, 2 H), 7.13 - 7.44 (m, 2 H), 3.78 - 3.94 (m, 1 H), 3.60 (d, J=10.1 Hz, 1 H), 3.00 (br. s., 2 H), 2.59 - 2.84 (m, 4 H), 2.00 (br. s., 2 H), 1.59 (br. s., 2 H), 1.38 - 1.53 (m, 1 H). MS (LC/MS) R.T. = 0.81; [M+H]+ = 381.2。
(R)−N−(5−クロロ−6−メチルピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.81 (br. s., 1 H), 7.59 (br. s., 1 H), 6.64 (br. s., 1 H), 3.82 (br. s., 1 H), 3.56 (d, J=10.4 Hz, 1 H), 2.97 (s, 2 H), 2.58 - 2.82 (m, 4 H), 2.48 (br. s., 3 H), 1.98 (br. s., 1 H), 1.81 - 1.93 (m, 1 H), 1.58 (br. s., 2 H), 1.28 - 1.51 (m, 1 H). MS (LC/MS) R.T. = 0.89; [M+H]+ = 307.08。
(R)−N−(5−フルオロ−4−メチルピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.59 - 8.97 (m, 1 H), 8.04 (s, 1 H), 6.50 - 6.95 (m, 1 H), 3.79 (br. s., 1 H), 3.53 (d, J=10.4 Hz, 1 H), 2.96 (br. s., 2 H), 2.60 - 2.84 (m, 4 H), 2.21 (s, 3 H), 1.95 (br. s., 2 H), 1.52 - 1.66 (m, 2 H), 1.45 (ddd, J=6.9, 2.9, 2.7 Hz, 1 H). MS (LC/MS) R.T. = 0.63; [M+H]+ = 291.12。
(R)−N−(3,5−ジクロロ−6−メチルピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.83 (br. s., 1 H), 7.86 (d, J=2.1 Hz, 1 H), 3.85 (d, J=9.8 Hz, 1 H), 3.59 (d, J=10.1 Hz, 1 H), 3.00 (br. s., 1 H), 2.73 - 2.84 (m, 1 H), 2.67 (t, J=7.5 Hz, 1 H), 2.49 (dd, J=14.5, 2.0 Hz, 6 H), 2.01 (br. s., 1 H), 1.89 (br. s., 1 H), 1.59 (br. s., 2 H), 1.37 - 1.51 (m, 1 H). MS (LC/MS) R.T. = 1.07; [M+H]+ = 341.06。
(R)−N−(4,5−ジメチルピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.71 - 9.29 (m, 1 H), 7.92 (s, 1 H), 6.28 - 7.02 (m, 1 H), 3.80 (br. s., 1 H), 3.53 (d, J=10.1 Hz, 1 H), 2.87 - 3.03 (m, 2 H), 2.59 - 2.85 (m, 4 H), 2.04 - 2.26 (m, 6 H), 1.80 - 1.99 (m, 2 H), 1.33 - 1.64 (m, 3 H). MS (LC/MS) R.T. = 0.67; [M+H]+ = 287.20。
(R)−N−(5−メトキシピリジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, DMSO-d6) δ ppm 8.57 - 9.10 (m, 1 H), 7.91 (d, J=3.1 Hz, 1 H), 7.30 (dd, J=8.9, 3.4 Hz, 1 H), 6.54 - 7.04 (m, 1 H), 3.72 - 3.85 (m, 4 H), 3.52 (d, J=10.1 Hz, 1 H), 2.88 - 3.03 (m, 2 H), 2.76 (d, J=5.8 Hz, 2 H), 2.66 (t, J=7.6 Hz, 2 H), 1.81 - 2.02 (m, 2 H), 1.51 - 1.64 (m, 2 H), 1.38 - 1.49 (m, 1 H). MS (LC/MS) R.T. = 0.46; [M+H]+ = 289.17。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.86 (s, 1 H), 7.93 (d, J=7.6 Hz, 1 H), 7.79 (d, J=8.5 Hz, 1 H), 7.68 (td, J=6.7, 1.8 Hz, 1 H), 7.24 - 7.35 (m, 1 H), 6.32 (br. s., 2 H). MS (LC/MS) R.T. = 1.50; [M+H]+ = 178.96。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.98 - 9.10 (m, 1 H), 8.57 - 8.95 (m, 1 H), 7.99 - 8.18 (m, 2 H), 7.79 (s, 1 H), 7.51 (s, 1 H), 3.84 (d, J=9.8 Hz, 1 H), 3.35 - 3.51 (m, 1 H), 3.02 (d, J=5.5 Hz, 2 H), 2.78 (s, 2 H), 2.61 - 2.73 (m, 2 H), 2.00 (s, 2 H), 1.55 - 1.65 (m, 2 H), 1.42 - 1.54 (m, 1 H). MS (LC/MS) R.T. = 0.92; [M+H]+ = 343.09。
1H NMR (500 MHz, クロロホルム-d) δ ppm 7.23 - 7.40 (m, 2 H), 7.07 (t, J=7.9 Hz, 1 H), 4.93 (s, 1 H), 4.54 (s, 2 H), 3.50 - 3.74 (m, 4 H), 1.18 - 1.35 (m, 6 H). MS (LC/MS) R.T. = 1.78; [M+H]+ = 289.17。
1H NMR (500 MHz, DMSO-d6) d ppm 8.97 (s, 1 H), 7.47 - 7.57 (m, 1 H), 7.38 - 7.45 (m, 1 H), 6.67 (s, 1 H), 6.33 (s, 2 H). MS (LC/MS) R.T. = 1.18; [M+H]+ = 196.95。
1H NMR (500 MHz, DMSO-d6) δ ppm 9.19 (d, J=2.1 Hz, 1 H), 8.30 - 8.85 (m, 1 H), 7.68 (br. s., 2 H), 6.93 - 7.43 (m, 1 H), 3.73 - 4.10 (m, 1 H), 3.48 - 3.70 (m, 1 H), 3.02 (br. s., 2 H), 2.59 - 2.86 (m, 4 H), 1.80 - 2.08 (m, 2 H), 1.60 (br. s., 2 H), 1.37 - 1.53 (m, 1 H). MS (LC/MS) R.T. = 1.22; [M+H]+ = 361.06。
(R)−N−(1−メチルイソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, MeOD) δ ppm 8.10 (d, J=8.2 Hz, 1 H), 7.72 (d, J=8.2 Hz, 1 H), 7.60 (t, J=7.5 Hz, 1 H), 7.44 (t, J=7.6 Hz, 1 H), 7.03 - 7.33 (m, 1 H), 4.01 (d, J=10.1 Hz, 1 H), 3.69 (d, J=10.1 Hz, 1 H), 3.19 - 3.31 (m, 2 H), 3.12 (d, J=15.0 Hz, 1 H), 2.90 - 3.01 (m, 5 H), 2.77 - 2.90 (m, 2 H), 2.17 (br. s., 2 H), 1.58 - 1.87 (m, 3 H). MS (LC/MS) R.T. = 1.09; [M+H]+ = 323.16。
(R)−N−(6−(4−フルオロフェニル)ピリミジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 8.75 (1 H, s), 7.93 - 8.11 (2 H, m), 7.06 - 7.30 (3 H, m), 4.03 (1 H, d, J=10.32 Hz), 3.73 (1 H, d, J=10.32 Hz), 3.18 - 3.27 (1 H, m), 3.05 - 3.16 (1 H, m), 2.66 - 3.00 (4 H, m), 2.01 - 2.20 (2 H, m), 1.49 - 1.87 (3 H, m). LC/MS RT=1.53; [M+H]+ = 354.24。
(R)−N−(6−(3−フルオロフェニル)ピリミジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 8.80 (1 H, d, J=1.26 Hz), 7.71 - 7.85 (2 H, m), 7.50 (1 H, td, J=7.99, 5.92 Hz), 7.11 - 7.36 (2 H, m), 4.08 (1 H, d, J=10.58 Hz), 3.80 (1 H, d, J=10.58 Hz), 3.39 - 3.48 (1 H, m), 3.33 (1 H, s), 2.83 - 3.20 (4 H, m), 2.10 - 2.33 (2 H, m), 1.65 - 1.96 (3 H, m). LC/MS RT=1.59; [M+H]+ = 354.24。
(R)−N−(5−フルオロピリミジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD)δ ppm 8.50 (2 H, d, J=0.76 Hz), 4.03 (1 H, d, J=10.07 Hz), 3.77 (1 H, d, J=10.32 Hz), 3.47 - 3.57 (1 H, m), 3.36 - 3.43 (1 H, m), 3.01 - 3.24 (4 H, m), 2.15 - 2.40 (2 H, m), 1.68 - 2.03 (3 H, m). LC/MS RT=0.30; [M+H]+ = 278.19。
(R)−N−(4−クロロ−5−メトキシピリミジン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 7.99 (1 H, s), 4.13 (1 H, d, J=10.83 Hz), 3.91 (4 H, d, J=10.83 Hz), 3.76 - 3.84 (1 H, m), 3.64 - 3.71 (1 H, m), 3.30 - 3.51 (4 H, m), 2.43 - 2.52 (1 H, m), 2.37 (1 H, d, J=3.27 Hz), 2.09 (1 H, dd, J=9.32, 4.78 Hz), 1.88 - 2.03 (2 H, m). LC/MS RT=0.30; [M+H]+ = 278.19。
(R)−N−(6,8−ジフルオロイソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
MS (LC/MS) R.T. = 1.42; [M+H]+ = 345.26。
(R)−N−(6,7−ジフルオロイソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, MeOD) δ ppm 8.97 (1 H, s), 7.73 - 7.91 (1 H, m), 7.58 (1 H, dd, J=11.14, 7.78 Hz), 7.30 (1 H, s), 4.01 (1 H, d, J=10.07 Hz), 3.71 (1 H, d, J=10.07 Hz), 3.31 (1 H, br. s.), 3.14 - 3.24 (1 H, m), 3.03 (2 H, d, J=7.32 Hz), 2.83 - 2.98 (2 H, m), 2.20 (2 H, br. s.), 1.61 - 1.91 (3 H, m). MS (LC/MS) R.T. = 1.45; [M+H]+ = 345.26。
(R)−N−(5,8−ジフルオロイソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, MeOD) δ ppm 9.25 (1 H, s), 7.43 (1 H, br. s.), 7.20 - 7.34 (1 H, m), 6.91 - 7.12 (1 H, m), 4.04 (1 H, d, J=10.07 Hz), 3.74 (1 H, d, J=10.07 Hz), 3.30 (1 H, br. s.), 3.13 - 3.23 (1 H, m), 3.03 (2 H, d, J=7.63 Hz), 2.82 - 2.96 (2 H, m), 2.21 (2 H, br. s.), 1.58 - 1.92 (3 H, m). MS (LC/MS) R.T. = 1.37; [M+H]+ = 345.33。
(R)−N−(7−フルオロキナゾリン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 9.22 (1 H, s), 7.95 (1 H, dd, J=8.81, 6.04 Hz), 7.47 (1 H, dd, J=10.45, 2.14 Hz), 7.24 (1 H, td, J=8.75, 2.39 Hz), 4.07 (1 H, d, J=10.07 Hz), 3.77 (1 H, d, J=10.07 Hz), 3.25 (1 H, s), 3.07 - 3.17 (1 H, m), 2.89 - 3.02 (2 H, m), 2.75 - 2.88 (2 H, m), 2.04 - 2.26 (2 H, m), 1.50 - 1.85 (3 H, m). MS (LC/MS) R.T. =1.06; [M+H]+= 328.33。
(R)−N−(5−クロロキナゾリン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 9.53 (1 H, s), 7.62 - 7.84 (2 H, m), 7.47 (1 H, dd, J=6.80, 1.51 Hz), 4.09 (1 H, d, J=10.32 Hz), 3.80 (1 H, d, J=10.32 Hz), 3.36 (1 H, s), 3.15 - 3.24 (1 H, m), 3.00 (2 H, t, J=7.68 Hz), 2.79 - 2.95 (2 H, m), 2.05 - 2.32 (2 H, m), 1.53 - 1.87 (3 H, m). MS (LC/MS) R.T. =1.36; [M+H]+= 344.29。
(R)−N−(5−フルオロキナゾリン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 9.46 (1 H, s), 7.77 (1 H, td, J=8.18, 6.30 Hz), 7.63 (1 H, d, J=8.56 Hz), 7.00 - 7.20 (1 H, m), 4.08 (1 H, d, J=10.07 Hz), 3.77 (1 H, d, J=10.07 Hz), 3.25 (1 H, s), 3.07 - 3.17 (1 H, m), 2.94 (2 H, t, J=7.68 Hz), 2.72 - 2.88 (2 H, m), 2.05 - 2.21 (2 H, m), 1.48 - 1.83 (3 H, m). MS (LC/MS) R.T. =1.10; [M+H]+= 328.33。
(R)−N−(7−フルオロ−4−メチルキナゾリン−2−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 8.13 (1 H, dd, J=9.07, 6.04 Hz), 7.46 (1 H, dd, J=10.45, 2.64 Hz), 7.22 (1 H, td, J=8.81, 2.77 Hz), 4.06 (1 H, d, J=10.07 Hz), 3.75 (1 H, d, J=10.07 Hz), 3.23 (1 H, s), 3.06 - 3.15 (1 H, m), 2.94 (2 H, t, J=7.68 Hz), 2.73 - 2.88 (5 H, m), 2.06 - 2.24 (2 H, m), 1.51 - 1.86 (3 H, m). MS (LC/MS) R.T. =1.25; [M+H]+= 342.29。
(R)−N−(6−フルオロ−1−メチルイソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, MeOD) δ ppm 8.23 (1 H, dd, J=9.16, 5.49 Hz), 7.44 (1 H, dd, J=9.92, 2.59 Hz), 7.22 - 7.38 (2 H, m), 4.17 (1 H, d, J=10.99 Hz), 3.94 (1 H, d, J=10.68 Hz), 3.71 - 3.79 (1 H, m), 3.61 - 3.69 (1 H, m), 3.39 - 3.49 (1 H, m), 3.33 - 3.39 (3 H, m), 2.95 (3 H, s), 2.49 (1 H, br. s.), 2.37 (1 H, tt, J=10.07, 3.36 Hz), 2.05 - 2.16 (1 H, m), 1.93 - 2.05 (2 H, m). MS (LC/MS) R.T. =1.47; [M+H]+= 341.25。
(R)−N−(6−クロロ−1−メチルイソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, MeOD) δ ppm 8.23 (1 H, dd, J=9.16, 5.49 Hz), 7.44 (1 H, dd, J=9.92, 2.59 Hz), 7.22 - 7.38 (2 H, m), 4.17 (1 H, d, J=10.99 Hz), 3.94 (1 H, d, J=10.68 Hz), 3.71 - 3.79 (1 H, m), 3.61 - 3.69 (1 H, m), 3.39 - 3.49 (1 H, m), 3.33 - 3.39 (3 H, m), 2.95 (3 H, s), 2.49 (1 H, br. s.), 2.37 (1 H, tt, J=10.07, 3.36 Hz), 2.05 - 2.16 (1 H, m), 1.93 - 2.05 (2 H, m). MS (LC/MS) R.T. =1.79; [M+H]+= 357.28。
(R)−N−(7−フルオロ−1−メチルイソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 7.55 - 7.81 (2 H, m), 7.38 (1 H, t, J=7.55 Hz), 7.16 (1 H, br. s.), 3.95 (1 H, d, J=9.82 Hz), 3.64 (1 H, d, J=9.82 Hz), 3.20 (1 H, d, J=14.86 Hz), 3.01 - 3.13 (1 H, m), 2.63 - 2.97 (7 H, m), 2.11 (2 H, br. s.), 1.41 - 1.81 (3 H, m). MS (LC/MS) R.T. =1.63; [M+H]+= 341.32。
(R)−N−(5,7−ジフルオロ−1−メチルイソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, MeOD) δ ppm 7.78 (1 H, d, J=9.77 Hz), 7.39 - 7.55 (2 H, m), 4.31 (1 H, d, J=10.99 Hz), 4.11 (1 H, d, J=10.99 Hz), 3.88 - 3.97 (1 H, m), 3.79 - 3.86 (1 H, m), 3.55 (1 H, t, J=11.90 Hz), 3.37 - 3.47 (3 H, m), 3.00 (3 H, s), 2.64 (1 H, br. s.), 2.32 - 2.45 (1 H, m), 2.18 (1 H, dddd, J=11.71, 7.13, 6.94, 6.56 Hz), 1.99 - 2.13 (2 H, m). MS (LC/MS) R.T. =1.67; [M+H]+= 359.22。
(R)−N−(6−(6−(メチルチオ)ピリジン−3−イル)ピリミジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 9.02 (1 H, d, J=2.52 Hz), 8.78 (1 H, s), 8.20 (1 H, dd, J=8.44, 2.39 Hz), 7.36 (1 H, d, J=8.56 Hz), 7.26 (1 H, br. s.), 4.06 (1 H, d, J=10.58 Hz), 3.77 (1 H, d, J=10.32 Hz), 3.34 (1 H, s), 3.14 - 3.22 (1 H, m), 2.82 - 3.08 (4 H, m), 2.58 (3 H, s), 2.08 - 2.24 (2 H, m), 1.60 - 1.88 (3 H, m). MS (LC/MS) R.T. =3.09; [M+H]+= 383.2。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.57 (1 H, ddd, J=9.95, 7.68, 2.01 Hz), 8.48 (1 H, d, J=1.26 Hz), 8.33 (1 H, td, J=3.02, 2.01 Hz), 7.51 (1 H, ddd, J=7.37, 4.97, 2.01 Hz), 7.12 (2 H, br. s.), 6.96 (1 H, d, J=1.26 Hz). MS (LC/MS) R.T. =0.43; [M+H]+= 191.15。
MS (LC/MS) R.T. = 2.48; [M+H]+= 233.08。
MS (LC/MS) R.T. = 1.82; [M+H]+= 389.27。
1H NMR (400 MHz, MeOD) δ ppm 8.83 (1 H, d, J=1.26 Hz), 8.55 (1 H, ddd, J=9.76, 7.62, 2.01 Hz), 8.29 (1 H, dt, J=3.02, 1.51 Hz), 7.46 (1 H, ddd, J=7.37, 5.10, 1.89 Hz), 7.33 (1 H, s), 4.06 (1 H, d, J=10.32 Hz), 3.76 (1 H, d, J=10.32 Hz), 3.25 (1 H, s), 3.09 - 3.19 (1 H, m), 2.95 (2 H, t, J=7.68 Hz), 2.74 - 2.91 (2 H, m), 2.04 - 2.26 (2 H, m), 1.55 - 1.87 (3 H, m). MS (LC/MS) R.T. = 1.24; [M+H]+= 355.28。
(R)−N−(6−(6−フルオロピリジン−3−イル)ピリミジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 8.88 (1 H, d, J=2.52 Hz), 8.82 (1 H, s), 8.51 - 8.60 (1 H, m), 7.25 (1 H, s), 7.19 (1 H, dd, J=8.56, 2.52 Hz), 4.06 (1 H, d, J=10.32 Hz), 3.76 (1 H, d, J=10.32 Hz), 3.22 (1 H, s), 3.07 - 3.14 (1 H, m), 2.86 - 2.98 (2 H, m), 2.70 - 2.87 (2 H, m), 2.03 - 2.20 (2 H, m), 1.54 - 1.87 (3 H, m). MS (LC/MS) R.T. = 1.21; [M+H]+= 355.28。
(R)−N−(6−(5−フルオロピリジン−3−イル)ピリミジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 9.06 (1 H, d, J=1.26 Hz), 8.81 (1 H, d, J=1.01 Hz), 8.56 (1 H, d, J=2.77 Hz), 8.26 (1 H, dt, J=9.82, 2.27 Hz), 7.30 (1 H, br. s.), 4.06 (1 H, d, J=10.32 Hz), 3.75 (1 H, d, J=10.32 Hz), 3.16 - 3.26 (1 H, m), 3.04 - 3.15 (1 H, m), 2.86 - 3.00 (2 H, m), 2.81 (2 H, t, J=7.30 Hz), 2.01 - 2.22 (2 H, m), 1.52 - 1.84 (3 H, m). MS (LC/MS) R.T. = 1.20; [M+H]+= 355.28。
(R)−N−(6−(1−メチル−1H−ピラゾール−5−イル)ピリミジン−4−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (500 MHz, MeOD) δ ppm 8.89 (1 H, s), 7.54 (1 H, d, J=2.14 Hz), 7.28 (1 H, br. s.), 6.84 (1 H, d, J=2.14 Hz), 4.23 (3 H, s), 4.18 (1 H, d, J=10.99 Hz), 3.98 (1 H, d, J=10.68 Hz), 3.81 - 3.88 (1 H, m), 3.72 - 3.80 (1 H, m), 3.53 (1 H, t, J=11.75 Hz), 3.34 - 3.46 (3 H, m), 2.53 (1 H, br. s.), 2.33 - 2.45 (1 H, m), 2.10 - 2.22 (1 H, m), 1.97 - 2.12 (2 H, m). MS (LC/MS) R.T. = 1.15; [M+H]+= 340.29。
1H NMR (400 MHz, クロロホルム-d) δ ppm 8.69 (1 H, d, J=0.76 Hz), 7.88 (1 H, d, J=1.01 Hz), 1.58 (18 H, s)。
1H NMR (400 MHz, クロロホルム-d) δ ppm 9.67 (1 H, d, J=1.01 Hz), 9.05 (1 H, d, J=1.26 Hz), 8.60 - 8.77 (3 H, m), 1.59 (18 H, s)。
1H NMR (400 MHz, DMSO-d6) δ ppm 9.44 (1 H, d, J=1.01 Hz), 8.63 - 8.86 (2 H, m), 8.51 (1 H, d, J=1.01 Hz), 7.38 (1 H, d, J=1.26 Hz), 7.17 (2 H, br. s.). MS (LC/MS) R.T. = 0.37; [M+H]+= 174.23。
MS (LC/MS) R.T. = 3.19; [M+H]+= 278.19。
1H NMR (400 MHz, MeOD) δ ppm 9.46 (1 H, d, J=1.51 Hz), 8.83 (1 H, d, J=1.26 Hz), 8.67 - 8.72 (1 H, m), 8.66 (1 H, d, J=2.52 Hz), 7.77 (1 H, br. s.), 4.05 (1 H, d, J=10.32 Hz), 3.75 (1 H, d, J=10.32 Hz), 3.18 - 3.26 (1 H, m), 3.04 - 3.15 (1 H, m), 2.87 - 3.00 (2 H, m), 2.70 - 2.85 (2 H, m), 2.04 - 2.19 (2 H, m), 1.54 - 1.83 (3 H, m). MS (LC/MS) R.T. = 0.97; [M+H]+= 338.29。
MS (LC/MS) R.T. = 0.32; [M+H]+ = 173.13。
MS (LC/MS) R.T. = 2.06; [M+H]+ = 215.1。
1H NMR (400 MHz, MeOD) δ ppm 8.87 (1 H, s), 7.90 (1 H, s), 7.67 (1 H, s), 7.50 (1 H, s), 3.97 (1 H, d, J=10.0 Hz), 3.65 (1 H, d, J=10.0 Hz), 3.19 - 3.27 (1 H, m), 3.04 - 3.17 (1 H, m), 2.94 (2 H, d, J=7.5 Hz), 2.76 - 2.90 (2 H, m), 2.38 - 2.50 (6 H, m), 2.11 - 2.21 (2 H, m), 1.57 - 1.85 (3 H, m). MS (LC/MS) R.T. = 0.92; [M+H]+ = 337.22。
1H NMR (400 MHz, クロロホルム-d) δ ppm 7.19 - 7.34 (1 H, m), 7.11 (1 H, s), 7.01 (1 H, d, J=7.8 Hz), 5.60 (2 H, br. s.), 2.43 (3 H, s). MS (LC/MS) R.T. = 0.89; [M+H]+ = 149.09。
MS (LC/MS) R.T. = 1.88; [M+H]+ = 252.95。
1H NMR (400 MHz, DMSO-d6) δ ppm 9.89 (br. s., 1 H), 9.15 (br. s., 1 H), 7.33 (d, J=8.03 Hz, 1 H), 7.31 (s, 1 H), 7.06 (d, J=8.78 Hz, 1 H), 4.00 (d, J=8.0 Hz, 1 H), 3.88 (d, J=10.29 Hz, 1 H), 3.64 - 3.80 (m, 2 H), 3.34 - 3.44 (m, 1 H), 3.20 - 3.34 (m, 3 H), 2.44 (br. s., 1 H), 2.40 (s, 3 H), 2.08 - 2.20 (m, 1 H), 1.80 - 2.03 (m, 3 H). MS (LC/MS) R.T. = 0.367, [M+H]+ = 313.2。
1H NMR (500 MHz, クロロホルム-d) δ ppm 7.28 (1 H, d, J=9.5 Hz), 6.92 (1 H, d, J=2.4 Hz), 6.80 (1 H, dd, J=8.5, 2.1 Hz), 5.28 (2 H, br. s.). MS (LC/MS) R.T. = 1.51; [M+H]+ = 165.00。
1H NMR (400 MHz, DMSO-d6) δ ppm 9.95 (br. s., 1 H), 9.10 (br. s., 1 H), 7.34 (d, J=8.78 Hz, 1 H), 7.17 (d, J=2.51 Hz, 1 H), 6.84 (dd, J=8.53, 2.51 Hz, 1 H), 3.99 (d, J=10.54 Hz, 1 H), 3.87 (d, J=10.54 Hz, 1 H), 3.79 (s, 3 H), 3.63 - 3.78 (m, 2 H), 3.34 - 3.44 (m, 1 H), 3.20 - 3.32 (m, 3 H), 2.43 (m, 1 H), 2.09 - 2.19 (m, 1 H), 1.91 - 2.02 (m, 1 H), 1.80 - 1.91 (m, 2 H). MS (LC/MS) R.T. = 0.867, [M+H]+ = 329.28。
(R)−N−(5−クロロイソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン(A)および(R)−N−(7−クロロイソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン(B)
1H NMR (400 MHz, DMSO-d6) δ ppm 7.14 - 7.50 (m, 4 H) 4.80 (br. s., 1 H) 4.29 (br. s., 2 H) 4.05 (q, J=7.11 Hz, 1 H) 3.40 - 3.73 (m, 4 H) 2.01 (s, 1 H) 1.05 - 1.29 (m, 6 H). LC/MS RT = 1.12分, [M+H] = 271.09。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.89 (s, 1 H) 8.81 (s, 2 H) 7.90 (d, J=2.26 Hz, 2 H) 7.82 (d, J=8.28 Hz, 1 H) 7.65 (dd, J=7.28, 1.00 Hz, 1 H) 7.58 (d, J=9.03 Hz, 2 H) 7.44 (dd, J=9.03, 2.26 Hz, 2 H) 7.07 - 7.19 (m, 1 H) 6.83 (s, 1 H) 6.64 (s, 2 H) 6.28 (s, 2 H) 6.05 (s, 4 H). LC/MS R.T. = 0.955分, [M+H] = 181.03。
LC/MS RT = 3.808分, [M+H] = 221.0。
1H NMR (400 MHz, DMSO-d6) δ ppm 9.14 (s, 1 H) 8.67 (br. s., 1 H) 8.03 (d, J=8.28 Hz, 1 H) 7.82 (d, J=7.28 Hz, 1 H) 7.41 (t, J=8.03 Hz, 1 H) 3.90 (br. s., 1 H) 3.63 (br. s., 1 H) 2.91 - 3.16 (m, 2 H) 2.65 - 2.92 (m, 4 H) 1.85 - 2.19 (m, 2 H) 1.16 - 1.81 (m, 4 H). LC/MS RT=1.578分, [M+H]=343.08。
1H NMR (400 MHz, DMSO-d6) δ ppm 9.06 (s, 1 H) 8.43 - 8.93 (m, 1 H) 8.13 (br. s., 1 H) 7.82 (br. s., 1 H) 7.61 (d, J=8.28 Hz, 1 H) 3.89 (br. s., 1 H) 3.61 (br. s., 1 H) 3.31 (br. s., 1 H) 2.90 - 3.18 (m, 2 H) 2.62 - 2.95 (m, 4 H) 1.82 - 2.13 (m, 2 H) 1.34 - 1.80 (m, 3 H). LC/MS R.T=0.898分, [M+H]=343.32。
1H NMR (500 MHz, クロロホルム-d) δ ppm 12.78 (br. s., 1 H) 9.25 (br. s., 1 H) 8.46 (br. s., 1 H) 7.94 (d, J=7.63 Hz, 2 H) 7.88 (d, J=2.44 Hz, 1 H) 7.69 (t, J=7.48 Hz, 1 H) 7.58 (t, J=7.78 Hz, 2 H)。
1H NMR (400 MHz, DMSO-d6) δ ppm 13.16 (br. s., 1 H) 8.48 - 8.58 (m, 2 H) 8.13 - 8.23 (m, 2 H) 7.61 - 7.69 (m, 1 H) 7.56 (t, J=7.53 Hz, 2 H). MS (LC/MS) R.T. = 2.8; [M+H]+ = 290.1。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.19 - 8.24 (m, 2 H) 8.09 (br. s., 2 H)。
1H NMR (500 MHz, クロロホルム-d) δ ppm 8.57 (s, 1 H) 8.09 (s, 1 H) 2.66 (s, 6 H)。
1H NMR (400 MHz, クロロホルム-d) δ ppm 8.31 (d, J=2.51 Hz, 1 H) 7.93 (d, J=2.26 Hz, 1 H) 3.99 (d, J=10.04 Hz, 1 H) 3.67 (d, J=10.04 Hz, 1 H) 3.20 - 3.39 (m, 2 H) 2.86 - 3.05 (m, 3 H) 2.67 - 2.87 (m, 2 H) 2.03 - 2.19 (m, 2 H) 1.74 (ddd, J=13.87, 9.35, 4.64 Hz, 1 H) 1.44 - 1.65 (m, 2 H). MS (LC/MS) R.T. = 1.49; [M+H]+ = 350.2。
1H NMR (500 MHz, クロロホルム-d) δ ppm 8.14 (dd, J=8.55, 7.02 Hz, 1 H) 6.98 (dd, J=8.70, 1.98 Hz, 1 H) 2.63 (s, 6 H)。
1H NMR (400 MHz, クロロホルム-d) δ ppm 9.17 (br. s., 1 H) 7.89 (dd, J=8.66, 6.90 Hz, 1 H) 6.91 (dd, J=8.53, 2.01 Hz, 1 H) 4.04 (d, J=9.54 Hz, 1 H) 3.73 (d, J=9.54 Hz, 1 H) 3.43 (dd, J=14.93, 1.63 Hz, 1 H) 3.08 (dd, J=15.06, 1.76 Hz, 1 H) 2.84 - 3.05 (m, 4 H) 2.16 - 2.28 (m, 2 H) 1.75 - 1.87 (m, 1 H) 1.53 - 1.70 (m, 2 H). MS (LC/MS) R.T. = 1.37; [M+H]+ = 334.2。
1H NMR (500 MHz, DMSO-d6) δ ppm 7.85 (s, 1 H) 6.42 (br. s., 2 H) 2.25 (s, 3 H). MS (LC/MS) R.T. = 0.93; [M+H]+ = 189.9。
1H NMR (400 MHz, DMSO-d6) δ ppm 12.48 (br. s., 1 H) 8.48 (s, 1 H) 4.30 (q, J=7.03 Hz, 2 H) 2.56 - 2.65 (m, 3 H) 1.31 (t, J=7.15 Hz, 3 H). MS (LC/MS) R.T. = 2.10 ; [M+H]+ = 239.17。
1H NMR (500 MHz, DMSO-d6) δ ppm 8.26 (s, 2 H) 8.12 (s, 1 H) 2.43 (s, 3 H). MS (LC/MS) R.T. = 0.66; [M+H]+ = 167.0。
1H NMR (500 MHz, クロロホルム-d) δ ppm 8.45 (s, 1 H) 2.66 - 2.68 (m, 9 H)。
1H NMR (400 MHz, クロロホルム-d) δ ppm 9.45 (br. s., 1 H) 8.26 (s, 1 H) 4.02 (d, J=9.79 Hz, 1 H) 3.69 (d, J=9.79 Hz, 1 H) 3.39 (dd, J=14.93, 1.63 Hz, 1 H) 2.72 - 3.06 (m, 5 H) 2.60 (s, 3 H) 2.11 - 2.22 (m, 2 H) 1.70 - 1.82 (m, 1 H) 1.49 - 1.64 (m, 2 H). MS (LC/MS) R.T. = 1.15; [M+H]+ = 331.2。
LCMS RT 0.96分, MH+= 297.2, 1H NMR (400 MHz, クロロホルム-d) δ ppm 6.79 - 6.93 (3 H, m), 4.94 (1 H, s), 4.41 (2 H, s), 3.84 - 3.90 (6 H, m), 3.52 - 3.70 (4 H, m), 1.19 - 1.28 (6 H, m)。
LCMS RT 0.72分, MH+ = 205.1; 1H NMR (500 MHz, クロロホルム-d) δ ppm 8.59 (1 H, s), 7.03 (1 H, s), 6.80 (1 H, s), 6.70 (1 H, s), 4.00 (3 H, s), 3.98 (3 H, s)。
1H NMR (500 MHz, クロロホルム-d) δ ppm 8.81 (1 H, s), 7.31 (1 H, s), 7.16 (1 H, s), 6.98 (1 H, s), 3.99 (6 H, s)。
LCMS RT 0.98分, MH+ = 403.2. 1H NMR (500 MHz, クロロホルム-d) δ ppm 8.73 (1 H, s), 7.28 (1 H, s), 7.09 (1 H, s), 6.96 (1 H, s), 4.01 (3 H, s), 4.00 (3 H, s), 3.96 (1 H, d, J=8.5 Hz), 3.63 (1 H, d, J=9.2 Hz), 3.39 (1 H, d, J=15.0 Hz), 2.79 - 3.10 (5 H, m), 2.24 (1 H, br. s.), 2.15 (1 H, br. s.), 1.75 (1 H, dddd, J=13.9, 9.3, 4.7, 4.4 Hz), 1.59 - 1.68 (1 H, m), 1.48 - 1.59 (1 H, m)。
LCMS RT 0.75分, MH+ = 149.1. 1H NMR (400 MHz, クロロホルム-d) δ ppm 7.78 (1 H, s), 6.26 (1 H, s), 4.29 (2 H, br. s.), 2.64 (4 H, ddd, J=10.6, 5.8, 5.5 Hz), 1.64 - 1.87 (4 H, m)。
1H NMR (500 MHz, クロロホルム-d) δ ppm 8.10 (1 H, s), 6.84 (1 H, s), 2.74 (4 H, t, J=6.3 Hz), 1.81 (4 H, dd, J=4.0, 2.7 Hz)。
1H NMR (500 MHz, クロロホルム-d) δ ppm 12.02 (1 H, br s), 8.23 (1 H, br s), 7.88 (1 H, s), 6.41 (1 H, s), 4.08 (1 H, dd), 3.89 (1 H, dd), 3.46 (2 H, s), 3.05-2.80 (5 H, m), 2.69 (4 H, dt), 2.10 (1 H, br s), 1.93 (1 H, br s), 1.85 (1 H, m), 1.77 (4 H, m), 1.66 (1 H, m), 1.45 (1 H, m); LCMS RT 1.11分, MH+ = 447.1。
LCMS RT 0.80分, MH+ =313.2; 1H NMR (500 MHz, クロロホルム-d) δ ppm 7.91 (1 H, s), 6.75 - 6.95 (1 H, m), 3.91 (1 H, d, J=9.5 Hz), 3.60 (1 H, d, J=9.5 Hz), 3.38 (1 H, s), 2.93 - 3.13 (4 H, m), 2.86 - 2.93 (2 H, m), 2.69 (4 H, td, J=11.4, 6.1 Hz), 2.21 - 2.32 (1 H, m), 2.16 (1 H, br. s.), 1.72 - 1.85 (5 H, m), 1.64 (1 H, dd, J=7.2, 4.4 Hz), 1.56 (1 H, dt, J=7.0, 2.6 Hz)。
LCMS RT 0.95分, MH+ =209.0, 211.0; 1H NMR (500 MHz, クロロホルム-d) δ ppm 8.66 (1 H, s), 7.78 (1 H, s), 6.83 (1 H, s), 6.63 (1 H, s), 4.36 - 4.58 (2 H, m), 3.99 (3 H, s)。
1H NMR (500 MHz, クロロホルム-d) δ ppm 8.90 (1 H, s), 7.99 (1 H, s), 7.36 (1 H, s), 7.08 (1 H, s), 4.05 (3 H, s)。
LCMS RT 1.28分, MH+ = 407.1, 409.0, 1H NMR (500 MHz, クロロホルム-d) δ ppm 11.85 (1 H, t, J=5.2 Hz), 9.15 (1 H, br. s.), 8.63 (1 H, s), 7.76 (1 H, s), 6.92 (1 H, s), 6.89 (1 H, s), 4.14 (1 H, dd, J=13.9, 5.6 Hz), 3.99 (2 H, s), 3.90 (1 H, dd, J=14.0, 5.2 Hz), 3.46 (3 H, s), 2.89 - 3.01 (2 H, m), 2.75 - 2.88 (3 H, m), 2.03 - 2.15 (1 H, m), 1.89 - 1.96 (1 H, m), 1.77 - 1.88 (1 H, m), 1.63 (1 H, ddd, J=13.4, 6.1, 3.4 Hz), 1.32 - 1.45 (1 H, m)。
LCMS RT 1.04分, MH+ = 373.2, 375.2, 1H NMR (500 MHz, MeOD) δ ppm 8.78 - 8.89 (1 H, m), 7.90 - 8.01 (1 H, m), 7.14 - 7.23 (1 H, m), 4.01 (3 H, s), 3.95 - 3.99 (1 H, m), 3.62 - 3.71 (1 H, m), 3.19 - 3.25 (1 H, m), 3.06 - 3.13 (1 H, m), 2.90 - 3.00 (2 H, m), 2.76 - 2.89 (2 H, m), 2.10 - 2.21 (2 H, m), 1.69 - 1.83 (2 H, m), 1.56 - 1.68 (1 H, m)。
1H NMR (500 MHz, CDCl3) δ ppm 7.3-6.9 (m, 4H), 4.9 (s, 1H), 4.4 (s, 2H), 3.8-3.5 (m, 4H), 1.27-1.20 (q, 6H). MS (LCMS, 酢酸アンモニウム系中) [M +H] = 254.7。
1H NMR (500 MHz, CDCl3) δ ppm 9.08 (s, 1H), 7.9-7.8 (m, 1H), 7.7-7.6 (m, 1H), 7.6-7.5 (m, 2H)。
1H NMR (500 MHz, CDCl3) δ ppm 9.15 (s, 1H), 7.9-7.8 (m, 1H), 7.7 (s, 1H), 7.6-7.5 (m, 1H), 7.5-7.4 (m, 1H)。
1H NMR (500 MHz, MeOD) δ ppm 9.09 (s, 1H), 7.80-7.75 (d, 1H), 7.50-7.30 (m, 3H), 4.02-4.00 (d, 1H), 3.70-3.60 (d, 1H), 3.4-3.2 (m, 1H), 3.2-3.1 (m, 1H), 3.1-2.9 (m, 2H), 2.9-2.8 (m, 2H), 2.2-2.1 (m, 2H), 1.8-1.6 (m, 3H). MS (LCMS) [M+H] = 327.08。
1H NMR (400 MHz, CDCl3) δ ppm 7.86 (1 H, br. s.), 4.77 (1 H, s), 3.78 (3 H, s), 3.55 (4 H, qd, J=6.97, 4.28 Hz), 1.21 (7 H, t, J=7.05 Hz)。
LC/MS (0.647分, MH+ = 205.92). 1H NMR (500 MHz, DMSO-d6) δ ppm 7.59 (1 H, dd, J=8.85, 5.49 Hz), 7.43 (1 H, dd, J=10.07, 3.05 Hz), 7.05 (1 H, td, J=8.47, 3.20 Hz), 3.72 (3 H, s), 2.00 (2 H, br. s.)。
LC/MS (1.188分, MH+: 334.92). 1H NMR (400 MHz, CDCl3) δ ppm 7.44 (1 H, dd, J=8.69, 5.16 Hz), 7.15 (1 H, dd, J=9.44, 2.90 Hz), 6.81 (1 H, td, J=8.25, 3.15 Hz), 5.48 (1 H, br. s.), 4.90 (1 H, s), 4.42 (2 H, s), 3.49 - 3.67 (4 H, m), 1.17 - 1.25 (6 H, m)。
LC/MS (1.052分, MH+: 242.99). 1H NMR (400 MHz, DMSO-d6) δ ppm 8.95 (1 H, s), 7.36 (1 H, dd, J=8.06, 4.53 Hz), 7.23 (1 H, dd, J=10.58, 8.06 Hz), 6.68 (1 H, s), 6.52 (2 H, s), 19F NMR (376 MHz, DMSO-d6) δ ppm -126.83 (1 F, s)。
LC/MS (2.098分, MH+: 284.93). 1H NMR (400 MHz, DMSO-d6) δ ppm 9.38 (1 H, s), 8.04 (1 H, dd, J=8.31, 4.78 Hz), 7.96 (1 H, s), 7.67 (1 H, dd, J=9.82, 8.31 Hz). 19F NMR (376 MHz, DMSO-d6) δ ppm -122.13 (1 F, s)。
LC/MS (0.997分, MH+: 406.98). 1H NMR (400 MHz, MeOD) δ ppm 9.30 (1 H, s), 7.60 (1 H, dd, J=8.18, 4.66 Hz), 7.22 (1 H, dd, J=10.07, 8.06 Hz), 4.00 (1 H, d, J=10.07 Hz), 3.69 (1 H, d, J=10.07 Hz), 3.23 (1 H, d, J=15.36 Hz), 3.07 - 3.13 (1 H, m), 2.90 - 2.96 (2 H, m), 2.76 - 2.85 (2 H, m), 2.15 (2 H, br. s.), 1.69 - 1.81 (2 H, m), 1.58 - 1.67 (1 H, m). 19F NMR (376 MHz, MeOD) δ ppm -126.72 (1 F, s)。
1H NMR (400 MHz, クロロホルム-d) δ ppm 8.85 (1 H, d, J=0.76 Hz), 8.45 (1 H, s), 7.62 (1 H, t, J=1.51 Hz), 7.34 (1 H, d, J=0.76 Hz), 7.23 (1 H, dd, J=1.38, 0.88 Hz). LCMS: RT = 0.47分, MH+ = 181.1。
LCMS: RT = 0.39分, MH+ = 162.1。
1H NMR (400 MHz, MeOD) δ ppm 8.79 (1 H, d, J=1.01 Hz), 8.65 (1 H, d, J=1.01 Hz), 7.96 (1 H, t, J=1.51 Hz), 7.33 (1 H, d, J=1.01 Hz), 7.12 - 7.19 (1 H, m), 2.58 (6 H, s). LCMS: RT = 0.63分, MH+ = 266.1。
1H NMR (400 MHz, クロロホルム-d) δ ppm 9.40 (1 H, br. s.), 8.60 (1 H, d, J=1.01 Hz), 8.37 (1 H, t, J=1.01 Hz), 7.55 (1 H, t, J=1.39 Hz), 7.16 (1 H, dd, J=1.39, 0.88 Hz), 6.84 (1 H, br. s.), 3.98 (1 H, d, J=9.57 Hz), 3.64 (1 H, d, J=9.57 Hz), 3.34 (1 H, dd, J=14.98, 1.64 Hz), 2.69 - 3.04 (5 H, m), 2.08 - 2.21 (2 H, m), 1.67 - 1.78 (1 H, m), 1.43 - 1.62 (2 H, m). LCMS: RT = 0.26分, MH+ =326.2。
1H NMR (400 MHz, クロロホルム-d) δ ppm 8.80 (1 H, d, J=0.50 Hz), 8.36 (1 H, d, J=1.26 Hz), 7.29 - 7.31 (1 H, m), 7.25 (1 H, d, J=1.01 Hz), 2.27 (3 H, d, J=1.01 Hz). LCMS: RT = 0.50分, MH+ = 195.1。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.31 (1 H, d, J=1.26 Hz), 8.28 (1 H, d, J=0.76 Hz), 7.49 (1 H, t, J=1.13 Hz), 7.16 (2 H, s), 6.50 (1 H, d, J=0.76 Hz), 2.15 (3 H, d, J=0.76 Hz). LCMS: RT = 0.39分, MH+ = 176.1。
1H NMR (400 MHz, MeOD) δ ppm 8.76 (1 H, d, J=1.01 Hz), 8.55 (1 H, d, J=1.26 Hz), 7.62 - 7.66 (1 H, m), 7.24 (1 H, d, J=1.01 Hz), 2.57 (6 H, s), 2.24 (3 H, d, J=1.01 Hz). LCMS: RT = 0.66分, MH+ = 280.1。
1H NMR (400 MHz, クロロホルム-d) δ ppm 9.40 (1 H, br. s.), 8.56 (1 H, d, J=1.01 Hz), 8.28 (1 H, d, J=1.26 Hz), 7.21 (1 H, s), 6.76 (1 H, br. s.), 3.97 (1 H, d, J=9.57 Hz), 3.63 (1 H, d, J=9.57 Hz), 3.33 (1 H, dd, J=14.86, 1.76 Hz), 2.62 - 3.05 (5 H, m), 2.24 (3 H, d, J=1.01 Hz), 2.03 - 2.19 (2 H, m), 1.65 - 1.81 (1 H, m), 1.39 - 1.62 (2 H, m). LCMS: RT = 0.25, 0.46分, MH+ = 340.3。
1H NMR (400 MHz, クロロホルム-d) δ ppm 8.86 (1 H, d, J=0.76 Hz), 8.33 (1 H, d, J=1.51 Hz), 7.54 (1 H, d, J=1.76 Hz), 7.30 (1 H, d, J=0.76 Hz). LCMS: RT = 0.81分, MH+ = 215.1。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.44 (1 H, d, J=1.51 Hz), 8.32 (1 H, d, J=0.76 Hz), 7.96 (1 H, d, J=1.51 Hz), 7.30 (2 H, br. s.), 6.58 (1 H, d, J=1.01 Hz). LCMS: RT = 0.57分, MH+ = 196.1。
回転異性体の約9:1混合物の1H NMR (400 MHz, MeOD) δ ppm 8.80 (0.8 H, d, J=0.76 Hz), 8.79 (0.2 H, d, J=0.50 Hz), 8.59 (1 H, d, J=1.51 Hz), 8.50 (0.1 H, d, J=1.26 Hz), 7.97 (0.9 H, d, J=1.51 Hz), 7.84 (0.1 H, d, J=1.51 Hz), 7.32 (0.9 H, d, J=0.76 Hz), 2.63 (0.6 H, s), 2.58 (5.4 H, s). LCMS: RT = 0.94分, MH+ = 300.0。
1H NMR (400 MHz, クロロホルム-d) δ ppm 9.41 (1 H, br. s.), 8.60 (1 H, d, J=1.01 Hz), 8.25 (1 H, d, J=1.51 Hz), 7.44 (1 H, d, J=1.51 Hz), 6.78 (1 H, s), 4.00 (1 H, d, J=9.82 Hz), 3.67 (1 H, d, J=9.57 Hz), 3.36 (1 H, dd, J=14.86, 1.51 Hz), 2.73 - 3.06 (5 H, m), 2.09 - 2.22 (2 H, m), 1.69 - 1.79 (1 H, m), 1.46 - 1.64 (2 H, m). LCMS: RT = 0.54分, MH+ = 360.2。
1H NMR (400 MHz, クロロホルム-d) δ ppm 8.77 (1 H, d, J=0.76 Hz), 8.55 (1 H, d, J=2.77 Hz), 7.96 (1 H, d, J=1.01 Hz), 7.80 (1 H, d, J=1.01 Hz), 6.51 (1 H, dd, J=2.64, 1.64 Hz). LCMS: RT = 0.86分, MH+ = 181.1。
1H NMR (400 MHz, DMSO-d6) δ ppm 8.53 (1 H, dd, J=2.52, 0.50 Hz), 8.30 (1 H, d, J=0.76 Hz), 7.82 (1 H, d, J=1.01 Hz), 7.19 (2 H, br. s.), 6.88 (1 H, d, J=1.01 Hz), 6.55 (1 H, dd, J=2.64, 1.64 Hz). LCMS: RT = 0.52分, MH+ = 162.1。
1H NMR (400 MHz, MeOD) δ ppm 8.74 (1 H, d, J=1.01 Hz), 8.64 (1 H, d, J=2.52 Hz), 7.82 (1 H, d, J=1.26 Hz), 7.40 (1 H, d, J=1.01 Hz), 6.57 (1 H, dd, J=2.64, 1.64 Hz), 2.58 (6 H, s). LCMS: RT = 0.96分, MH+ = 266.1。
1H NMR (400 MHz, クロロホルム-d) δ ppm 9.46 (1 H, br. s.), 8.58 (1 H, d, J=1.01 Hz), 8.50 (1 H, dd, J=2.64, 0.63 Hz), 7.74 (1 H, d, J=1.01 Hz), 7.47 (1 H, br. s.), 6.44 (1 H, dd, J=2.64, 1.64 Hz), 3.98 (1 H, d, J=9.57 Hz), 3.65 (1 H, d, J=9.57 Hz), 3.39 (1 H, dd, J=14.86, 1.51 Hz), 2.71 - 3.09 (5 H, m), 2.10 - 2.26 (2 H, m), 1.69 - 1.80 (1 H, m), 1.48 - 1.64 (2 H, m). LCMS: RT = 0.51分, MH+ = 326.2。
1H NMR (400 MHz, クロロホルム-d) δ ppm 9.21 (1 H, s), 8.87 (1 H, s), 8.15 (1 H, s), 7.91 (1 H, s). LCMS: RT = 0.68分, MH+ = 182.1。
1H NMR (400 MHz, DMSO-d6) δ ppm 9.30 (1 H, s), 8.35 (1 H, s), 8.30 (1 H, s), 7.39 (2 H, br. s.), 6.83 (1 H, d, J=0.76 Hz). LCMS: RT = 0.41分, MH+ = 163.1。
回転異性体の4:1混合物の1H NMR (400 MHz, MeOD) δ ppm 9.42 (0.74 H, s), 9.40 (0.35 H, s), 9.04 (0.32 H, s), 8.84 (0.76 H, d, J=1.01 Hz), 8.81 (0.33 H, d, J=1.01 Hz), 8.23 (1 H, s), 7.42 (0.75 H, d, J=1.01 Hz), 2.64 (1.2 H, s), 2.59 (4.8 H, s). LCMS: RT = 0.86分, MH+ = 267.1。
1H NMR (400 MHz, クロロホルム-d) δ ppm 9.45 (1 H, br. s.), 9.14 (1 H, s), 8.61 (1 H, d, J=1.01 Hz), 8.08 (1 H, s), 7.39 (1 H, s), 4.00 (1 H, d, J=9.57 Hz), 3.67 (1 H, d, J=9.57 Hz), 3.38 (1 H, dd, J=14.86, 1.76 Hz), 2.71 - 3.08 (5 H, m), 2.08 - 2.23 (2 H, m), 1.68 - 1.80 (1 H, m), 1.45 - 1.64 (2 H, m). LCMS: RT = 0.46分, MH+ = 327.2。
(S)−N−(イソキノリン−3−イル)−4H−1'−アザスピロ[オキサゾール−5,3'−ビシクロ[2.2.2]オクタン]−2−アミン
1H NMR (400 MHz, MeOD) δ ppm 9.00 (1 H, s), 7.91 (1 H, d, J=8.06 Hz), 7.70 (1 H, d, J=8.31 Hz), 7.58 (1 H, t, J=7.18 Hz), 7.40 (1 H, t, J=7.05 Hz), 7.30 (1 H, br. s.), 3.95 (1 H, d, J=9.82 Hz), 3.64 (1 H, d, J=10.07 Hz), 3.16 - 3.25 (1 H, m), 3.02 - 3.13 (1 H, m), 2.92 (2 H, t, J=7.30 Hz), 2.80 (2 H, t, J=7.05 Hz), 2.05 - 2.23 (2 H, m), 1.52 - 1.84 (3 H, m). MS (LC/MS) R.T. =1.39; [M+H]+= 309.21。
Claims (5)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2009/062492 WO2011053292A1 (en) | 2009-10-29 | 2009-10-29 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014092959A Division JP5714745B2 (ja) | 2014-04-28 | 2014-04-28 | α7ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013509405A JP2013509405A (ja) | 2013-03-14 |
JP5619907B2 true JP5619907B2 (ja) | 2014-11-05 |
Family
ID=41361291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012536772A Expired - Fee Related JP5619907B2 (ja) | 2009-10-29 | 2009-10-29 | α7ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2493892B1 (ja) |
JP (1) | JP5619907B2 (ja) |
KR (1) | KR20120099060A (ja) |
CN (1) | CN102791718B (ja) |
AU (1) | AU2009354790A1 (ja) |
BR (1) | BR112012010054A2 (ja) |
CA (1) | CA2779177C (ja) |
EA (1) | EA201270610A1 (ja) |
ES (1) | ES2544970T3 (ja) |
IL (1) | IL219366A0 (ja) |
MX (1) | MX2012004560A (ja) |
NZ (1) | NZ600240A (ja) |
TN (1) | TN2012000191A1 (ja) |
WO (1) | WO2011053292A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY170236A (en) | 2010-10-06 | 2019-07-11 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
KR102148355B1 (ko) * | 2012-07-27 | 2020-08-26 | 사토 파머슈티컬 가부시키가이샤 | 디플루오로메틸렌 화합물 |
US10174052B2 (en) * | 2014-11-04 | 2019-01-08 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
JP7032903B2 (ja) * | 2016-10-12 | 2022-03-09 | 田辺三菱製薬株式会社 | スルホンアミド化合物の製造方法 |
CN116217571A (zh) * | 2023-03-28 | 2023-06-06 | 上海锐谱医药科技有限公司 | 一种制备药物砌块1,2,4-三唑并[4,3-a]吡啶-3-胺的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808433D0 (en) * | 1988-04-11 | 1988-05-11 | Merck Sharp & Dohme | Therapeutic agents |
IL97726A (en) * | 1990-04-10 | 1994-12-29 | Israel Inst Biolog Res | Pharmaceutical preparations containing compounds with bridged and unbridged heterocyclic groups connected via spiro-atop with oxazoline and thiazoline groups, and sharp compounds |
US5534520A (en) * | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
KR20070090922A (ko) * | 2004-12-15 | 2007-09-06 | 아스트라제네카 아베 | 니코틴성 아세틸콜린 수용체 리간드 |
ITMI20061279A1 (it) * | 2006-06-30 | 2008-01-01 | Consiglio Nazionale Ricerche | Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche |
US7863291B2 (en) * | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
-
2009
- 2009-10-29 MX MX2012004560A patent/MX2012004560A/es active IP Right Grant
- 2009-10-29 KR KR1020127013587A patent/KR20120099060A/ko not_active Application Discontinuation
- 2009-10-29 EP EP09744572.0A patent/EP2493892B1/en not_active Not-in-force
- 2009-10-29 CN CN200980163221.8A patent/CN102791718B/zh not_active Expired - Fee Related
- 2009-10-29 EA EA201270610A patent/EA201270610A1/ru unknown
- 2009-10-29 AU AU2009354790A patent/AU2009354790A1/en not_active Abandoned
- 2009-10-29 CA CA2779177A patent/CA2779177C/en not_active Expired - Fee Related
- 2009-10-29 BR BR112012010054A patent/BR112012010054A2/pt not_active IP Right Cessation
- 2009-10-29 ES ES09744572.0T patent/ES2544970T3/es active Active
- 2009-10-29 WO PCT/US2009/062492 patent/WO2011053292A1/en active Application Filing
- 2009-10-29 NZ NZ600240A patent/NZ600240A/en not_active IP Right Cessation
- 2009-10-29 JP JP2012536772A patent/JP5619907B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-23 IL IL219366A patent/IL219366A0/en unknown
- 2012-04-25 TN TNP2012000191A patent/TN2012000191A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN102791718A (zh) | 2012-11-21 |
MX2012004560A (es) | 2012-05-08 |
NZ600240A (en) | 2014-04-30 |
KR20120099060A (ko) | 2012-09-06 |
JP2013509405A (ja) | 2013-03-14 |
BR112012010054A2 (pt) | 2016-05-24 |
EA201270610A1 (ru) | 2013-02-28 |
ES2544970T3 (es) | 2015-09-07 |
IL219366A0 (en) | 2012-06-28 |
CN102791718B (zh) | 2015-11-25 |
TN2012000191A1 (en) | 2013-12-12 |
WO2011053292A1 (en) | 2011-05-05 |
EP2493892A1 (en) | 2012-09-05 |
AU2009354790A1 (en) | 2012-06-14 |
CA2779177A1 (en) | 2011-05-05 |
EP2493892B1 (en) | 2015-07-01 |
CA2779177C (en) | 2016-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5389905B2 (ja) | α−7ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 | |
US8309577B2 (en) | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | |
US10287299B2 (en) | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | |
JP5619907B2 (ja) | α7ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 | |
US9458179B2 (en) | Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands | |
JP2013509413A (ja) | α7ニコチン性アセチルコリン受容体リガンドとしてのアザビシクロ[2.2.1]ヘプタン化合物 | |
JP2013509417A (ja) | α7ニコチン性アセチルコリン受容体リガンドとしてのアザ二環式化合物 | |
JP5714745B2 (ja) | α7ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20140212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140428 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140902 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140917 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5619907 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |